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Neuroimaging has advanced the knowledge of genetic generalised epilepsy via the 
improvement of methods and technology. The current understanding is that patients with 
GGE are characterised by abnormalities in the cortical-thalamic network, functionally 
and also structurally; and in the default mode network, mainly functionally. However, 
most studies have been performed on treated patients often with poor seizure control. 
This leaves uncertainty regarding the status of the brain at the onset of the disease and 
mechanisms that lead to positive and negative treatment outcome. Also, the systematic 
measurements of epileptic activity during resting fMRI has left questions about the 
interaction between cognitive status and the brain networks that have been identified as 
associated with generalised spike waves (GSW).   
In this thesis I focused on three rarely and/or uniquely explored issues in the field of 
neuroimaging in GGE to reach a more comprehensive understanding of GGE.  
First, I undertook a study of brain structure and function free from any effects of anti-
epileptic medication. In drug naïve patients, I measured grey matter volume and shape 
and fMRI BOLD changes related to GSW onset and prior to GSW. I showed that 
previous findings can be interpreted and confirmed without the potential influence of 
AEDs.  
Secondly, I applied a prospective approach via longitudinally following patients from 
pre-treatment to post-treatment stages to explore treatment response and to identify 




naïve pre-treatment patients with good and bad outcomes. I identified a trend of 
decreased grey matter volume in patients with bad outcome suggesting the existence of 
differences at baseline between patients with different treatment response. I compared 
cerebral blood flow (CBF) longitudinally and found a trend of decreased CBF post-
treatment. This suggests that BOLD changes post-treatment may be related to CBF 
differences.  
Thirdly, I explored the relationship between brain networks associated with GSW and 
the brain state via measuring BOLD changes associated with GSW recorded during 
periods of rest and while watching a cartoon. Evidence of different BOLD maps during 
rest and cartoon is reported suggesting the need to consider initial brain state in defining 
the GSW related BOLD response.   
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This thesis presents the first body of research aimed to study the first sample of drug 
naïve patients diagnosed with genetic generalised epilepsy which was followed 
longitudinally from the diagnosis up to 6 months after the first drug intake. The 
motivations behind the acquisition of brain measures in such a challenging group of 
patients came from the continuous requirement by the neuroscience and clinical 
communities to understand generalised epilepsy further, via the acquisition of unbiased 
neuroimaging data. Indeed, current knowledge is mainly based on studies of patients 
taking treatment for a long time, mostly with a poor treatment outcome and, in the 
majority of the cases, the epileptic network was only investigated during rest. 
We (Prof. Richardson, Dr Carmichael, Prof. Cross and I) took the challenge of acquiring 
neuroimaging data in a group of 31 drug naïve patients diagnosed with GGE and related 
follow-up. Here, I present different measures we used to explore treatment effect on 
grey matter structures and GSW related BOLD maps. I report that structural grey matter 
volume may contribute to understanding treatment outcome. I present results suggesting 
that BOLD maps post-treatment may be influenced by differences in the level of 
cerebral blood flow due to treatment. I describe how the interaction with brain state (for 
example at rest or during a task) may influence brain networks involved in GSW.  
Bearing in mind the rarity of this sample, I believe that the results I report give novel 
insights to the current knowledge of GGE mechanisms.  
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most comprehensive picture of the evolution of GGE and differences in treatment 
outcome in the first longitudinal sample.  
In Chapter 9 I conclude summarising the main findings and providing a comprehensive 
picture of the relationship between these discoveries and the novelty they provide to 
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SECTION 1: INTRODUCTION 
 
Chapter 1 : Introduction to Genetic Generalised Epilepsy 
Epilepsy is a common disease known from Mesopotamian civilisations that has been 
considered a medical condition since the late 19
th
 century (Chaudhary et al., 2011). 
Since then, the knowledge of epilepsy has expanded thanks to the invention of anti-
epileptic drugs, neuroimaging methods, and genetics (Magiorkinis et al., 2014). 
Nevertheless, neuroscience and medicine are working together to understand unknown 
elements such as the cause/origin of epilepsy, the unpredictability of seizures (Carney et 
al., 2011; Ramgopal et al., 2014) and the unknown predictors of treatment outcome 
(Perucca, 1997).    
Clinical definition and classifications of epilepsies has been reached via the taxonomy 
that the ILAE (International League Against Epilepsy) has drafted (Berg et al., 2010; 
Fisher et al., 2014). Generalised and focal epilepsies are defined by seizures engaging 
bilateral distributed networks or circumscribed within one smaller region, respectively. 
This thesis will be exclusively concerned with what is defined as generalised seizures 
manifested in the presence of a diagnosis of genetic generalised epilepsy (GGE) 
syndromes such as childhood and juvenile absence epilepsies, juvenile myoclonic 
epilepsy and generalised tonic-clonic seizures only.  
1.1 Genetic Generalised epilepsies - GGE 
Genetic generalised epilepsy is the current term for what was called idiopathic 
generalised epilepsy (IGE) in the previous ILAE classification (Engel and International 




League Against, 2001). The name has been changed under the assumption that the 
aetiology of the syndromes is a genetic defect directly contributing to the epilepsy, and 
that seizures are the core symptom of the disorder (Berg et al., 2010). Idiopathic was 
previously regarded as meaning “presumed genetic aetiology”. GGEs are characterised 
by different ages of onset and seizure semiology. Given that this work is focusing on 
childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic 
epilepsy (JME) and epilepsy with generalised tonic-clonic seizures only (GTCSO) 
(Caraballo and Dalla Bernardina, 2013), specification of each syndrome will be 
presented in the following paragraphs.  
There are commonalties across these syndromes. For example, they are all characterised 
by electrophysiological changes recorded with electroencephalography (EEG) of a 
frequency of 3-5 Hz called Generalised Spike Wave (GSW) discharges which disrupt 
normal background activity (Smith, 2005). Photosensitivity is found in about 5% of 
patients diagnosed with GGEs and 75% of them have had the first photic induced 
seizure between the ages of 8 and 20 years old (Quirk et al., 1995).  
1.1.1 Absence epilepsy 
The first recording of GSW in absence epilepsy was performed by Gibbs and colleagues 
in 1935 (Gibbs et al., 1935). 
Absence epilepsy is divided in two syndromes based on age: childhood absence epilepsy 
(CAE) and juvenile absence epilepsy (JAE).  





Absence epilepsy is a common type of generalised epilepsy in childhood (about 
7/100,000 children per year) (Chang and Lowenstein 2003). Typical CAE occurs in 
otherwise normal children during childhood (onset between age 4 and 10) and it has a 
strong genetic predisposition. Seizures are characterised by typical absences described 
as brief non-convulsive absence seizures (AE) which can be detected by 
electroencephalography (EEG) showing electrophysiological changes at 2.5–4 Hz 
generalised, bilaterally and synchronous GSW (Blumenfeld 2005). The interictal EEG is 
normal, or may show runs of occipital rhythmic delta (in 15–40% of cases) which might 
be a sign of good treatment outcome (Caraballo and Dalla Bernardina, 2013), persisting 
in some children after remission of absences. Seizures are frequent, varying from tens to 
hundreds per day and lasting from 4 to 20 seconds. Clinically, the most important 
feature of the absences is severe impairment of consciousness with unresponsiveness 
and interruption of the ongoing voluntary activity, which is restored immediately after 
the seizure finishes. Automatisms occur in two-thirds of the seizures, and are 
stereotyped. At the beginning of the absences, mild myoclonic movements of the eyes, 
eyebrows, and eyelids may be seen. Absences are often easily triggered by 
hyperventilation (Caraballo and Dalla Bernardina, 2013). As part of the GGEs, CAE has 
a strong genetic aetiology given recent evidence suggesting mutation in genes encoding 
GABA receptors or brain-expressed voltage-dependant calcium channels 
(Panayiotopoulos, 2010b). Diagnosis of epilepsy is effectively made via clinical history 
and routine EEG with hyperventilation and photic stimulation, but may require short 
ambulatory EEG recording. CAE is treated with monotherapy AED with valproate, 




ethosuximide or lamotrigine. In refractory patients, polytherapy with valproate 
combined with ethosuximide or lamotrigine is the most common combination. 
Prognosis is good for CAE with usually a remission before age 12 and less than 10% 
develops GTCSs during adolescence or adulthood (Caraballo and Dalla Bernardina, 
2013).  
1.1.1.2 JAE 
Juvenile absence epilepsy onset is around 9-13 years of age. JAE is characterised by 
typical absence seizures like CAE. Automatisms are also present and eye myoclonic 
movements are often seen. Patients with JAE present with GTCSs in 80% of cases and 
myoclonic jerks in 15-25%. Ictal EEG is similar to CAE, however, they are more likely 
to show polyspike discharges or a spike wave frequency above 3 Hz; runs of occipital 
rhythmic delta are not found (Smith, 2005). Additionally, focal abnormalities and 
spike/polyspike discharges are seen asymmetrically. Background EEG is otherwise 
normal. Ictal events are triggered by photosensitivity in 8% of patients 
(Panayiotopoulos, 2010b). As for CAE, there is a strong component of genetic aetiology 
in JAE. JAE is easily diagnosed with video-EEG. The only way to distinguish JAE from 
CAE is the age of onset and the presence of occasional myoclonus. Drug therapy is the 
same as for CAE. JAE has a worse prognosis than CAE and is typically a life-long 
disorder. However, 80% of patients are well controlled with AED if the treatment is 
initiated at the early stage of onset (Panayiotopoulos, 2010b).  





Juvenile myoclonic epilepsy was recognised as a distinct clinical syndrome in 1957 
(Janz, 1957).  
In juvenile myoclonic epilepsy, the interictal and ictal EEG characteristic is brief bursts 
of polyspike (sometimes single spike) and wave discharge at 3-6Hz. Variable 
asymmetry or lateralised emphasis of discharge is common, and focal abnormalities are 
described in up to 40% of cases during interictal period (Smith, 2005). 
Juvenile myoclonic epilepsy accounts for 8-10% of patients with epilepsy. It is 
characterised by myoclonic jerks in the limbs particularly on awakening. Most of the 
patients also manifest with GTCS which may follow on from periods of continuous 
myoclonic jerks. One third of patients also have absences that are brief compared to 
those typically found in CAE and JAE. Seizures are triggered by sleep deprivation, 
fatigue, stress, emotion and alcohol intake. Personality, behavioural, cognitive, and 
psychological disturbance are often observed in JME (Koepp et al., 2014). A family 
history of epilepsy was found in about 40-50% of patients with JME showing a big 
genetic component in the aetiology. Treatment with valproate is the most effective for 
men but is teratogenic, hence lamotrigine or levetiracetam is often the best solution for 
women; a combination of lamotrigine with valproate or topiramate are alternatives. 
Benzodiazepines may be used during clusters of myoclonic jerks. As for JAE, seizures 
are probably suffered life-long but 90% of patients have seizures well controlled with 
AED (Caraballo and Dalla Bernardina, 2013).    





Epilepsy with GTCS only is characterised by generalised tonic clonic seizures 
predominantly occurring 1 or 2 hours after awaking. However, undetected jerks or 
absence seizures may occur before the onset of GTCS. Age of onset varies from 6 to 47 
years of age with a peak between 16 and 17 years. The prevalence of GTCSO is debated 
as some studies reported that these patients account for only 0.9% of all GGE 
(Panayiotopoulos, 2005), others for 13-15% (Roger, 1994). Seizures are triggered by 
sleep deprivation, fatigue and alcohol consumption. There is a strong genetic aetiology 
for GTCSO with high incidence of family history in patients. GTCSO is a life-long 
disease with an 83% relapse rate on withdrawal of treatment. (Panayiotopoulos, 2010b) 
1.2 Diagnoses of GGE 
As mentioned in the previous paragraphs, EEG is the best clinical tool to provide 
evidence for a diagnosis of epilepsy. In a clinical setting, it is used to determine seizure 
type and specific epilepsy syndrome along with the clinical history and to help identify 
possible precipitants to epileptic seizures. Clinical EEG is routinely recorded in 
outpatient clinics first in normal wakefulness before asking the patients informed 
consent to perform intermittent photic stimulation and hyperventilation. If the diagnosis 
is still unclear, sleep EEG can be advised. The EEG recording is abnormal in about 80-
90% of patients in a population with untreated GGE, especially absence epilepsies with 
presence of photosensitivity (Panayiotopoulos, 2010c).  




1.3 Treatment in GGE 
Treatment of genetic generalised epilepsy consists of a daily long-term intake of 
antiepileptic drug (AED) regime. There is a long list of AED available in the market. 
However, we will only cover those used in GGE. Those are: clobazam (CLB), 
clonazepam (CLZ), ethosuximide (ETX), lacosamide (LCM), lamotrigine (LTG), 
levetiracetam (LEV), phenobarbital (PBT), topiramate (TPM) and valproate (VPA) 
(Panayiotopoulos, 2010a). These are, in reality, anti-seizure drugs as they stop the 
manifestation of seizures but do not cure epilepsy (French et al., 2004). 
General guidelines suggest that for patients with GTCS of unknown cause (ie. not 
known whether due to GGE or focal epilepsy), valproate is effective. Valproate is the 
drug of choice for patients with GSW on the EEG in general and in particular for all the 
forms of GGE. Ethosuximide and lamotrigine (French et al., 2004) are also useful drugs 
for absence seizures. For patients who have both absence seizures, GTCS and/or 
myoclonic jerks, valproate is preferable (Brodie and Dichter, 1996).  
Clobazam is licensed only as adjunctive therapy in epilepsy. Its efficacy is not the same 
as that of clonazepam. It may be more efficacious in focal than generalised epilepsies 
(Childhood, 1998; Montenegro et al., 2001). Clonazepam is licensed for any type of 
epileptic seizure, but it is mainly used as one of the most efficacious AEDs for 
myoclonic jerks. It may not suppress GTCS of juvenile myoclonic epilepsy and patients 
may be deprived of the warning jerks, which herald the onset of GTCS (Obeid and 
Panayiotopoulos, 1989). Ethosuximide may be effective in negative myoclonus (Oguni 
et al., 1998). Lamotrigine may aggravate myoclonic jerks in juvenile myoclonic epilepsy 
and some progressive myoclonic epilepsies (Guerrini et al., 1998b; Guerrini et al., 1999; 




Gayatri and Livingston, 2006). The effect of levetiracetam on absences is not well 
documented, although clinical series have shown a significant beneficial effect in 
childhood and juvenile absence epilepsy (Di Bonaventura et al., 2005; Verrotti et al., 
2008). 
In case the first AED does not control seizures, polytherapy is advised. In the case of 
refractory epilepsy in patients with GTCS of unknown cause, the combination of the 
first drug with carbamazepine, valproate acid and/or phenytoin is advised. For patients 
with myoclonic seizures who do not have a response to valproate, clonazepam can be 
added, whereas patients with intractable typical or atypical absence seizures may have a 
response to valproate combined with ethosuximide (Brodie and Dichter, 1996). 
The type of AED prescribed depends not only on the specific diagnosis but also on the 
specific medical situation of the patient. For example, women in their first trimester of 
pregnancy might have an increased risk of foetal malformation if under valproate 
monotherapy and/or polytherapy (Harden et al., 2009) and therefore a different drug 
might be preferable. For example, levetiracetam is advisable if myoclonic seizures are 
predominant; lamotrigine would be favoured if absence seizures are the main seizure 
type to control (Montouris, 2009). Another risk factor to account for is weight gain and 
loss. For those people already overweight, AED with weight gain as a side effect 
(valproate) may be avoided; vice versa, in people under weight, AED of which side 
effect is weight loss may be avoided (ethosuximide and topiramate) (Panayiotopoulos, 
2010a).  





Although the mechanisms of action of AED are not fully clarified, the main mechanisms 
of action known of the available AEDs are blockage of voltage-dependent ion channels 
(K+, Na+ and Ca2+ channels), increasing the activity of the inhibitory GABAergic 
system and decreasing the activity of the excitatory glutamatergic system.  
Among those AEDs used in GGE, phenobarbitan, topiramate and valproate are found to 
use all mechanisms, clobazam and clonazapam function by increasing GABA inhibition, 
ethosuximide blocks Ca2+ channels and lamotrigine blocks voltage dependent Na+ 
channels (Panayiotopoulos, 2010a).   
In clinical practice, knowledge about the mechanism of action is important, particularly 
in the treatment of seizure types with known pathophysiology; for example, primarily 
GABA-ergic AEDs such as clobazam are contraindicated in absence seizures that are 
facilitated by GABA activation. Furthermore, in polytherapy, combining AEDs with the 
same action is ill-advised because their combination is unlikely to have a better success 
and more likely to have additive side effects (Panayiotopoulos, 2010a). 
1.4 Treatment outcome 
It has been estimated that more than 30% of patients diagnosed with GGE have an 
inadequate control of seizures (Kwan and Brodie, 2000). In fact, monotherapy with an 
appropriately selected AED at an appropriate target dose achieves complete control of 
seizures in 50–70% of patients (Panayiotopoulos, 2010a).  
Rational polytherapy is often needed for 30–50% of patients who are unsatisfactorily 
controlled with a single AED. Recent studies showed that the chance to become seizure 




free declines by 50% every 1.5-2 AEDs that has proved ineffective in the past, leaving 
up to 16.6% of patients uncontrolled after failure of three previous AEDs (Kwan and 
Brodie, 2001; Schiller and Najjar, 2008). Polytherapy with more than three drugs is 
discouraged because adverse reactions become more prominent, with little, if any, 
seizure improvement (Panayiotopoulos, 2010a).  
For those patients who are seizure free for more than 3–5 years, consideration of total 
withdrawal of AEDs is needed. However, particular attention is required for those who 
suffer from epileptic syndromes requiring long-term treatment such as JME. 
Discontinuation of AEDs should be extremely slow, in small doses and in long steps of 
weeks or months. The rate of relapse increases with a faster rate of AED discontinuation 
(Panayiotopoulos, 2010a).  
The current state of knowledge is that treatment outcome cannot be predicted. This 
leaves clinicians and patients with the only option of trying an AED and adjusting 
treatment based on the patient-specific outcome. Some studies have tried to estimate 
treatment response based on number of seizures pre-treatment but this measure was 
found not be a key element to predict treatment outcome (Kwan and Brodie, 2000). 
However, given the reduced percentage of treatment response from first AED to 
polytherapy or change of first drug (< 14%) (Kwan and Brodie, 2000), it is important to 
identify predictors for unsuccessful treatment outcome.  
1.5 Animal models of GGE 
Understanding the mechanisms of GGE would help in understanding also mechanisms 
of treatment outcome. There are two well-established inbred rat strains with inherited 




GSW, accompanied by absence seizure-like phenomena: Wistar Albino Glaxo from 
Rijswijk (WAG/Rij) (Coenen et al., 1992) and Genetic Absence Epilepsy Rats from 
Strasbourg (GAERS) (Danober et al., 1998). Given the similarities between the ictal 
EEG and behavioural manifestations of GAERS and WAG/Rij rats and those of typical 
absence (Crunelli and Leresche, 2002), rat models provide important insight regarding 
mechanisms of seizure generation in humans.  
It has been possible to identify different theories of GSW generation from these models: 
the centrencephalic theory in which GSW have been described as originating from 
subcortical areas (Jasper HH, 1947; Buzsaki, 1991) and the cortical theories in which 
GSW has a focus in the cortex (Gloor, 1968; Niedermeyer, 1972; Luders et al., 1984). A 
compromise of the two is the cortico-reticular theory in which a functionally intact 
thalamo-cortical network is required for the generation of spike-wave discharges. This 
theory was generated by results in GAERS and WAG/Rij in which GSW were recorded 
at first in somatosensory cortex and 500ms after in the thalamus. The proposed 
mechanism describes that the first cycles of the seizure in the cortex drives the thalamus, 
while thereafter cortex and thalamus drive each other, thus amplifying and maintaining 
the rhythmic discharge (Meeren et al., 2002; Meeren et al., 2005).  
More recent evidence supports the cortico-reticular theory. For example, intracerebral 
electrodes in several brain sites in GAERS showed that the neural driver of GSW was in 
somatosensory cortex (David et al., 2008). Preictal activity has been found in 
somatosensory cortex. In WAG/Rij rats, increased EEG power was seen prior to GSW 
in a range of brain areas, especially in somatosensory cortex (Luttjohann et al., 2013). 
Multisite local field potential recordings in GAERS showed that the onset of GSW was 




preceded by abnormal 5-9Hz oscillations in a localised area of somatosensory cortex 
(Zheng et al., 2012). Additionally, strong functional connectivity between hemispheres 
was demonstrated in the interictal state, particularly involving somatosensory regions 
where seizures appear to arise (Mishra et al., 2013). Whole-brain network imaging in 
both strains has shown a very similar pattern to that seen during GSW in humans. 
Simultaneous EEG-fMRI in WAG/Rij and GAERS rats during GSW showed increased 
BOLD in bilateral sensorimotor cortex and thalamus, as well as decreased BOLD in 
striatum (David et al., 2008; Mishra et al., 2013).  
Neuroimaging results in humans are discussed in the following Chapter.   
1.6 Conclusion 
In this chapter the clinical picture of GGEs was presented. Clinical practice and 
classification of syndromes are well established allowing researchers to easily and 
unequivocally target patients with a consistent electro-clinical features and a well-
defined syndrome. However, there is lack of knowledge of the mechanisms behind 
variability in treatment outcome which has prevented the improvement of good 
treatment outcome rate, patient management and health services costs. Given that 
treatment outcome may be linked with the underlying mechanisms of GGEs itself, in the 
following chapter I will cover the broad range of knowledge that neuroscience has 





Chapter 2 : Introduction to Neuroimaging in Genetic 
Generalised Epilepsy 
 
The importance of neuroimaging to study genetic generalised epilepsy has been fully 
recognised (Anderson and Hamandi, 2011; Richardson, 2012) given the progress made 
over the last 20 years in the imaging of the brain in epilepsy. Different techniques, as for 
example T1-weighted, magnetic resonance spectroscopy (MRS), single photon emission 
tomography (SPECT), positron emission tomography (PET) and functional magnetic 
resonance imaging (fMRI) have contributed to enrich with information the current status 
of knowledge of the disease (Duncan, 2005) underlying how the relationship of structure 
with function is essential in the understanding of disease aetiology, progression and 
outcome. In the clinical domain, the Neuroimaging Commission of the International 
League Against Epilepsy has developed guidelines for the implementation of MRI 
protocol in epilepsy. The rationale for imaging the brains of patients with epilepsy is 
first to identify underlying pathologies; and second to assist the formulation of 
syndrome and etiological diagnoses (Duncan, 2000). However, there are still numerous 
unknown mechanisms behind epilepsies, particularly GGE. Yet, with the advanced in 
MR methods and technology, some advanced in knowledge have been achieved. For 
example, it was long established that brains of patients with GGE do not show 
radiological abnormalities, but abnormalities in grey matter volume reduction have been 
identified with more advanced measures (Duncan, 2005). Therefore, further use of 




neuroimaging techniques will provide additional information regarding underpinning 
mechanisms in GGE. 
In the following chapter, I will focus on MRI techniques that have contributed to 
improve current knowledge in GGE, particularly emphasising those applied in this 
thesis. Those methods are T1-weighted imaging, simultaneous video-EEG-fMRI and 
arterial spin labelling. Although DTI was acquired in our MRI protocol (Chapter 3, 
Paragraph3.4), I will not cover the contribution of this MRI technique as no analysis of 
DTI data is presented in this thesis (Chapter 8, Paragraph 8.4).     
2.1 T1 weighted imaging 
A T1-weighted image is a standard MRI technique in which differences in the T1 
relaxation times of the tissues are used to create the contrast. The computer-based 
analysis of grey matter from T1-weighted MRI scans can provide estimates of local 
brain volume, shape and cortical thickness that are indicative of underlying patho-
physiological processes (Ashburner et al., 2003). For example, this technique is applied 
to reveal grey matter malformation and, or, lesions in focal epilepsy (Urbach, 2012). In 
GGE, although visual inspection of routine MRI in patients appears normal, 
neuropathological autopsy studies have provided evidence of grey and white matter 
microdysgenesis (Meencke and Janz, 1984). Therefore, quantitative analysis of 
structural MRI like T1-weighted image can elucidate subtle changes in the ratio of 
cortical and subcortical tissues, providing a means of detecting structural changes not 
normally visible using high-resolution MRI (Sisodiya et al., 1995).  




2.1.1 Quantitative measures 
Quantitative measures of high-resolution T1-weighted MRI of the human brain provide 
a powerful tool for characterizing individual differences and abnormalities in brain 
anatomy. Several methods have been developed to quantify and systematically compare 
morphological differences in grey matter brain structures.  
One of the method most commonly used is voxel-based morphometry (VBM) 
(Ashburner and Friston, 2000). Typically, VBM involves segmentation of anatomical 
MRI images into tissue types such as grey matter, white matter and cerebrospinal fluid. 
Images from each participant are then spatially warped into a common stereotactic space 
and the gross morphological differences across participants are removed. These pre-
processing procedures ensure that the original regional grey matter volume is 
maintained (Ashburner, 2007). Processed images represent regional grey/white matter 
volumes or density of each participant and are used for statistical analysis. In most VBM 
studies the quantity assessed is the local grey matter volume at individual locations 
(voxels) in the brain (Raz et al., 2005).  
Another quantitative method involves the use of an anatomical segmentation procedure 
for grey matter and statistically measure volumes of specific areas of interest. This 
method creates masks of the structures that can be additionally used to measure the 
shape of the selected grey matter structures by providing a local and direct measure of 
geometric changes (Patenaude et al., 2011). 
However, as grey matter volume is a product of thickness and surface area, differences 
in local grey matter volume can also arise from differences in cortical thickness and 
variation in surface area due to the folding pattern (Bernhardt et al., 2009). Cortical 




thickness and surface area can be independently estimated at each point on the cortical 
surface using fully automated procedures (Fischl and Dale, 2000; MacDonald et al., 
2000; Hutton et al., 2008).   
2.1.2 Grey matter changes in GGE 
T1-weighted imaging has been used to demonstrate subtle but widespread cerebral 
structural changes in patients with GGE (Woermann et al., 1998). In fact, studies in 
humans have shown compelling evidence for thalamic dysfunction and structural 
abnormality in GGE (Bernasconi et al., 2003; Chan et al., 2006; Pardoe et al., 2008) in 
which a reduction of the grey matter volume in thalamus, putamen, caudate and globus 
pallidus was found (Seeck et al., 2005; Bernhardt et al., 2009; Du et al., 2011; Keller et 
al., 2011; Kim et al., 2013; Saini et al., 2013). VBM studies on cortical grey matter, 
however, provided conflicting results. While some reported increased grey matter in 
frontal areas (Woermann et al., 1999; Kim et al., 2007), others found decreased volumes 
in frontal, parietal, and temporal cortices (Ciumas and Savic, 2006; Tae et al., 2006; Tae 
et al., 2008; Bernhardt et al., 2009; O'Muircheartaigh et al., 2011a).  
Although current genetic evidence supporting that the same inherited factor may give 
rise to different GGE syndromes in different individuals (Kjeldsen et al., 2003; Dibbens 
et al., 2009; Helbig et al., 2009; de Kovel et al., 2010), most of the studies looked at  
heterogeneous GGE syndromes (Savic et al., 2004), therefore it is possible to speculate 
that inconsistencies in the cortical grey matter structures may underlie differences 
among syndromes. However, other factors can explain such differences. For example, 
there is evidence supporting correlations between the status of grey matter and disease 
durations (Bernhardt et al., 2009; Kim et al., 2013; Saini et al., 2013). Variability in this 




parameter may lead to inconsistent results. Moreover, the effects of antiepileptic drug 
effects on brain atrophy are unclear. Some studies have indicated that antiepileptic drugs 
can influence nerve morphology, causing changes such as pseudoatrophy of the brain 
(Papazian et al., 1995; Guerrini et al., 1998a) or neurogenesis (Hao et al., 2004). 
Therefore, given that in the majority of cases, patients had taken multiple antiepileptic 
drugs for several years before participating in these studies, medication effects need to 
be considered in the interpretation of the results together with disease duration. 
To date, the effects of disease duration and AEDs on structural changes in the brain have 
been explored in just two studies. Pulsipher et al. (2001) measured prospective changes 
in the grey matter volumes in a group of CAE, JAE and JME (together and separated) 
longitudinally from maximum to 12 months after the diagnoses and to 24 months after 
the diagnoses for the follow-up. Therefore, for the first time, the experimental design 
was built to look at prospective rather than retrospective changes in grey matter 
volumes, and different and homogenous syndromes were considered. However, the 
effect of AED was not fully controlled as patients were already taking AEDs. Their 
contribution is still valuable as they found no differences between syndromes in grey 
matter volumes, but rather consistent changes compared to controls, suggesting 
commonalities across syndromes. Also, they reported a smaller thalamic volume at 
follow-up but not at baseline and no differences in the frontal lobe volumes suggesting 
that effects of disease durations were most prominent in subcortical areas (Pulsipher et 
al., 2011). Only recently, one study examined grey matter volume in a group of drug 
naïve CAE finding differences in bilateral thalami before starting treatment (Wang et al., 
2016) providing evidence that these structures may show abnormalities independently of 




AED. However, this study does not provide proof of prospective changes to AED 
intake.  
The next step is to build a study using the prospective approach as Pulsipher et al. 
(2011) possibly enlarging the group to other GGE syndromes but using drug naïve 
patients as in Wang et al. (2016). This will be useful to verify previous results and 
achieve the gold standard for longitudinal comparisons. Indeed, this was one drive for 
the foundation of the studies I present in the following thesis. 
Overall, to date, the findings all suggests abnormalities in cortico-thalamic structures 
underlying GGE.  
2.2 Simultaneous video EEG-fMRI 
Simultaneous video EEG-fMRI is a neuroimaging technique that combines the 
recording of electroencephalography with functional MRI.   
Since its invention (Ogawa and Lee, 1990; Ogawa et al., 1990b; Ogawa et al., 1990a; 
Kwong, 2012), fMRI has been used to map physiological and pathological BOLD 
networks during task-based experiments (Cabeza and Nyberg, 2000; Richardson et al., 
2006; Price, 2010; Bonelli et al., 2011) and in the resting state (Biswal et al., 1995; Fox 
and Raichle, 2007).  
Functional MRI has a good spatial resolution (millimetres) but low temporal resolution 
(seconds); particularly when compared to the timescale of epileptic activity which is 
typically occurring in the range of milliseconds. On the other hand, EEG has good 
temporal resolution (milliseconds) but low spatial resolution (centimetres). Therefore, 
the combination of the two techniques has allowed the acquisition of data that has high 




spatial-temporal resolution. This technique has been used, and was initially developed to 
map haemodynamic changes related to epileptic event (Ives et al., 1993; Lemieux et al., 
2001). Indeed, the application of EEG-fMRI to study both focal and generalised 
epilepsies is well established (Rosenkranz and Lemieux, 2010; Gotman and Pittau, 
2011; Centeno and Carmichael, 2014). In focal epilepsy EEG-fMRI is typically used to 
map the irritative zone which is often similar to the seizure onset zone and so can 
improve the localisation of epilepsy foci (Salek-Haddadi et al., 2006; van Houdt et al., 
2013; Centeno et al., 2016). In generalised epilepsy EEG-fMRI has been used to identify 
the brain networks that are related to GSW in humans (Gotman et al., 2005; Hamandi et 
al., 2006; Kay and Szaflarski, 2014).  
In the following paragraphs I will separately describe both EEG and fMRI techniques 
before moving on to examine the potential gain in information when the simultaneous 
combination of the techniques is used to perform what is termed EEG-fMRI. I will then 
explain how the two signals can be related to each other with a focus on epilepsy.    
2.2.1 Electroencephalography recording 
Neurons are excitable cells with characteristic intrinsic electrical properties, and their 
activity produces electrical and magnetic fields. The EEG signals consist of the summed 
electrical activities of populations of neurons. These fields are recorded by means of 
electrodes at a long distance from the source (usually at the scalp) using EEG 
(Speckmann, 2005). 
We have two types of neuronal activation. The first is the fast depolarisation and 
repolarisation of neuronal membranes, known as an action potential which is mediated 




by the sodium and potassium voltage-dependent channels. The action potential in a 
neuron is propagated along axons and dendrites, with no propagation to the extra-
cellular space. The second kind of neuronal current is a post-synaptic potential (PSP) 
and it is related to slow changes (from 15 to more than 200 ms) in membrane potential 
due to synaptic activity. PSPs may be excitatory (EPSP) or inhibitory (IPSP) potentials. 
At the level of synapses, in the case of ESPS, the transmembrane current is carried by 
positive sodium (Na+) ions inwards. In the occurrence of IPSP, negative ions such as 
chlorine (Cl¯) are carried inwards and positive ions as potassium (K+) outwards. Thus, 
the positive electric current is directed to the extracellular medium in the case of an 
EPSP and is directed from the inside of the neuron to the extracellular medium in the 
case of IPSP (Lopes da Silva, 2010). The two mechanisms are connected as action 
potentials occur when the neuronal membrane is depolarised beyond a critical level and 
by depolarising and inducing the same sequence of events in neighbouring membrane, 
the action potential travels from the axon to the dendrite terminal where the 
depolarisation releases neurotransmitter from the cell causing the EPSP or IPSP in other 
neurons (Lopes da Silva, 2005; Speckmann, 2005).   
The electrical signals recorded by scalp EEG are the weighted sum of EPSP and IPSP 
predominantly from the vertically oriented pyramidal cells in the cortex (Lopes da Silva, 
2005; Olejniczak, 2006). Indeed, a PSP can sum into an effective current source due to 
the particular geometry and organisation of cortical pyramidal cells which are arranged 
parallel to each other, with apical dendrites on one side and soma on the other making 
these neurons able to receive similar input and response to it with potential changes that 
produce electrical currents. Due to the head tissue conductor properties, this current 




source can be large enough to be remotely recorded by scalp EEG (Niedermeyer, 2005; 
Speckmann, 2005). For example, IEDs recorded on the human scalp using EEG 
represent synchronised cortical activity from 6-10 cm2 area of brain (Tao et al., 2005; 
Ray et al., 2007).  
Different distributions of intracerebral sources can result in the same distribution of 
electrical potentials recorded by the scalp EEG. This is called the inverse problem and it 
has no unique solution (Lopes da Silva, 2005). Although, currently, there are methods 
that are attempting to solve the problem by making prior assumptions on the number, 
geometry, and/or location of the current sources (Lopes da Silva, 2005; Yao and 
Dewald, 2005), fundamental uncertainty on the origin of the measured signals is 
introduced (Yao and Dewald, 2005). This and the need of large cortical generators to 
allow the signal to be detected from the scalp are the main sources of the limited spatial 
resolution intrinsic to EEG.   
2.2.2 fMRI and the BOLD response 
During information processing, there is an increase of neuronal activity in parts of the 
brain allocated for a specific function. This increase in neuronal activity elicits an 
increase in oxygen and glucose consumption supplied by the vascular system, as a 
result, the ratio of diamagnetic oxy-haemoglobin to paramagnetic deoxy-haemoglobin 
changes. The MRI signal recorded in functional imaging measures changes in this 
microvasculature oxygenation level non-invasively over the entire brain. The 
relationship between venous oxygenation and the MR signal strength corresponds to 




images called Blood Oxygenation Level Dependent (BOLD) images (Ogawa and Lee, 
1990; Ogawa et al., 1990a).  
The standard time course of the BOLD signal response to a stimulus has been well 
described and it defines the poor temporal resolution of fMRI. It has been reported that 
the BOLD signal starts with an initial dip (although this is not always found) and 
increases about 2s after the neural activity; it then reaches a plateau at about 5-6s post-
stimulus. Once the neural activity stops, the signal returns to baseline by around 8s post-
stimulus and a transient change referred to as the undershoot then occurs around 8-12s 
and resolves approximately 20-30s post stimulus (Logothetis et al., 1999). This time 
course shape has been called the canonical haemodynamic response function (HRF) 
(Glover, 1999) and can be thought of as the transfer function between neural input and 
fMRI signal changes.  
Physiological correlates to the HRF have been shown. For example, the initial dip in the 
signal is attributed to the rapid increase in deoxy-haemoglobin (Malonek and Grinvald, 
1996; Zhong et al., 1998), although there are controversial findings regarding this initial 
change (Hu and Yacoub, 2012). The increase in BOLD signal reflects increased blood 
flow overcompensation for the decreased oxygen due to the oversupply of oxygenated 
blood. The under shoot reflects changes in blood volume and the decrease in BOLD 
signal from peak maybe also be reflecting neuronal inhibition (Logothetis et al., 1999; 
Logothetis et al., 2001; Logothetis and Pfeuffer, 2004; Logothetis and Wandell, 2004).  
However, variance of the BOLD response has been observed between subjects and 
across different brain regions (Aguirre et al., 1998; Buckner, 1998). This has led to 
revisiting the exclusive use of a standard and completely fixed HRF in fMRI models 




where more flexible shapes of the BOLD response have been used instead (Dale and 
Buckner, 1997; Josephs et al., 1997; Friston et al., 1998; Bagshaw et al., 2004). This is 
the case of fMRI studies using pathological features where the effect of interest to be 
modelled is treated as if it was a ‘stimulus’, such as epileptic EEG features in epilepsy 
studies (Jacobs et al., 2008; Storti et al., 2013). This is particularly relevant for the 
analysis presented in the following chapters where we used a more flexible model of 
BOLD responses as introduced in Chapter 5, Paragraph 5.2.4. This is consistent with a 
reduced certainty regarding the nature of the responses to epileptic events.   
2.2.3 BOLD effect and neuronal activity 
Over the last decade, efforts have been made to understand the exact relationship 
between the haemodynamic changes recorded with fMRI and the neuronal activity 
recorded with EEG. It has been found that the BOLD signal reflects the firing of neural 
populations as a correlation exists between the BOLD amplitude and Multi Unit Activity 
(MUA)
1
; however the strongest correlate was the local field potential (LFP)
2
 data in 
anesthetised (Logothetis et al., 2001) and awake (Goense and Logothetis, 2008) 
monkeys.  
The contribution of LFP activity to the BOLD signal has also been supported by 
autoradiography studies of the energy consumption underlying neuronal signals 
(Jueptner and Weiller, 1995). As for example, measures of the energy budgets required 
                                                 
1
 MUA reflects the weighted sum of the output signal of a neuronal population within a radius of 50-350 
microns (Legatt AD, Arezzo J, Vaughan HG (1980) Averaged Multiple Unit-Activity as an Estimate of 
Phasic Changes in Local Neuronal-Activity - Effects of Volume-Conducted Potentials. Journal of 
neuroscience methods 2:203-217.). 
2
 “The local field potential is the extracellular current flow that reflects […] the linearly summed 
postsynaptic potentials from local cell groups” (Buzsaki G (2004) Large-scale recording of neuronal 
ensembles. Nat Neurosci 7:446-451.)  




for different processes have shown that post-synaptic effects of glutamatergic neurons 
(glutamate recycling) accounts for 74% of the brain energy consumption (Attwell and 
Laughlin, 2001; Lennie, 2003).  
The sustained BOLD increases (Logothetis and Wandell, 2004) and decreases (Shmuel 
et al., 2002) for a particular stimulus or task can be conceptualised to reflect a balance 
between local neuronal excitation and inhibition (Lauritzen, 2005). Although there are 
still uncertainty regarding the relationship between direct and indirect inhibitory activity 
and changes in metabolic energy consumption (Logothetis, 2008), there is evidence 
supporting that increases in synaptic inhibition is likely to reflect decreased BOLD 
response (Logothetis, 2008) and that negative BOLD response seems to reflect neural 
activity decreases (Shmuel et al., 2006; Devor et al., 2007).  
Accordingly, data in humans suggest that in conditions where mainly inhibitory circuits 
are involved, inhibition and negative BOLD responses could be detected (Shmuel et al., 
2002; Stefanovic et al., 2004; Pasley et al., 2007). Current understanding is thus that 
synaptic activity related to PSP leads to observe a positive BOLD response; but a 
decrease in the same neural activity leads to a negative BOLD response (Shmuel et al., 
2002; Shmuel et al., 2006; Devor et al., 2007; Carmichael et al., 2008). 
From current evidence, it is clear that there is a strong coupling between the 
haemodynamic changes and neuronal signals (Logothetis and Pfeuffer, 2004) during 
visual and or motor tasks (Shmuel et al., 2002; Stefanovic et al., 2004). In particular, the 
coupling was not seemingly altered during neurological activity such as epileptic 
activity (Stefanovic et al., 2005; Carmichael et al., 2008).  




2.2.4 Recording EEG inside MRI scanner 
Combining EEG and MRI together raises challenges for EEG data quality and patient 
safety. Following well-established set-up procedure of the EEG in the MR environment, 
both EEG quality and patients’ safety can be ensured.  
2.2.4.1 Safety and data quality considerations 
Scalp EEG recording inside the scanner requires the electrodes and leads to be placed 
within the imaging field of view (FOV) which can result in possible interactions 
between the magnetic fields of the scanner and metal electrodes. The main sources of 
artefact on EEG recorded inside the scanner are the strong static magnetic field, 
switching magnetic fields gradient, electrical and magnetic components of radio 
frequency (RF) pulses, cardiac pulse-related and head and body movements within the 
static magnetic field. Any change in magnetic flux over time through a conducting 
medium (loop, surface, volume) can produce an induced current. This change in 
magnetic flux and the induced current can be caused by movement (i.e. change of 
position, orientation or shape) of the conducting medium in a magnetic field or due to a 
change in the magnetic field to which the conducting medium is exposed (i.e. MRI 
gradient switching and RF pulses). This can cause additional health hazards and EEG 
quality degradation in the form of EEG artefacts related to image acquisition (Lemieux 
et al., 1997; Goldman et al., 2000; Konings et al., 2000; Krakow et al., 2000a; Krakow 
et al., 2000b; Lemieux et al., 2001; Benar et al., 2003; Laufs et al., 2008).  
An important safety consideration to reduce the risk of heating is to limit the RF power 
exposure. This can be done by only using low RF power MRI sequences when the EEG 
cap is used. To avoid RF antenna effects, the length of wires (exposed to the electrical 




component of the field) has to be as short as possible and their path avoids regions of 
high electric RF field. (Lemieux et al., 1997; Goldman et al., 2000; Konings et al., 2000; 
Krakow et al., 2000a; Krakow et al., 2000b; Lemieux et al., 2001; Benar et al., 2003; 
Laufs et al., 2008).  
Current commercially available MR-compatible EEG system, as used by most of the 
EEG-fMRI studies in epilepsy to date (i.e. http://www.brainproducts.com) (Hamandi et 
al., 2006; Laufs et al., 2006; Moeller et al., 2008a; Gotman and Pittau, 2011; Centeno et 
al., 2016), provides customised electrode caps. In this MR-compatible scalp EEG 
system, an extra 10 kΩ current-limiting resistor is used in each electrode lead and 
electrode leads are twisted in a bundle which has been designed to reduce the possibility 
of forming large loops between subject’s head, electrode, electrode lead and EEG 
amplifier. This is aimed at preventing health hazards from induced currents in the loops 
causing heating of EEG components in contact with the subject.  
Additional safety guidelines are provided, as for example, regarding EEG cap 
preparation. Indeed, it is recommended to have low impedance (≤10 kΩ) to guarantee 
good safety and artefact characteristics. The amount of conductive agent between 
electrodes and scalp should be minimised to avoid forming bridges between electrodes 
and the wires connecting the cap to the EEG recording system needs to be secured in 
place by sand bag to avoid vibration and or formation of loops (Lemieux et al., 1997; 
Laufs et al., 2008). 
2.2.4.2 EEG-fMRI setup 
The signal recorded by EEG electrodes is relayed to the EEG recording amplifier 
through wires. Currently, with the availability of MR-compatible equipment, the EEG 




signals are amplified and digitised within the scanner room using MR-compatible 
amplifiers and passed to the recording equipment, outside of the electro-magnetically 
shielded room, through optical fibres. In the recording suite, the EEG clock is 
synchronised with the MRI clock to allow perfect simultaneous recording and to 
improve scanner artefact removal from EEG (Mandelkow et al., 2006; Laufs et al., 
2008).  
2.2.5 EEG-fMRI networks in GGE 
The first study by Salek-Haddadi and colleagues (Salek-Haddadi et al., 2003) using 
simultaneous EEG-fMRI has described two patterns of BOLD changes during absence 
seizures in a single patient: BOLD increases bilaterally in thalamic nuclei, and 
widespread and symmetrical decreases in the cortex, maximum in the frontal lobes. 
Subsequently, group studies of GGE patients (Aghakhani et al., 2004; Gotman et al., 
2005; Hamandi et al., 2006; Moeller et al., 2010a) also revealed common patterns of 
BOLD decrease in the frontal and parietal cortices, posterior cingulate and precuneus, 
and predominant BOLD increase in the thalamus and medial frontal region. 
2.2.5.1 GSW-related brain networks significance 
Areas involved in GSW related cortical BOLD decrease resemble the default mode 
network (DMN) which is found active in healthy control during rest (Raichle et al., 
2001). It can be argued that the BOLD signal decreases in these areas, in relation to 
GSW, represents the physiologic suspension of conscious rest or an fMRI signature of 
the negative clinical phenomenology of absences during which cognitive processes may 
be impaired (Laufs et al., 2006). However, another valid argument refers to the idea that 




DMN deactivation is an epiphenomenon related to the brain state during the recording 
rather than strictly related to GGE (Archer et al., 2003; Aghakhani et al., 2004; Gotman 
et al., 2005). Current evidence is lacking to determine which potential explanation is 
correct; Chapter 6 explores this issue further.  
Further evidence regarding the direct involvement of the thalamic-cortical network in 
GGE comes from animal models (Danober et al., 1998) and studies in humans using 
other technique such as transcranial Doppler, H2(15)O PET (Prevett et al., 1995; Diehl 
et al., 1998) and invasive recordings (Avoli and Kostopoulos, 1982; Avoli et al., 2001).  
To summarise, although there are still open questions regarding the direct role of DMN 
in GGE, it has been proven that the cortico-subcortical/striato-cortico-thalamic network 
is associated to GSW in patients with GGE. 
2.2.5.2 GSW duration effect and BOLD signal 
Although GSW have stereotypical features of 3Hz frequency discharges, their durations 
vary across events. Evidence showed that BOLD changes were in the same brain areas 
for shorter (< 3s) and longer (> 3s) bursts of GSW in 3/4 cases and one case did not 
reveal any BOLD changes for shorter discharges but diffuse response for long bursts 
(Aghakhani et al., 2004). On the contrary, it has been discussed that BOLD changes 
were of greater magnitude (Carney et al., 2010) and more frequent in the thalamus 
(Hamandi et al., 2006; Li et al., 2009) when GSW were of longer duration (suggesting 
the presence of seizures) and higher in number. This may be explained by a simple 
signal to noise ratio phenomena or may reflect the role of thalamus in maintaining the 
GSW (Avoli et al., 2001) for longer duration discharges which is reflected in stronger 
thalamus BOLD changes. A recent study reported a linear relationship between GSW 




duration and BOLD response identifying that a larger amplitude BOLD response was 
associated with longer GSW. However, the same thalamic-cortical and DMN were 
found associated with short and long GSW across different GGE syndromes (Pugnaghi 
et al., 2014). Given that this relationship was found significant with GSW of a range 
duration of 0-5.2s and that the conventional and pragmatic definition of the interictal 
state required the presence of GSW < 3s (Goode et al., 1970), these results provide 
evidence for the involvement of the same brain networks during ictal and interictal 
states in GGE.      
2.2.5.3 BOLD changes before GSW onset 
Recent studies tried to evaluate the dynamics of GGE to understand if there is a 
signature prior to GSW events that might elucidate the mechanisms of seizures 
generation and transition between inter-ictal and ictal states (Petkov et al., 2014; 
Schmidt et al., 2014). Animal models of absence seizures reported BOLD changes prior 
to GSW onset showing changes in concentration of oxy/deoxy-haemoglobin (Roche-
Labarbe et al., 2010). Invasive recordings in rats also identified that low frequency 
activity in the delta range was predictive of GSW onset. This activity was measured first 
in the cortex and next from the thalamus (van Luijtelaar et al., 2016).  
GLM based data analysis of EEG-fMRI have also evaluated the presence of activity 
prior to the electrophysiological onset of GSW and earlier studies found that BOLD 
increases peaked earlier than BOLD decreases (Aghakhani et al., 2004; Moeller et al., 
2008a; Bai et al., 2010). Different results have been presented by different studies in 
which both positive and negative responses were reported in the same brain areas. In 
fact, by modelling the HRF before the EEG onset of GSW in the GLM framework 




(Moeller et al., 2008b) the temporal pattern of BOLD changes was different from a 
canonical response. By investigating the mean time course of GSW-related 
haemodynamic changes, it was shown that BOLD increased in the thalamus (Moeller et 
al., 2008b), parietal cortex and precuneus (Carney et al., 2010) before GSW onset. In 
contrast, the thalamus was mostly found activated at GSW onset only (Carney et al., 
2010; Kay and Szaflarski, 2014) and the BOLD changes in various anatomical areas 
such as thalamus, cortex and caudate, were dynamic (evolving at different time points) 
throughout the duration of absence seizure rather than static (Moeller et al., 2010b). 
BOLD increases in frontal cortex preceding GSW onset and followed by BOLD 
decreases in the same areas lasting after GSW have also been reported (Bai et al., 2010). 
This is important because it suggests that BOLD responses to GSW are not canonical 
and that they may precede EEG changes which suggest there is a hemodynamic 
signature of the transition to the GSW before they occur electrographically. Further 
discussion on this issue is presented in Chapter 5. 
The inconsistency of the temporal evolution of GSW related BOLD changes in GGE 
may result from variable modelling strategies applied (Moeller et al., 2008b; Bai et al., 
2010), different types of epileptic discharges (polyspikes and waves and GSW) (Pillay 
et al., 2013), biological differences between adults (Benuzzi et al., 2012) and children 
(Moeller et al., 2008b), genetic and phenotypic heterogeneity of individuals (Bai et al., 
2010; Carney et al., 2010), and of our main interest, treatment outcome (Szaflarski et al., 
2010) and treatment intake (Szaflarski et al., 2013).  
Although more studies need to be conducted to resolve the inconsistency across the 
results presented, evidence reporting focal BOLD increases in cortex prior to GSW 




electrophysiological onset (Bai et al., 2010; Carney et al., 2010; Benuzzi et al., 2012) is 
consistent with the theory that seizures in GGE have a focal cortical initiation (Koepp, 
2005; Meeren et al., 2005; Vaudano et al., 2009; Westmijse et al., 2009; van Luijtelaar 
et al., 2014) which would, if true, challenge the current approach to classification of 
epilepsy. 
2.3 Arterial Spin Labelling for pharmacological studies 
Arterial spin labelling (ASL) is a perfusion MRI sequence that uses radiofrequency 
pulses to magnetically label the water molecules in the subject’s own arterial blood, 
usually at the base of the brain. The magnetically labelled blood water is then used as an 
endogenous tracer for the measurement of CBF, which has a half-life (determined by 
blood T1), on the order of 1s to 2s. The effects of ASL are measured by comparing 
images acquired with active or control labelling, and this signal difference is used to 
non-invasively quantify CBF (Buxton et al., 1998b; Buxton et al., 1998a).  
In focal epilepsy, the use of ASL has been limited to identifying seizure onset zone 
(Pizzini et al., 2008; Storti et al., 2014), and in studying metabolic abnormalities related 
to interictal activity (Wolf et al., 2001; Lim et al., 2008; Pizzini et al., 2013).  
In GGE, ASL was implemented in combination with simultaneous EEG-fMRI to 
examine the relationship between CBF and BOLD measurements in pathological 
condition. This is important for interpreting studies using fMRI given the interconnected 
relationship between neuronal activity and oxygenation, the basis of the BOLD signal 
(Ogawa et al., 1990b; Hoge et al., 1999; Stefanovic et al., 2005). A positive correlation 
between BOLD changes and CBF irrespective of the sign of BOLD change was 




reported. Particularly, this association was found to be stronger during GSW than during 
background activity suggesting preserved (i.e. within normal limits) neurovascular 
coupling (Carmichael et al., 2008; Hamandi et al., 2008). 
However, all these analyses were performed in patients under the influence of AEDs. 
Given the alteration in CBF after drug intake (Bartenstein et al., 1991; Gaillard et al., 
1996; Spanaki et al., 1999; Joo et al., 2006), further analysis needs to disentangle the 
association between CBF alteration, BOLD response alteration and AED effects. 
Because of the lack of absolute quantification and poor reproducibility over time scales 
longer than hours or across scanning sessions, BOLD fMRI may not be suitable to track 
long-term drug effects on baseline brain function. An alternative and non-invasive 
method is therefore ASL which provides absolute quantification of cerebral blood flow 
both at rest and during task activation. ASL perfusion measurements have been shown 
to be highly reproducible over minutes and hours to days and weeks. These two 
characteristics make ASL an ideal tool in pharmaco-MRI for studying both intravenous 
and oral drug action as well as understanding drug effects on baseline brain function and 
brain activation. When ASL is combined with BOLD fMRI, drug-induced changes in 
cerebral metabolic rate of oxygen can also be inferred (Wang et al., 2011).   
2.4 Anti-epileptic medication effect 
All the studies presented in the previous paragraphs included patients who were already 
taking antiepileptic medication (monotherapy and/or polytherapy) for various lengths of 
time. Treatment outcome was mostly unknown or unreported.   




There is no clear understanding of the effects that AEDs have on the measures of the 
brain we are acquiring with neuroimaging techniques. There is evidence supporting 
differences in BOLD signals in patients responding and not responding to VPA 
(Szaflarski et al., 2013) but the effects that VPA has on cortical excitability is still 
unclear (Reutens et al., 1993; Cantello et al., 2006). Further evidence has indicated that 
antiepileptic drugs can influence nerve morphology, causing changes such as pseudo-
atrophy of the brain (Papazian et al., 1995) or neurogenesis (Hao et al., 2004). Alteration 
in CBF after drug intake has been reported (Bartenstein et al., 1991; Gaillard et al., 
1996; Spanaki et al., 1999; Joo et al., 2006) supporting that an alteration of neuronal 
functioning related to AEDs might influence BOLD findings.  
There are numerous studies recording cortical excitability with TMS in patients who 
were naïve to AEDs (Cantello et al., 2006; Badawy et al., 2007; Joo et al., 2008b; 
Badawy et al., 2009; Badawy et al., 2010). They reported that cortical excitability is 
reduced after the administration of AED (Joo et al., 2008b) only in patients responding 
to treatment but not in those who are not responding (Badawy et al., 2010) casting light 
on possible treatment outcome measures and measures which relate to AED exposure.  
The field of neuroimaging lacks this information despite the importance of AED effects 
measure to understand the origin, the evolution and potential treatment outcome of the 
disease. To my knowledge, only two studies used EEG-fMRI to investigate GSW 
related BOLD response in drug naïve patients (Moeller et al., 2008a; Li et al., 2009), 
two studies recorded MEG data (Tenney et al., 2013; Miao et al., 2014), one study 
measured regional cerebral blood flow with SPECT (Joo et al., 2008a), one study looked 




at white matter integrity (Yang et al., 2012) and one explored grey matter volume 
(Wang et al., 2016).  
Although their results reported an involvement of thalamic-cortical areas (in agreement 
with the findings reported in treated patients), the number of studies and especially the 
number of patients reported in each study are too small to allow definitive conclusions. 
Moreover, no follow-up comparisons were made to relate findings to treatment 
outcome. 
The work presented in the following chapters was conceived to address this need of 
providing measures from drug naïve patients in which there is no AED effects and 
prospective longitudinal outcome information.  
2.5 Data quality 
Combined multimodal measurement is generally prone to data quality degradation due 
to interactions between the recording instruments such as EEG and fMRI. Here, I 
discuss these issues in some detail. 
2.5.1 EEG-fMRI specific artefacts 
EEG recordings inside an MRI scanner are obscured by gradient artefact (GA) and pulse 
artefact (PA) or ballistocardiographic (BCG). The GA is produced by the rapidly 
changing magnetic field used for fMRI acquisition and is superimposed on the EEG 
signal making it uninterpretable (Allen et al., 2000). Current equipment with sufficient 
bandwidth, sampling rate (1-20 KHz) and dynamic range (~20 mV) can capture the 
artefact in detail, allowing its removal, and significantly improve the quality of EEG 
recorded inside the scanner (Laufs et al., 2008; Mulert, 2010). 




Different methods are available for GA correction: frequency domain method 
(Hoffmann et al., 2000), average image artefact subtraction, average image artefact 
subtraction and adaptive noise cancellation (Allen et al., 2000) and principal component 
analysis (PCA) (Negishi et al., 2004; Niazy et al., 2005). To date the most commonly 
used method is average image artefact subtraction and adaptive noise cancellation 
(Allen et al., 2000), which is used both for online and off-line EEG artefact removal. 
This works on the basis of the principle that physiological signals and the GA are not 
correlated and the gap between acquired volumes and slices and the pattern of the GA 
remains stable. As a result, the GA is estimated and removed by averaging the EEG over 
a number of epochs corresponding to individual volume (Allen et al., 2000) or slice 
(Niazy 2005) repetitions. 
BCG artefact results from the pulsatile movement of the head and scalp due to blood 
vessel expansion in relation to the cardiac cycle which results in induced voltages 
(artefacts) in the EEG recording circuit (Debener et al., 2008), head rotation originating 
from blood momentum transfer into axial body motion (Bonmassar et al., 2002), and 
Hall
3
 voltages arising from the flow of conductive blood in the magnetic field (Yan et 
al., 2010). BCG artefact may make the identification of epileptic events difficult in some 
patients, especially for focal discharges. Here again methods based on the average 
artefact subtraction principle (Allen et al., 1998) are the most commonly applied 
technique for removing the BCG artefact. Other methods include applying adaptive 
                                                 
3
 When an electric current flows through a conductor in a magnetic field, the magnetic field exerts a 
transverse force on the moving charge carriers which tends to push them to one side of the conductor. A 
build-up of charge at the sides of the conductors will balance this magnetic influence, producing a 
measurable voltage between the two sides of the conductor. The presence of this measurable transverse 
voltage is called the Hall effect after E. H. Hall (Hall EH (1879) On a new action of the magnetic on 
electric currents. Am J Math 2:287-292. 




filtering (Bonmassar et al., 2002), weighted average subtraction (Goldman et al., 2000), 
median filter template (Ellingson et al., 2004) or independent component analysis (ICA) 
(Srivastava et al., 2005). All these methods have been validated in a number of studies 
and provide adequate solutions although methods to improve the quality of EEG inside 
the scanner are under continuous development (LeVan et al., 2013; Maziero et al., 
2016). Despite these improvements, it is a common view that a certain degree of loss of 
EEG data quality cannot be avoided (Debener et al., 2007; Debener and Herrmann, 
2008; Debener et al., 2008). 
2.5.2 Motion artefacts 
The imaging sequence mostly used for simultaneous EEG-fMRI is gradient echo-planar 
imaging (EPI) which is prone to distortion and local signal dropout (Krakow et al., 
2000b). Artefacts produced in the imaging data due to electromagnetic interference can 
be minimised by proper selection, design and placement of EEG recording equipment as 
introduced in Paragraph 2.2.4.  
However, head motion is unavoidable, especially in paediatric population (i.e. drug 
naïve CAE), together with intrinsic pulse and respiration related motion artefacts. 
Methods to reduce and correct for this are needed. Currently, one practical way to 
diminish head motion is the usage of vacuum cushion that braces the head limiting 
motions.  
The effect of motion on fMRI is tackled using available off-line motion correction 
methods. One of the most commonly used is implemented in the SPM framework and 
calculates rigid-body realignment of the image data and provides motion-related 




nuisance regressors that are included as nuisance covariates in GLM analyses (Friston et 
al., 1996; Ashburner J, 2012a). From this method, other nuisance regressors have been 
implemented to improve motion and physiological artefact suppression. For example, a 
vector with values of volumes with gross movements that are discarded from the 
analysis (Lemieux et al., 2007; Power et al., 2012) and extra physiological noise 
regressors (Chaudhary et al., 2012a). However, these approaches required the inclusion 
of several numbers of regressors and while extra explanatory regressors can increase 
specificity, it should be noted that they can also dramatically reduce sensitivity by 
reducing the amount of degrees of freedom (Friston et al., 1999). Therefore, another 
method that creates a mask of the total displacement (motion fingerprint) at each voxel 
per subject and generates a synthetic time series individually for each subject was 
implemented (Wilke, 2012) to try to ameliorate the statistical power for single-subject 
and group analyses. However, these methods rely on the realignment for providing 
motion measurements which have been shown to be a poor representation of subject 
movement in some circumstances (Beall and Lowe, 2014). 
In addition, in common across all these methods is the focus on global corrections which 
leads to the assumption that any motion/noise would affect the whole brain. Therefore, 
in the case of data scrubbing, this would mean for example the removal of 35%-39% of 
the total amount of volumes acquired when scanning a paediatric population (Power et 
al., 2012). Given that it has been proven that local changes in the data would not affect 
the entire volume (Tierney et al., 2016), a new method for noise correction that corrects 
local changes called FIACH will be applied in this thesis. It is a newly implemented 
prospective and automated motion and physiological-noise correction method designed 




for paediatric population but applicable to adult populations. This method provides a 
local assessment and correction of non-physiological fMRI signal changes and a 
parsimonious model of noise (e.g. motion, cardiac and respiration changes) from the 
data. The advantages of this approach are the ability to correct local changes due to fast 
motion, discarding only the noisy data-point via the interpolation of the nearest noise-
free corresponding data and a model of physiological noise and motion which does not 
dramatically alter the degrees of freedom. These have been proven to increase statistical 
power during movement in particular recovering changes in problematic areas for fMRI 
such as temporal poles and the hippocampus (Tierney et al., 2016).  
Motion artefact affects structural imaging as well, provoking misclassification of tissues 
and preventing from correct segmentation of the structures. This leads to reduced 
volume or cortical thickness estimates and reduce reliability (Reuter et al., 2015). To 
date, the most common approach applied in the literature is the visual inspection of the 
MR images and consequent qualitative assessment of the image. If corrupted, then the 
data are removed from the analysis.    
2.6 General consideration 
It is evident, from previous paragraphs, that we have reached an advanced stage in using 
neuroimaging to study GGE. However, there are some gaps in our knowledge that need 
to be addressed to reach a more comprehensive understanding of GGE. In this thesis I 
will be focussing on three.  
I am particularly interested in AED effects. By imaging the brain of newly diagnosed 
and AED free patients, previous findings can be interpreted without the potential 




influence of AEDs and cement the current knowledge. Therefore, I will answer the 
question: do the neuroimaging results in drug naïve patients replicate those reported in 
patients on treatment?  
I will explore treatment effects as follow: 
 Measuring grey matter volume and shape in drug naïve patients (Chapter 4). 
 Measuring BOLD changes related to GSW in drug naïve patients at GSW onset 
and pre-GSW. This will explore not only spatial EEG-fMRI models but it will 
add knowledge regarding temporal aspects of the signal changes to examine 
evidence for the focal onset theory and a pre-ictal state (Chapter 5).   
Secondly, there is a missing prospective approach. Most of the treatment outcome and 
disease duration effect evidence is from retrospective data. By following patients 
longitudinally from pre-treatment to post-treatment we aim to answer questions related 
to treatment response and find markers of treatment outcome prior to treatment in the 
long-term.   
I will apply a prospective/longitudinal approach as follow: 
 Grey matter volume and shape will be compared between drug naïve pre-
treatment and post-treatment and between drug naïve responding and not 
responding patients to identify baseline differences following treatment 
outcome (Chapter 4). 
 Global CBF will be measured before treatment intake and after treatment intake 
to identify changes that may be linked with BOLD changes post-treatment 
(Chapter 7).  




Thirdly, I am interested in disentangling the relationship between brain networks related 
with GSW and brain state given that most of the current studies performed EEG-fMRI 
during resting state. Therefore I will answer these questions: What is the relationship 
with GSW related brain network in a situation different from rest? And, what is the role 
of the DMN? 
I will then explore the effect of brain state as follow: 
 BOLD response of GSW recorded during period of rest and during a low 
demand task will be compared (Chapter 6).  
2.7 Conclusion 
The state of knowledge in GGE is advanced, however multimodal imaging needs to 
provide missing and complementary knowledge regarding treatment effects in GGE via 
the study of drug naïve patients. Longitudinal follow-up of these patients will contribute 
in exploring how baseline measures pre-treatment can disentangle possible treatment 
outcome measures. Functional brain states different from rest will also help in 
understanding roles of GSW related brain networks. In the following chapters I present 
work that I have performed to explore this. I will present results from the data I have 
obtained in drug naïve patients newly diagnosed with CAE, JAE, GTCSO and JME and 




SECTION 2: GENERAL METHODS 
Chapter 3 : METHODS 
In this chapter I describe the experimental methods commonly used for the empirical 
studies I will present in chapters 4, 5, 6 and 7.  
The experimental methods were specifically designed to achieve the highest data quality 
taking into consideration a paediatric population.  
3.1 Recruitment 
The targeted population included 15 drug naïve AE patients, 15 drug naïve 
JME/GTCSO patients, 30 age matched controls, 5-10 refractory AE patients, 5-10 
refractory JME/GTCSO patients.  
Drug naïve patients’ inclusion criteria: i) diagnosis of GGE made by an epilepsy 
specialist based on clinical decision following examination; ii) normal cognitive 
development from age 6 to allow MRI scan without sedation. Exclusion criteria: i) 
history of any neurological condition other than epilepsy; ii) history of brain active drug 
intake (i.e. drug or alcohol misuse and active brain prescribed medications).  
Refractory patients’ inclusion criteria: i) diagnosis of GGE made by an epilepsy 
specialist based on clinical decision following examination; ii) on treatment for at least 1 
year and continuing to have seizures; iii) cognitive age from age 6 to allow MRI scan 
without sedation. Exclusion criteria: i) history of any neurological condition other than 
epilepsy; ii) presence of seizures occurrence as a consequence of drug/alcohol misuse 





Healthy controls inclusion criteria: i) cognitive age from age 6 to allow MRI scan 
without sedation. Exclusion criteria: i) history of brain active drug intake (i.e.: drug or 
alcohol misuse, active brain prescribed medications); ii) medical history of any 
neurological/neurodevelopmental conditions; iii) family history of epilepsy in a first 
degree relatives.   
All participants had minimum age of 5.9 years; no upper age limit was set. All 
participants were included if they did not present any contraindication of having MRI. 
Patients were identified by the treating clinicians in clinics across London (King’s 
College Hospital NHS Foundation Trust, Great Ormond Street Hospital for Children 
NHS Foundation Trust, University College London Hospitals NHS Foundations Trust, 
Barnet and Chase Farm Hospitals NHS Trust, Lewisham and Greenwich NHS Trust, 
East Kent Hospital University NHS Foundation Trust, Maidstone and Tunbridge NHS 
Trust, Barts Health NHS Trust, Guy’s and St Thomas’ NHS Foundation Trust, Croydon 
Health Service NHS Trust, Royal Free Hampstead NHS Trust) and via screening 
neurophysiological reports at King’s College Hospital and Evelina London Children 
Hospital.  
In order to study patients while drug naïve, the timing of recruitment was crucial given 
that our intervention had to fit between the first declaration of the diagnosis to 
patients/families and the start of AED. Therefore, patients were approached in different 
ways based on advice from the clinical team. Going from the least common to the 
commonest strategy: i) the clinical team contacted us with names and contact details 
after having explained the project to the patient and obtained consent from 





department. We then contacted the clinical team with names and project information and 
the clinical team discussed the project with the patient/family in clinic and obtained 
consent to be contacted by us. Following notification of the consent from the clinical 
team, we contacted the patient; iii) patient was identified by us in the EEG department. 
We then contacted the clinical team with names and we attended the clinic on the day of 
the appointment with the named patient to discuss the project directly with 
his/her/family.   
An appointment within 5 working days from the day of the diagnosis was provided to all 
the drug naïve patients to avoid treatment delay.   
Refractory patients were identified from clinic lists from King’s College Hospital 
(KCH), Evelina London Children Hospital and Great Ormond Street Hospital (GOSH). 
As this sample did not need to be scanned urgently, their study visit was arranged at a 
convenient time.  
Healthy controls from age 18 were identified using advertisement on King’s College 
London Research Volunteer Recruitment Webpage. Healthy controls from age 6 to 18 
were identified via advertisement on the Great Ormond Street Hospital webpage in 
collaboration with an ongoing project funded by Action Medical Research, led by Dr 
David Carmichael and Dr Maria Centeno. 
The study took place in two centres: King’s College Hospital and Great Ormond Street 
Hospital, London, UK. Individuals were allocated to be studied in one centre or the 
other on the basis of age and syndrome. Patients (drug naïve and refractory) with a 
diagnosis of AE and healthy controls from age 5.9 to about 14 were invited to GOSH for 





healthy controls from about age 14 were invited to come to King’s College Hospital. 
This allocation of subjects was based on child oriented facilities available at Great 
Ormond Street Hospital.  
All subjects having legal age of 18 gave informed, written consent. One parent or the 
nominated legal carer gave informed and written consent on behalf of the participant 
below the age of 18. The study was approved by the Riverside Research Ethics 
Committee (REC approval number 12/LO/2006). The study from which we shared the 
healthy control children population was approved by the London-Surrey Border 
Research Ethics Committee.  
3.2 Prospective longitudinal approach 
We designed the experiment longitudinally to allow comparisons related to AED 
changes. Drug naïve patients were invited for the first visit before starting treatment and 
for a second visit after six months since the first drug intake. The same experimental 
protocol was applied for both visits. Six months’ time for the repeated measure was 
decided accordingly as the minimum clinical time needed to judge treatment outcome. 
Throughout the manuscript, I will refer to drug naïve for scan time 1 and post-treatment 
for scan time 2. 
Healthy control and refractory subjects were studied only once as the experimental 
design was built to compare pre and post-treatment with healthy control and refractory 






We acquired data in 16 drug naïve patients diagnosed with AE and in 15 drug naïve 
patients diagnosed with JME/GTCSO (3 drug naïve of JME/GTCSO presented only 
GTCS at the drug naïve stage). For simplicity, this group will be referred as JME only 
through the thesis. The number of patients recruited was different in the AE group 
compared to the original target and to the JME group. This was due to the greater 
proportion of drug naïve patients diagnosed with AE in clinics. Most of the JME we 
encountered had a history of epilepsy in their past; therefore, they were not classified as 
drug naïve. 54.8% (17 patients) of all the drug naïve patients came back for the post-
treatment scan. Among this group, 62.5% (10 patients) were diagnosed with AE and 
46.6% (7 patients) diagnosed with JME. In regards to the patients who did not come for 
the follow-up, 64.2% (9 patients) decided not to start treatment, 7.1% (1 patient) got 
pregnant and decided to stop treatment, 21.4% (3 patients) are currently still waiting to 
start treatment due to clinical delay.  
We acquired data in 9 refractory AE patients and in 9 refractory JME patients. We 
acquired a total of 42 healthy controls, 21 children below age 18 and 21 








Table 3.1: Demographic characteristics of the sample. 






#1 M 6.03 6 / 
#2 M 14.00 5 / 
#3 M 10.51 10 / 
#4 M 6.37 6 / 
#5 M 10.58 10 / 
#6 F 13.65 13 / 
#7 M 8.03 8 / 
#8 F 7.73 7 / 
#9 M 10.28 10 / 
#10 F 9.72 9 / 
#11 F 16.18 6 / 
#12 M 7.15 7 / 
#13 M 9.26 9 / 
#14 M 5.92 5 / 
#15 M 6.84 6 / 









#5b M 11.30 unknown 








#7b M 8.54 VPA (dose 
unknown) 
#8b F 8.25 VPA 300 
mg BD 
#9b M 10.77 VPA 500 
mg 
AM+100 
mg PM  
#11b F 16.78 ETX (dose 
unknown) 
#13b M 9.78 ETX 200 
mg BD 
#14b M 6.43 VPA (dose 
unknown) 
#15b M 7.56 VPA 500 
mg + LMT 
10 mg BD 
REFRACTORY 
AE 
#17 M 8.60 4 VPA + 
ETX 
#18 F 12.33 ~6 ETX 650 
mg + TPM 
50 mg BD 
#19 M 10.45 2.5 LMT 150 
mg + LEV 
750 mg BD 
#20 M 8.34 4 VPA + 
ETX (dose 
unknown) 
#21 F 13.12 4/5 VPA 700 
mg BD 
#22 F 9.66 4.5 LMT 100 
mg AM + 
125 mg PM 
#23 F 9.93 6/7 LMT 25 mg 
BD 
#24 F 7.00 2 LMT 50 mg 






#25 M 10.98 2.5  ETX 700 
mg + CBZ 
7.5 mg BD 
CONTROL 
CHILDREN 
#26 M 14.08 
N/A N/A 
#27 F 9.72 
#28 F 13.62 
#29 F 15.59 
#30 F 18.08 
#31 M 8.34 
#32 F 16.73 
#33 F 8.32 
#34 F 9.08 
#35 M 6.61 
#36 M 12.00 
#37 F 12.14 
#38 F 9.08 
#39 M 10.32 
#40 F 8.85 
#41 M 14.20 
#42 M 7.50 
#43 F 7.23 
#44 F 14.22 





#46 F 9.58 
DRUG NAÏVE 
JME 
#47 M 21.71 21 / 
#48 M 16.75 16 / 
#49 F 16.58 16 / 
#50 F 13.64 13 / 
#51 F 20.11 20 / 
#52 M 35.98 16 / 
#53 F 15.38 15 / 
#54 F 17.69 17 / 
#55 F 26.04 26 / 
#56 M 14.44 14 / 
#57 F 25.94 25 / 
#58 F 31.23 31 / 
#59 F 16.46 16 / 
#60 M 20.86 20 / 









#50b F 14.14 LMT 100 
mg BD 
#51b F 20.78 LEV 250mg 
BD 
#52b M 36.44 VPA 500 
mg BD 
#54b F 18.26 (treatment 
unknown) 










#62 F 18.18 14 LEV, LMT 
(dose 
unknown) 
#63 F 22.18 18 LMT (dose 
unknown) 
#64 M 39.10 28 LEV 500 
mg BD 
#65 M 40.06 8 VPA 1500 
mg BD 




#67 M 20.69 16 VPA 1200 
mg + LEV 
1000 mg 
BD 




mg + LEV 
1250 mg 
BD 
#69 F 30.86 7 AE, 15 
GTCS 
VPA 600 






PM only  





#71 F 23.89 
N/A N/A 
#72 F 20.28 
#73 M 24.98 
#74 F 25.64 





#76 M 23.00 
#77 F 25.14 
#78 F 23.34 
#79 F 22.85 
#80 F 20.47 
#81 M 21.09 
#82 M 21.28 
#83 F 28.71 
#84 F 27.00 
#85 M 24.00 
#86 M 34.77 
#87 M 26.00 
#88 F 17.10 
#89 M 29.00 
#90 M 24.00 
 #91 F 24.00   
LMT=Lamotrigine, ETX=Ethosuximide, TPM=Topiramade, VPA=Valproate, 
LEV=Levetiracetam, CBZ=Clobazam, BD=(bis die) – 2 times a day, PM=post 
meridiem, AM=ante meridiem, #...b=post-treatment.  
 
Descriptive statistics of the sample are summarised in Table 3.2. There were no 
significant differences between the age of drug naïve AE patients and the age of AE 
refractory patients groups, U=63, p=0.61. No differences were also found between the 
age of drug naïve AE patients and children healthy control groups, U=120.5, p=0.145. 





was found, U=78.5, p=0.469. Drug naïve JME patients were found to be statistically 
significantly younger than adults/adolescents healthy control groups, U=85, p=0.019. 
No differences between the refractory JME group and the adults/adolescents healthy 
control group were found, U=86, p=0.722. Significant difference was found between the 
age of the drug naïve JME patients and the age of JME refractory patients, U=29, 
p=0.022. The effect of age will be accounted for as a covariate in the analysis performed 
where we have reasons to believe that the differences in age might impact the results. 






SD AGE GENDER 
DRUG NAÏVE AE 9.49 9.73 3.19 5F, 11M 
POST-TREATMENT AE 10.28 10.51 3.15 3F, 7M 
REFRACTORY AE 9.93 10.05 1.94 5F, 4M 
CONTROL CHILDREN 10.32 11.33 3.31 14F, 7M 
DRUG NAÏVE JME 19.18 20.80 6.44 10F, 5M 
POST-TREATMENT JME 20.78 22.00 7.71 3F, 4M 
REFRACTORY JME 28.40 28.40 9.35 4F, 5M 
CONTROL 
ADULTS/ADOLESCENTS 
23.00 24.22 3.7 11F, 10M 
 
 
We classified the patients that completed the post-treatment scan as responding or not 
responding to the first AED. We considered 2 aspects for the classifications: i) 
family/personal report following clinical practice; ii) presence/absence of GSW in the 
EEG recording during the second visit. Details of classification are listed in Table 3.3. 





2 years from first diagnoses for some patients. We have 4 patients diagnosed with AE 
who are responding to treatment and the information from families and the EEG is 
concordant as we did not record any GSW. We classified them as responders. We have 
1 patient who started presenting with seizures after the 6
 
moths of follow-up; we 
considered this subject as not responder as the seizures re-occured whilst under the first 
medication prescribed. We have two patients who did not present with any GSW during 
the EEG but the family reported seizures occurrence. We classified them as not-
responders considering that we may not have sampled spontaneous GSW during the 
limited time in which the post-treatment EEG was recorded. We have 1 patient in which 
the family has reported seizures occurrence and we recorded GSW during the EEG 
therefore we classified this participant as a not responder. In 2 patients we recorded 
GSW in the EEG post-treatment but families reported a good improvement in the 
clinical situation. This complexity exemplifies the difficulty in defining a good outcome 
measure: is it seizure freedom or presence of GSW in the EEG? As we were not able to 
answer this question, we did not allocate them to a specific category but we considered 
them as responders based on family report and not responders from EEG recording. 
None of the patients with JME presented GSW in the EEG recorded post-treatment and 








Table 3.3 : Treatment outcome classification at post-treatment scan of drug naïve     
patients. 







#3b YES NO No seizures 
#5b / YES No seizures noticed 
#6b NO NO Family was reporting 
no seizures at 6 moths 
but now she is having 
seizures with the same 
treatment  
#7b NO NO Dad said the treatment 
was going ok. He 
noticed few seizures 
#8b YES NO No seizures 
#9b YES NO Parents are concerns 
as patient had cardiac 
problem so they think 
it is the AED  
#11b / YES No seizures 
#13b YES NO No more seizures 
#14b NO YES Mum was concerned 
about side-effects – 
impression she was 
not given AED 




#47b YES NO No seizures reported 
#50b YES NO She did report no 
seizures 
#51b YES NO No more seizures 





#54b YES NO No more seizures 
#56b YES NO No more seizures 
#57b YES NO Seizures free 
 
3.4 MRI acquisition  
Data were acquired at 1.5 Tesla, Avanto, Siemens Healthcare GmbH, Germany, at 
GOSH and 3.0 Tesla, MR750, General Electric, USA at King’s College Hospital. 
The MRI protocol was first designed for the 1.5T Avanto at GOSH and then adapted to 
ensure consistency for the 3.0T MR750 at KCH. Previous studies demonstrated that the 
variability of a multicentre study providing MRI data from different manufactures, does 
not interfere with data quality and experimental designs (Schnack et al., 2004; Davids et 
al., 2014; Pugnaghi et al., 2014). Based on this, we are confident that our matching 
protocols would not interfere with data quality and data analysis across centres.   
We acquired T1-weighted image for volumetric measurements, simultaneous video-
EEG-fMRI to measure functional activation related to epileptic activity, diffusion tensor 
imaging (DTI) to measure white matter structures, and arterial spin labelling (ASL) to 
measure variability of blood perfusion due to AED. Imaging parameter specifications 
for each scanner are specified in Table 3.4.  
T2 and FLAIR were acquired in the 3.0T at King’s College Hospital as prescribed by 
the protocol used by the Centre for Neuroimaging Sciences (CNS), King’s College 
London. These images are reported to the general practitioner in case of incidental 





The data acquisition procedure involved first, the preparation of the MRI-compatible 
EEG cap (Brain Products, Germany). Baseline scalp EEG was recorded outside the 
scanner for 5-10 minutes and then participants were moved to the MRI room. The MRI 
recording was started after participants and the EEG MRI-compatible equipment were 
positioned into the MRI bed following standard safety guidelines (Ives et al., 1993; 
Lemieux et al., 1997; Laufs, 2012).    
Next, we acquired T1 weighted image with no EEG recording and 4 times 10 minutes 
simultaneous video-EEG-fMRI. During simultaneous video-EEG-fMRI, participants 
were instructed to watch for two sessions video-clips of the cartoon “Tom and Jerry” 
(details are explained in Chapter 3 Paragraph 3.5) alternating with two sessions of rest-
eyes-closed, allocating the first randomly. After EEG cap removal, DTI and ASL were 
acquired with a random order considering participant tolerability. All participants were 
instructed to remain still during the scanning. 





 COIL 12 channels 
received head coil 
12 channels 
received head coil 
T1-WEIGHTED SEQUENCE FLASH MPRAGE 
 TE 4.94ms 3.016ms 
 TR 11ms 7.312ms 
 MATRIX 224x224x176 256x256x196 
 FOV 256mm 270mm 
 VOXEL SIZE 1x1x1mm 1.05x1.05x1.2mm 
EEG-fMRI SEQUENCE EPI EPI 
 FOV 210mm 211mm 
 TR 2160ms 2160ms 
 TE 30 25 











 SLICE GAP 1mm 0.8mm 
 MATRIX 64x64x30 64x64x36 
 NUMBER OF 
VOLUMES 
300 300 
 VOXEL SIZE 3.3x3.3x4.0mm 3.3x3.3x3.3mm 
ASL INVERSION TI 1500ms 1525ms 
 TR 3770ms 4834ms 
 TE 18.82ms 11.08ms 
 VOXEL SIZE 3.6×3.6×5.0mm 1.875x1.875x3.0mm 




 BOLUS LENGHT 700ms 1500ms 
 FOV 230mm 24 
DTI DIRECTIONS 60 32 
 RESOLUTIONS 2.5×2.5×2.5 mm 2.4x2.4x2.4mm 
 FOV 240mm 256mm 
 TE 81ms 75ms
4
 
 TR 7300ms Pulse gated 







3.5 Child-friendly approach   
Given the young population we investigated and the length of the MRI protocol (90 
minutes), a child-friendly approach was used. The usefulness of this approach for data 
quality purpose and feasibility has been demonstrated (Centeno et al., 2016). We 
                                                 
4
 Approximate value as TEs are optimised for each patient as slices are angled differently for each patient; 
the scanner does a per-scan optimisation of the echo time, to get the shortest possible (and thus the highest 





performed all the data collection with no sedation. This decision was supported by 
problems related to sedation such as unknown effects on epileptic activity and related 
BOLD response, increased scanning complexity (due to the need for close medical 
supervision), risk of medical complications, limitation of comparison of methods/results 
to an adult population in whom sedation is not used, limitation of comparing group 
results within patients due to variation of level of sedation needed per individual, and 
between patients and controls as using sedation is rarely ethically possible in control 
subjects. Natural stimulation has been proposed as a way to improve compliance and 
reduce movement as well as to create a more comfortable experience in the scanner for 
paediatric populations (Barnea-Goraly et al., 2014). Natural stimulation aims to provide 
sensory (audio-visual) stimulation whilst minimally interfering with cognitive networks, 
provided that this stimulation has a low cognitive demand. A video clip of “Tom & 
Jerry” where there is no talking or writing (no language areas involved) but only 
background music in rhythms with the characters movements was chosen for this 
purpose. Two episodes of the cartoon “Tom & Jerry” were presented for 8 minutes. At 
the end of each episode, a 1.24 minutes of black screen with written “PLEASE WAIT” 
was played as pictured in Figure 3.1 .   
 






Youngest participants and, at their discretion for the adolescents/adults, choose a DVD 
to watch during EEG cap preparation and structural acquisition (T1-weighted, DTI and 
ASL). We fitted a mirror facing a TV screen inside the MRI bed on the patient’s head 
coil to allow the chosen DVD to be seen, projected to a screen fitted at the end of the 
MRI room.   
As expected, 90% (28 patients) of the JME groups underwent the full protocol. One 
patient (both for pre and post-treatment scan) did not tolerate the noise of the MRI. The 
other patient had braces implanted; therefore, we terminated the MRI protocol after the 
simultaneous EEG-fMRI for safety and data quality purposes. 90.4% (19 participants) of 
the adult healthy control group underwent full protocol. One participant did not tolerate 
extra time needed to acquire ASL; for the other participant, the noise of the EPI 
sequence was intolerable. 48.5% (17 patients) of the AE patients underwent the full 
MRI protocol. In the remaining 51.4% (18 patients) of patients we acquired enough 
good quality data to pursue empirical studies. Only 19.04% of the healthy control group 
has the full MRI protocol acquired because ASL sequence was designed after the 
beginning of the study from which we shared the healthy control group. Specifications 















DRUG NAÏVE AE #1 Y 4/4 Y Y 
#2 Y 4/4 Y Y 
#3 Y 4/4 / Y 
#4 Y 2/4 / / 
#5 Y 2/4 / Y 
#6 Y 4/4 Y Y 
#7 Y 4/4 Y Y 
#8 Y 3/4 / Y 
#9 Y 3/4 Y Y 
#10 Y 4/4 Y Y 
#11 Y 4/4 Y Y 
#12 Y 3/4 Y Y 
#13 Y 3/4 Y Y 
#14 Y 2/4 / / 
#15 Y 2/4 / Y 
#16 Y 4/4 / Y 
POST-TREATMENT AE #3b Y 4/4 Y Y 
#5b / 3/4 / / 
#6b Y 4/4 Y Y 
#7b Y 3/4 Y Y 
#8b Y 4/4 / Y 
#9b Y 4/4 Y Y 
#11b Y 4/4 Y Y 
#13b Y 4/4 Y Y 
#14b Y 4/4 / Y 
#15b Y 4/4 Y Y 





REFRACTORY AE #17 Y 3/4 Y Y 
#18 Y 4/4 Y Y 
#19 Y 4/4 Y Y 
#20 Y 4/4 / / 
#21 Y 4/4 Y Y 
#22 Y 4/4 Y Y 
#23 Y 4/4 Y Y 
#24 Y 3/4 / / 
#25 Y 4/4 / Y 
HEALTHY CONTROL 
CHILDREN 
#26 Y 4/4 Y Y 
#27 Y 4/4 / Y 
#28 Y 4/4 / Y 
#29 Y 4/4 Y Y 
#30 Y 4/4 / Y 
#31 Y 4/4 / Y 
#32 Y 4/4 / Y 
#33 Y 4/4 Y Y 
#34 Y 4/4 / Y 
#35 Y 4/4 / Y 
#36 Y 4/4 / Y 
#37 Y 4/4 / Y 
#38 Y 4/4 / Y 
#39 Y 4/4 / Y 
#40 Y 4/4 / Y 
#41 Y 4/4 / Y 
#42 Y 4/4 / Y 
#43 Y 3/4 Y Y 
#44 Y 4/4 / Y 
#45 Y 4/4 / Y 





DRUG NAÏVE JME #47 Y 4/4 Y Y 
#48 Y 4/4 / / 
#49 Y 4/4 Y Y 
#50 Y 4/4 Y Y 
#51 Y 4/4 Y Y 
#52 Y 4/4 Y Y 
#53 Y 4/4 Y Y 
#54 Y 4/4 Y Y 
#55 Y 4/4 Y Y 
#56 Y 1/4 / / 
#57 Y 4/4 Y Y 
#58 Y 4/4 Y Y 
#59 Y 4/4 Y Y 
#60 Y 4/4 Y Y 
#61 Y 4/4 Y Y 
POST-TREATMENT JME #47b Y 4/4 Y Y 
#50b Y 4/4 Y Y 
#51b Y 4/4 Y Y 
#52b Y 4/4 Y Y 
#54b Y 4/4 Y Y 
#56b Y 3/4 / / 
#57b Y 4/4 Y Y 
REFRACTORY JME #62 Y 4/4 Y Y 
#63 Y 4/4 Y Y 
#64 Y 4/4 Y Y 
#65 Y 4/4 Y Y 
#66 Y 4/4 Y Y 
#67 Y 4/4 Y Y 
#68 Y 4/4 Y Y 





#70 Y 4/4 Y Y 
HEALTHY CONTROL 
ADULTS/ADOLESCENTS 
#71 Y 4/4 Y Y 
#72 y 4/4 / Y 
#73 Y 4/4 Y Y 
#74 Y 4/4 Y Y 
#75 Y 4/4 Y Y 
#76 Y 4/4 Y Y 
#77 Y 4/4 Y Y 
#78 Y 4/4 Y Y 
#79 Y 4/4 Y Y 
#80 Y 4/4 Y Y 
#81 Y 4/4 Y Y 
#82 Y 4/4 Y Y 
#83 Y 4/4 Y Y 
#84 Y 2/4 Y Y 
#85 Y 4/4 Y Y 
#86 Y 4/4 Y Y 
#87 Y 4/4 Y Y 
#88 Y 4/4 Y Y 
#89 Y 4/4 Y Y 
#90 Y 4/4 Y Y 
 #91 Y 4/4 Y Y 
 
 
3.6 Simultaneous video-EEG-fMRI setup 
To record simultaneous scalp video-EEG-fMRI, participants were fitted with a 64 
channels (62 EEG electrodes, 1 ECG electrode and 1 reference electrode) MRI 





the modified combinatorial nomenclature referenced to FCz electrode. The preparation 
time of the EEG cap varied between 20 to 40 minutes depending on the population.  
Two people (I and another member of Dr Carmichael’s team) applied the EEG cap for 
the children whilst only I prepared the EEG cap for the adults/adolescents. Participants 
were then moved to the scanner room, they were fitted with ear plugs, ear phones and 
their head was immobiised using a vacuum cushion. EEG wires were straightened along 
the Z axis, immobiised and connected to 2x32 MRI-compatible Amplifiers (Brain 
Products, Germany) at the back of the scanner. EEG data were transmitted from the 
amplifiers to the recording computer located in the control room via fibre-optic cables. 
Scalp EEG was recorded simultaneously during fMRI with a sampling rate of 5000 Hz 
and was synchronised to the scanner’s 20 KHz gradient clock. Other recording 
parameters for EEG were: resolution = 0.5 μV; digitization = 16-bit. ECG was recorded 
with a single electrode which was placed just below the left clavicle and connected to 
the same amplifier as for EEG electrodes. 
Video was recorded via a MR-compatible camera (MR-Cam 12M, MRC Systems 
GmbH, Heidelberg, Germany) that was positioned inside the bore of the scanner 
focusing on the subject’s face, recording facial expressions related to seizures and 
subject’s motion. The video signal from the camera was transmitted to the recording 
computer placed outside the scanner room through shielded cable and low-pass filter 
(1MHz: MRC Systems GmbH, Heidelberg, Germany) to provide radio frequency (RF) 





Video and EEG were recorded synchronously using Brain Vision Recorder software 
(Brain Products, Munich, Germany). The recording was monitored using RecView 
software (Brain Products, Munich, Germany) which provides online artefact correction. 
3.7 EEG pre-processing 
MR gradient and pulse-related artefacts were removed off-line from the EEG recorded 
inside the MRI using template artefact subtraction (Allen et al., 1998; Allen et al., 2000) 
implemented in a commercial EEG processing package (Brain Analyzer, Brain 
Products). EEG was down sampled to 250 Hz. GSW were identified after visual 
inspection and manually marked on the EEG traces for each session. Because of the 
stereotypical shape of GSW, consensus with clinical neurophysiologist was not required.  
However, the EEGs were reviewed in both bipolar and referential montages to ensure 
accurate identification of epileptiform abnormalities. 
3.7.1 GSW recording 
As reported in Table 3.6, a total of 285 runs of GSW were successfully marked in the 
EEG. 55.51% (34 patients) of all the patients presented GSW during simultaneous EEG-
fMRI recording. 73.52% (25 patients) of those patients belong to the AE groups and the 
remaining 26.5% (9 patients) belong to JME groups. Among the AE groups, 75% (12 
patients) of the drug naïve group, 50% (5 patients) of the post-treatment group and 
88.8% (8 patients) of the refractory group presented with GSW. Amongst the JME 
groups, 40% (6 patients) of the drug naïve group, 0% of the post-treatment and 33.3% (3 
patients) of the refractory group presented GSW. AE patients had longer GSW mean 










=5.65) to post-treatment (M=2.51, SD=2.74) in the AE groups which has 
been found to be significantly decreased t(36)=2.433, p=0.020. As this comparison was 
not possible in the JME groups, we compared drug naïve JME (M=1.78, SD=1.33) with 
refractory JME (M=0.97, SD=0.5) and we did not find statistical differences between 
the length of GSW t(24)=1.65, p=0.111, although the mean length is less in the 
refractory group. This has been also the case for the drug naïve AE group (M=6.87, 
SD=5.65) compared to the refractory AE group (M=5.84, SD=4.81), t(38)=0.57, 
p=0.572. A trend was found between the GSW duration of the post-treatment AE group 
(M=2.51, SD=2.74) with the refractory AE group (M=5.8, SD=4.81), t(22)=-2.02, 
p=0.055. 
Table 3.6: GSW incidence during simultaneous EEG-fMRI. 
GROUP ID SESSION 1 SESSION 2 SESSION 3 SESSION 4 
N MD N MD N MD N MD 
DRUG NAÏVE 
AE 
#1 / / / / / / / / 
#2 / / 5 9.4032 6 15.816 13 3.7822 
#3 2 7.302 8 5.205 1 8.184 / / 
#4 3 3.8667 17 3.0252 / / / / 
#5 / / / / / / / / 
#6 1 28.6756 / / / / 1 5.672 
#7 1 5.34 2 6.84 10 1.5632 / / 
#8   1 7.9505 3 6.8027 / / 
#9 / / / / 1 3.616 / / 
#10 / / / / / / / / 
#11 / / 4 0.4969 / / 2 1.8783 









#12 3 5.46 14 5.1434 5 6.8776 / / 
#13 1 10.728 3 8.6013 1 11.464 / / 
#14   3 9.8853 / / / / 
#15 3 0.984 2 1.1559 / / / / 




#3b / / / / / / / / 
#5b / / / / 1 0.712 / / 
#6b / / / / / / / / 
#7b / / / / 1 5.0609 / / 
#8b / / 1 7.924 3 6.78 / / 
#9b / / / / / / / / 
#11b 1 1.7538 2 0.9853 1 2.116 3 0.2893 
#13b / / / / / / / / 
#14b 1 0.888 3 0.4853 1 0.6823 / / 
#15b / / / / / / / / 
REFRACTORY 
AE 
#17 / / / / / / / / 
#18 / / / / / / / / 
#19 6 3.6107 6 5.2147 / / 1 10.234 
#20 / / / / / / / / 
#21 / / / / / / / / 
#22 / / 4 9.9431 / / 3 7.3472 
#23 




#24 1 1.24 7 1.216 4 0.739 / / 
#25 / / 1 0.92 / / 1 0.388 
DRUG NAÏVE 
JME 
#47 10 1.6721 6 0.9279 7 0.8858 4 1.9539 
#48 / / 4 3.5081 / / 2 2.5320 
#49 1 1.5280 / / / / / / 
#50 / / / / / / / / 





#52 3 3.3520 / / 1 5.196 / / 
#53 1 0.36 / / / / / / 
#54 / / / / / / / / 
#55 / / 2 3.528 / / / / 
#56 7 1.7331 / / / / / / 
#57 / / / / / / / / 
#58 4 0.606 3 0.8147 4 0.4 1 1.48 
#59 / / / / / / / / 
#60 / / / / / / / / 




#47b / / / / / / / / 
#50b / / / / / / / / 
#51b / / / / / / / / 
#52b / / / / / / / / 
#54b / / / / / / / / 
#56b / / / / / / / / 
#57b / / / / / / / / 
REFRACTORY 
JME 
#62 / / / / / / / / 
#63 / / / / / / / / 
#64 / / / / / / / / 
#65 / / / / / / / / 
#66 / / 1 0.4056 / / / / 
#67 / / / / / / / / 
#68 / / / / / / / / 
#69 1 1.796 1 1.22 11 1.1549 11 1.3178 
#70 6 0.8540 3 0.7867 2 0.384 2 0.27 







3.8 MRI processing and statistical analysis 
All fMRI data were analysed using the software package Statistical Parametric Mapping 
(SPM8) (http://www.fil.ion.ucl.ac.uk/spm) running under Matlab (Mathworks Inc., 
U.S.A.). After discarding the first four volumes to avoid T1-saturation effect, the EPI 
time series images were realigned to the first image, corrected with Functional Image 
Artefact Correction Heuristic (FIACH) (Tierney et al., 2016), normalised to MNI space 
and spatially smoothed using an isotropic Gaussian kernel of 8mm FWHM (Friston et 
al., 1995). 
The fMRI data were analysed within the GLM framework to measure GSW related 
haemodynamic changes. GSW marked in the EEG were represented as blocks of 
variable duration depending upon the length of the discharge and considered effects of 
interest in the GLM. Details of GLM specifications are listed in experimental Chapters 5 
and 6 as different models were used. For each effect of interest, SPM[T+] were used at 
the single subject-level. Images generated from SPM[T+] (con images containing the 
betas) for the effects of interests were used for group comparison at the second-level 
analysis where SPM[F] maps were generated. The presence of significant BOLD 
changes was assessed by applying a family wise error corrected threshold using 
extended threshold available in the random field theory framework in SPM. The 
resulting SPM[F] maps were overlaid on normalised T1-weighted MRI scans to evaluate 
the anatomical localisation of effects. BOLD time courses were plotted for BOLD 
clusters when required to classify the BOLD change as increases or decreases according 





Structural data were analysed using FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL), free-
surfer (http://freesurfer.net/) and locally-written Matlab scripts depending upon the 
research questions of interests. Specifications of these methods are found in Chapters 4 




SECTION 3: EXPERIMENTAL STUDIES 
 
In this section I will introduce the experimental studies conducted on the recruited 
sample introduced in Chapter 3.  
Firstly, we explored the effect of AED on structural grey matter and GSW related 
BOLD responses. Secondly, we studied differences in grey matter structures and 
cerebral blood flow using a longitudinal approach. With this, we aimed to identify 
markers of treatment outcomes by comparing grey matter volume and shape between 
drug naïve and post-treatment measures. Thirdly, we measured GSW BOLD response in 
different brain states to identify if BOLD deactivation in DMN during GSW is an 
epiphenomenon specific to resting state.  
In Chapter 4 I will describe our investigation of structural abnormalities in grey matter 
volume and shape in drug naïve patients with early diagnoses of GGE. Via the 
application of the longitudinal approach, we will describe if grey matter measures can 
function as marker of treatment outcome. Chapter 5 contains the first simultaneous 
EEG-fMRI analysis in which we tested changes in BOLD response prior and related to 
the onset of GSW in the biggest group of drug naïve patients. Chapter 6 describes the 
second simultaneous EEG-fMRI study where we interrogated differences in BOLD 
changes related to GSW when patients are in different brain states. Chapter 7 contains 
the analysis on ASL where we compared blood perfusion parameters before and after 
treatment intake. 




Chapter 4 : Volumetric analysis 
4.1 Background 
Patients diagnosed with GGE are expected to have a normal-looking brain when studied 
with a conventional clinical MRI scan (Berg et al., 2010). However, structural 
abnormalities in grey matter are supported by emerging evidence. For example, it is now 
well established that there are abnormalities in thalamic-cortical connections that might 
underlie disease manifestation (Bernasconi et al., 2003).   
Previous studies have used standard measurements of T1-weighted image and grey 
matter volume to compare patients with GGE and healthy controls. Among all measures, 
voxel based morphometry (VBM) (Mechelli et al., 2005; Whitwell, 2009), volumetric 
measures and shape analysis (Kim et al., 2013) have been widely used. Studies to date 
have shown conflicting results with regard to the areas of abnormalities, whether they 
show increased or decreased GM volume in patients compared to healthy controls, and 
the effect that AED have had on the results.   
The brain area that has shown most consistent results across studies is the thalamus. 
However, different nuclei of the thalamus have been reported to be atypical in GGE, 
together with different additional areas of the basal ganglia. For example, patients with 
GTCS revealed reduced grey matter ratio compared to healthy controls in the ventral 
anterior and lateral nuclei of the thalamus (Ciumas and Savic, 2006). Consistent with 
this study, a deflation of the thalamus, in addition to putamen and pallidum, was 
reported (Du et al., 2011). In a group of JME patients, shape analysis showed surface 





(Saini et al., 2013). Decreased grey matter volume in anteromedial thalamus has also 
been found in a group of mixed GGE patients (Kim et al., 2014) and in JME patients 
(Kim et al., 2007). Similar abnormalities of grey matter volume reduction in bilateral 
thalami (Chan et al., 2006) were also reported in patients with AE. 
While there is some consensus regarding basal ganglia changes, abnormalities in the 
cortical areas remain more controversial. For example, a decrease in volume was found 
in the frontal cortex of a group of JME patients (O'Muircheartaigh et al., 2011a). In 
addition, medial frontal gyrus and areas related with BOLD changes in the presence of 
GSW such as the precuneus, were found to have decreased grey matter volume (Chan et 
al., 2006) in groups of GTCS (Ciumas and Savic, 2006; Huang et al., 2011). However, 
contrasting evidence was reported in a group of JME in which increased grey matter 
volume was found in the superior mesial frontal cortex (Kim et al., 2007).  
All the results currently reported are extracted from populations of patients having i) 
refractory GGE, ii) long-term AED treatment intake and iii) long disease durations. As 
such, controlled measures of disease duration are essential to understand the progression 
of structural abnormalities in the disease although it has been found that GM matter 
volume (cortical and subcortical) is negatively correlated with disease duration (Huang 
et al., 2011). However, concerns regarding the selection of refractory patients from 
tertiary centres might have biased the evidence. For example, one study used treated 
patients with different IGE syndromes who were seizure free and found no differences 
between grey matter volume between patients and controls neither in thalamus nor in the 
total grey matter volume. The only difference was found in the putamen (Seeck et al., 





seizures and/or AED treatment? Or are these debated structural abnormalities intrinsic in 
GGE patients? Or is this phenomenon the results of a combination of the three? As most 
of the available studies selected refractory patients and have samples of patients already 
on treatment, it has been difficult to separate the effects of these different factors. 
Almost all of the studies mentioned have been cross-sectional and measured the degree 
of modification of the grey matter in patients with GGE retrospectively to identify the 
aetiology and/or progression of structural abnormalities related to GGE. Only one study 
has investigated longitudinally to determine grey matter volume changes from 
maximum of 12 months after the diagnoses with a follow-up scan at 24 months after the 
diagnoses. However, all the patients were on treatment (Pulsipher et al., 2011), thus the 
potential confounding effect of medication could not be excluded. Although the 
antiepileptic drug effects on brain atrophy are unclear, some research has indicated that 
antiepileptic drugs can influence nerve morphology, causing changes such as pseudo-
atrophy of the brain (Papazian et al., 1995) or neurogenesis (Hao et al., 2004). As such, 
removing the potential effect of medication when examining brain volumes is crucial. 
There is only one study that is currently available which reported decreased grey matter 
volume in a group of drug naïve CAE only (Wang et al., 2016). Therefore, it is essential 
to identify if results of this study are reproducible not only in CAE but in all the GGE 
syndromes.  
This work aimed to measure, for the first time, structural abnormalities in a group of 
drug naïve patients diagnosed with GGE syndromes. We compared their structural brain 
scan acquired before starting treatment with a group of age-matched healthy controls to 





were able to compare pre-treatment brain scans with post-treatment brain scans allowing 
us to measure any structural differences related to disease progression and the effect of 
treatment. Finally, in order to understand whether brain abnormalities were related to 
treatment outcome, we investigated if there were differences in our measurements of 




The sample for this study consisted of 16 drug naïve patients with AE (mean age= 9.73, 
5 F), 15 drug naïve patients with JME (mean age= 20.79, 8 F), 17 post-treatment 
patients from these 31 drug-naïve (AE: mean age= 10.5, 3F; JME: mean age= 21.9, 3 F), 
9 refractory (long-term) AE (mean age=10.04, 5 F), 9 refractory (long-term) JME (mean 
age= 28.4, 4 F). In addition we studied 16 age-matched healthy controls (mean age= 
10.38, 10 F) to compare with the drug naïve AE group and 15 age-matched healthy 
controls (mean age= 23.06, 10 F) to compare with the JME drug naïve group. A full list 
of the demographic characteristics of the participants is available in Table 4.1. For 
specification of the sample refer to Chapter 3.  
We will refer to the drug naïve (DN) when we consider DN AE and JME together. 
Otherwise, we will specify if we refer to DN JME or DN AE. The post-treatment (PT) 
group will be divided in PT responders as those patients who presented good outcome at 





scan. We will refer to DN responding when we measure grey matter volume at the drug 
naïve stage but we know from PT that they subsequently responded to treatment. 
Similarly, DN refractory will refer to those patients who subsequently showed bad 
outcome at PT scan. We will refer to refractory long-term patients for those patients 
who are on treatment for more than 1 year and presenting seizures. We will refer to 
refractory when in the group we will include refractory long-term and PT refractory. 
Classification of PT responding and PT refractory was based on family report and EEG 
(Table 3.3).     
Table 4.1: Sample selected for T1-weighted structural analysis 
GROUP CODE GENDER AGE 
DRUG NAÏVE 
AE 
#1 M 6.03 
#2 M 14.00 
#3 M 10.51 
#4 M 6.37 
#5 M 10.58 
#6 F 13.65 
#7 M 8.03 
#8 F 7.73 
#9 M 10.28 
#10 F 9.72 
#11 F 16.18 
#12 M 7.15 
#13 M 9.26 
#14 M 5.92 
#15 M 6.84 
#16 F 13.50 








#3b M 11.49 
#5b M 11.30 
#6b F 14.21 
#7b M 8.54 
#8b F 8.25 
#9b M 10.77 
#11b F 16.78 
#13b M 9.78 
#14b M 6.43 
#15b M 7.56 
REFRACTORY 
AE 
#17 M 8.60 
#18 F 12.33 
#19 M 10.45 
#20 M 8.34 
#21 F 13.12 
#22 F 9.66 
#23 F 9.93 
#24 F 7.00 
#25 M 10.98 
CONTROL 
CHILDREN 
#26 M 14.08 
#27 F 9.72 
#28 F 13.62 
#31 M 8.34 
#33 F 8.32 
#34 F 9.08 
#35 M 6.61 
#36 M 12.00 
#37 F 12.14 
#38 F 9.08 





#40 F 8.85 
#42 M 7.50 
#44 F 14.22 
#45 F 12.67 
#46 F 9.58 
DRUG NAÏVE 
JME 
#47 M 21.71 
#48 M 16.75 
#49 F 16.58 
#50 F 13.64 
#51 F 20.11 
#52 M 35.98 
#53 F 15.38 
#54 F 17.69 
#55 F 26.04 
#56 M 14.44 
#57 F 25.94 
#58 F 31.23 
#59 F 16.46 
#60 M 20.86 




#47b M 22.95 
#50b F 14.14 
#51b F 20.78 
#52b M 36.44 
#54b F 18.26 
#56b M 14.94 
#57b M 26.48 
REFRACTORY 
JME 
#62 F 18.18 
#63 F 22.18 





#65 M 40.06 
#66 M 21.39 
#67 M 20.69 
#68 F 22.33 
#69 F 30.86 




#71 F 23.89 
#72 F 20.28 
#73 M 24.98 
#74 F 25.64 
#76 M 23.00 
#77 F 25.14 
#78 F 23.34 
#79 F 22.85 
#80 F 20.47 
#82 M 21.28 
#84 F 27.00 
#85 M 24.00 
#88 F 17.10 
#90 M 24.00 
   #91 F 24.00 
   
4.2.2 MRI acquisition 
Three-dimensional T1-weighted MPRAGE was acquired in the sagittal plane (echo 
time= 3.016ms, repetition time= 7.312 ms, acquisition matrix= 256 x 256 x 196 over a 
field of view of 27 cm3, voxel size 1.05 x 1.05 x 1.2 mm3) using a 3T 750 General 
Electric scanner. Inversion recovery spoiled gradient-recalled echo images were used for 





healthy control adults/adolescents participants (Table 4.1). A three-dimensional 
isotropic T1-weighted FLASH was acquired in a sagittal plane (echo time= 4.94 ms, 
repetition time= 11 ms, acquisition matrix= 192 x 256 x 176 mm over a field of view of 
256 mm3, voxel size 1 x 1 x 1 mm3) using a 1.5T Siemens scanner in the AE drug 
naïve, post-treatment, refractory and children included in the healthy control sample 
(Table 4.1).   
4.2.3 MRI processing 
T1-weighted images were transformed from dicom to nifti format using the SPM8 
dicom import tool. Nifti images were then imported into FSL software 
(http://fsl.fmrib.ox.ac.uk) and reoriented to match the Montreal Neurological Institution 
152 (MNI152) (Mazziotta et al., 2001a; Mazziotta et al., 2001b) standard template so 
that they appear in the same orientation in FSLView by applying a 90, 180 or 270 
degree rotations about the different axes as necessary to obtain the labels in the same 
position as the standard template using fslreorient2std 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Fslutils).   
4.2.4 MRI analysis 
Using the extensive literature in the field we generated an a priori hypothesis that the 
following specific cortical and subcortical areas would show grey matter volume loss 
and abnormalities in: thalami, putamen, caudate, pallidum and hippocampi; and 






4.2.4.1 Volumetric analysis (subcortical and cortical) 
We used FSL-integrated registration and segmentation toolbox (FSL-FIRST) software, 
version 5.0 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/first) for the automated segmentation of 
the subcortical structures of interest, which included the thalami and the major structures 
of the basal ganglia (putamen, caudate, and pallidum) and hippocampi. As described in 
detail elsewhere (Patenaude et al., 2011; Kim et al., 2013), FSL-FIRST automatically 
segmented the subcortical structures from the MR images and produced volumetric 
outputs (from which each structure’s global volume was obtained using FSL statistical 
tools).  
Grey matter volumes of the subcortical areas were extracted per hemisphere and the 
mean volume for each subcortical area across both hemispheres was calculated. To 
account for possible effects of global brain volume and head size, each region volume 
was corrected for global brain volume. To accomplish this, we made use of a widely-
implemented method available through the FSL platform, SienaX (Smith et al., 2002; 
Smith et al., 2007). This method measures brain volume from a single MRI scan. This is 
achieved by normalising an individual’s image to a standard template for both the skull 
and brain surface (both obtained using BET (Smith, 2002)) followed by tissue 
segmentation (including correction for partial volume effects) to yield a normalised 
brain volume (NBV). This methodological choice was supported by evidence showing 
that volumes of the subcortical areas of interest are positively correlated with the 
cranium size (Goodro et al., 2012) and that SienaX measures are an excellent surrogate 
for the intracranial vault volume (Fein et al., 2004). Thus NBV takes into account of 





subcortical region volume by the subject-specific NBV, and compared each NBV-
corrected subcortical region between groups. ANOVA as implemented in SPSS was 
used to compare the corrected bilateral volumes between DN and HC, AE DN and HC, 
JME DN and HC, DN and PT, DN and refractory, PT responders and refractory, 
refractory and HC, DN responders and DN refractory. Age, gender and scanner type 
were introduced as covariates in the univariate model. For each region, a p-value 
threshold adjusted for multiple comparisons using false discovery rate (FDR) was 
applied.  
Measurements of the cortical volumes were calculated using Freesurfer software 
(http://freesurfer.net/) (Fischl, 2012). All images were processed using the standard 
‘recon-all’ processing stream (https://surfer.nmr.mgh.harvard.edu/fswiki/recon-all), 
which supplies the surfaces and morphometry data for each subject. We used region-
based analysis, based on the automated parcellation of the cortex into 34 regions. 
FSLstats (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Fslutils) was used to extrapolate the grey 
matter volumes from the parcellated cortical regions. Differences in the volumes of 
cortical regions were calculated applying the same procedure as described for the sub-
cortical regions. To account for possible effects of global brain volume and head size on 
cortical region volumes, each was corrected for global brain volume using the NBV 
from SienaX consistent with the procedure used for subcortical areas. Scanner type, age 
and gender (Sowell, 2002) were used as covariates of no interest. Comparison between 
the mean volume of bilateral cuneus, prefrontal cortex, precentral cortex and cingulate 
were made between DN and HC, JME DN and HC, AE DN and HC, DN and PT, DN 





DN refractory. We selected these cortical areas as consistently reported in the literature 
as involved in GGE syndromes.   
We performed a separated ANOVA with scanner type, age and gender as covariates, to 
measure differences in NBV between groups (DN and HC, JME DN and HC, AE DN 
and HC, DN and PT, DN and refractory, PT responding and refractory, refractory and 
HC, DN responding and DN refractory). This was calculated as a control measure to 
ensure that differences in sub-cortical and cortical grey matter were not driven by 
differences in NBV. 
4.2.4.2 Shape analysis 
FSL-integrated registration and segmentation toolbox (FSL-FIRST) software, version 
5.0 (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/first) was also used for surface shape analysis of 
the subcortical structures of interest: thalami, putamen, caudate, pallidum and 
hippocampi. FSL-FIRST outputs parameterised volumetric labels (meshes) from 
surfaces of the selected structures after affine registration of raw T1-weighted images to 
MNI 152 standard space. Vertex-wise shape analysis along the surface of the segmented 
structures was then performed via the measures of differences in mean vertex position 
between groups (Patenaude et al., 2011; Kim et al., 2013). Registration to MNI space 
ensured that global brain volume effects were fully taken into account for the vertex-
wise shape analysis. Comparisons of thalami, putamen, caudate, pallidum and 
hippocampi shapes were made between healthy control, drug naïve patient, and ‘not-
responders’ patient groups.  
For the shape analysis, permutation testing using ‘randomise’ was used to calculate 





p<0.05 and corrected for multiple comparisons using False Discovery rate (FDR). 
Scanner type, age and gender (Sowell, 2002) were introduced as covariates in the model.  
4.2.4.3 VBM 
For voxel-based morphometry (VBM) preprocessing we used SPM12 software 
(Ashburner and Friston, 2000). In SPM12, the ‘segment’ procedure was used applying a 
new generation of tissue probability maps (TPM) with improved anatomical delineation 
of sub-cortical areas (Lorio et al., 2016). Unified tissue segmentation applies 
normalisation to MNI space, tissue segmentation and bias field correction within a 
single step to warp tissue probability maps to match the image (Ashburner and Friston, 
2005). Next, Diffeomorphic Anatomical Registration Through Exponentiated Lie 
algebra (DARTEL) was used to account for more detailed shape variability in the 
population (Ashburner, 2007). The DARTEL registration involves alternating between 
computing a template, based on the average tissue probability maps of all subjects, and 
warping the GM and WM tissue maps of all subjects into increasingly good alignment 
with the template. A sample specific template was created selecting the best quality data 
per group (9 HC adults, 9 HC children, 9 JME DN and 9 AE DN). Images were spatially 
normalised to standard Montreal Neurological Institute (MNI) space, followed by a 
smoothing procedure with a Gaussian Kernel of 8 mm. A region of interest (ROI) mask 
of bilateral thalamus, caudate, pallidum and hippocampi was applied given a priori 
hypothesis. Scanner type, age and gender (Sowell, 2002) were introduced as covariates 
in the model consistent with the previous analysis. Two-samples T-tests were calculated 





4.3 Results  
The quality of subcortical and cortical segmentation was inspected visually. All the 
participants included in the analysis were judged as good quality; participants, in which 
cortical and subcortical segmentation did not visually match the brain structures, were 
excluded. We excluded one refractory JME patient (#61) due to poor T1-weighted 
image quality. One refractory AE patient (#17) was excluded from cortical volume 
measures due to poor quality of cortical segmentation. Two patients from the AE drug 
naive group (#15, #14) and one healthy control (#35) were excluded from voxel based 
analysis due to misclassification of brain tissues because of motion artefacts.  
4.3.1 Volumetric analysis (subcortical and cortical) 
The results of volume analysis for bilateral thalami, putamen, pallidum, hippocampi and 
caudate are shown in Table 4.2. We found a trend of decreased grey matter volume in 
drug naive (DN) patients in all the subcortical areas considered compared with healthy 
controls (HC). Thalamus (F(1,57)=6.591, p=0.013) and pallidum (F(1,57)=5.936, 
p=0.018) were the areas surviving significant statistical threshold corrected for multiple 
comparisons (Figure 4.1). In the AE drug naïve group, thalamus, putamen and pallidum 
appeared to be smaller in volume compared with their age matched HC participants, 
although the value did not survive statistical threshold (Figure 4.2). Similarly, but 
surviving statistical significance threshold, JME drug naïve (DN JME) patients had 
smaller volumes than healthy controls (HC) in thalamus (F(1,26)=5.334, p=0.029), 






Eleven patients post-treatment were classified as responding and 4 as not responding to 
treatment. Two patients had discordant information from the EEG and from families. In 
one of them, a post-treatment T1-weighted image was not acquired due to the patient not 
tolerating the scan, therefore this individual was not included in the analyses; the second 
patient was alternatively assigned to PT responder and PT refractory groups in two 
separate alternative analyses. Independent of which category this individual was put into 
we found consistent results, therefore (in Table 4.2), we reported the results for when 
this patient is classified as PT refractory and DN refractory. We found no statistically 
significant differences between grey matter volumes of DN and refractory (Figure 4.5). 
However, we found lower mean values of grey matter volume in the sub-cortical areas 
in the refractory patients compared to the PT responding patients (Figure 4.7). We found 
statistically significant differences in thalamus (F(1,49)=11.208, p=0.002) and 
hippocampus (F(1,49)=12.740, p=0.001) comparing refractory patients and HC (Figure 
4.4). We compared volumetric measures of drug naïve patients who were classified as 
responders (DN responder) with drug naïve patients who were classified as not 
responders (DN refractory). Although we found no statistically significant differences 
between the groups, patients who did not respond to treatment showed smaller mean 
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Comparison of subcortical volumetric measures. DN= Drug Naïve, HC= Healthy 
Controls, PT= Post-treatment, M=mean (the first value corresponds to the first 
group specified in the comparison column). Number in parenthesis in the 
comparison column refers to the number of participants considered per group. 
Comparison resulted significantly different for multiple comparisons are 
highlighted in yellow. The last 3 comparisons were run twice using different 







Figure 4.1: Volumetric measures in mm3 of Drug Naïve Patients (DN) vs Healthy 
Controls (HC). Thalamus and Pallidum are statistically significant (see text). * 
marks statistical significance surviving multiple comparisons between groups, 
upper limit of the box represents the upper quartile, lower limit represents the 
lower quartile, red line in the box is the median, error bars represent minimum 







Figure 4.2: Volumetric measures in mm3 of AE Drug Naïve Patients (DN) vs 
Healthy Controls (HC). Upper limit of the box represents the upper quartile, lower 
limit represents the lower quartile, red line in the box is the median, error bars 






Figure 4.3: Volumetric measures in mm3 of JME Drug Naïve Patients (DN JME) 
vs Healthy Controls (HC). Thalamus, Pallidum and Hippocampus are statistically 
significant (see text); * marks differences between groups surviving statistical 
significance corrected for multiple comparisons. Upper limit of the box represents 
the upper quartile, lower limit represents the lower quartile, red line in the box is 







Figure 4.4: Volumetric measures in mm3 of Refractory Patients (post-treatment 
not–responders and Refractory) vs Healthy Controls (HC). Thalamus, Putamen 
and Hippocampus are statistically significant (see text); * marks differences 
between groups surviving statistical significance corrected for multiple 
comparisons. Upper limit of the box represents the upper quartile, lower limit 
represents the lower quartile, red line in the box is the median, error bars 






Figure 4.5: Volumetric measures in mm3 of Refractory Patients (long term 
Refractory and PT refractory) vs Drug Naive. Upper limit of the box represents the 
upper quartile, lower limit represents the lower quartile, red line in the box is the 






Figure 4.6: Volumetric measures in mm3 of DN vs Post-treatment (PT). Upper 
limit of the box represents the upper quartile, lower limit represents the lower 







Figure 4.7: Volumetric measures in mm3 of Refractory vs post-treatment 
responding (PT responding). Upper limit of the box represents the upper quartile, 
lower limit represents the lower quartile, red line in the box is the median, error 






Figure 4.8: Volumetric measures in mm3 of Drug naïve patients with positive 
treatment outcome (DN responding) vs Drug Naïve patients with negative 
treatment outcome (DN refractory). Upper limit of the box represents the upper 
quartile, lower limit represents the lower quartile, red line in the box is the median, 
error bars represent minimum and maximum values. 
 
We measured grey matter volume in the cortex to identify any differences in cortical 
structures (Table 4.3). We focused the comparison on specific cortical areas involved in 
the manifestation of GGE: prefrontal cortex, precentral cortex, cuneus and cingulate. We 
found that only the grey matter volume of the prefrontal cortex was significantly 
different between patients and HC participants if not correcting for multiple 





due to the lack of numbers of not-responders (in 2 patients cortical parcellation was poor 
due to motion). Given the lack of differences in the volume of cortical areas, we focused 
the next analysis only on subcortical areas. 












































































































































Comparison of cortical volumetric measures. DN= Drug Naïve, HC= Healthy 
Controls, PT= Post-treatment, M=mean (the first value corresponds to the first 
group specified in the comparison column). Number in parenthesis in the 
comparison column refers to the number of participants considered per group. 
Comparison resulted significantly different if not corrected for multiple 
comparisons are highlighted in green. The last 3 comparisons were run twice using 
different patients’ classification for responders/not responders.   
 
We compared the NBV across all the groups and we did not find any significant 
differences between DN and HC, JME DN and HC, AE DN and HC, DN and refractory, 
PT responding and refractory, refractory and HC, DN responding and DN refractory. 
NBV was found to be statistically significantly bigger in DN (M=1687323.122, 
SD=115370.1020) compared to PT (M=1639581.737, SD=116283.7651) (F(1,42)=4.28, 
p=0.045).  
4.3.2 Shape analysis 
Surface shape analysis indicated that drug naïve patients (DN) showed significant 
localised inward surface deflation of right and left thalami, right and left pallidum and 





comparisons. Left thalamus showed differences between DN and HC in a continuum 
strip that connects anteriorly to posteriorly, whilst the right thalamus presented two 
different localised regions of differences, one anterior and one posterior. Left pallidum 
showed a deflection on its superior part which crosses from the anterior to the posterior 
part of the structure. The deflection of the right pallidum showed a difference in 
deflection only in its anterior part. Left and right hippocampi show a similar deflection 
in the more anterior part of the structures (Figure 4.9). No significant deflections were 
seen in the bilateral caudate or putamen (Table 4.4). No significant differences were 
found between AE DN and HC. Right pallidum was found statistically significant 
between JME DN and HC in the more anterior part of the structure (Table 4.4, Figure 
4.10). No significant differences were found between DN and PT, between DN and 
refractory, between PT responders and refractory (Table 4.4). A significant difference 
was found between DN responder compared with DN refractory in the lateral part of the 
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Figure 4.9: Shape differences between Drug naïve patients (DN) and healthy 
controls (HC). A) Left thalamus; B) right thalamus; C) left pallidum; D) right 
pallidum; E) left hippocampus; F) right hippocampus. Orange surfaces are the 







Figure 4.10: Shape differences between JME drug naïve (DN JME) and healthy 
controls (HC) in the right pallidum. Orange surface is the area of difference 
between JME drug naïve patients and healthy controls.   
 
 
Figure 4.11: Shape differences between drug naïve patients responding to the 
treatment (DN responding) vs Drug naïve patients not responding to the treatment 
(DN refractory) in the left pallidum. Orange surface is the area of difference 
between drug naïve patients responding to the treatment vs drug naïve patients not 






4.3.3 Voxel-based Morphometry 
No statistically significant differences at a threshold of p=0.05 FWE were found 
between drug naïve patients and healthy controls using VBM. We explored the data 
below this threshold and found differences in bilateral thalamus and right hippocampus 
between DN and HCs at p=0.05 (uncorrected). Although this is not statistically 
significant, it suggests that there were changes in these regions in accordance with 
volumetric analysis and shape analysis results that our study was insufficiently powered 
to detect these using VBM.  
4.4 Discussion 
For the first time, we measured structural abnormalities in a drug naïve population 
diagnosed with GGE. Our unique sample of drug naïve patients followed-up 
longitudinally, allowed us to separate grey matter structural abnormalities and any 
potential influences of treatment; a subject of debate in this field of research.  
We found that thalamus and pallidum were smaller in volume in the entire drug naïve 
group compared to healthy controls. Dividing the subjects between AE and JME, we 
found no significant volume differences comparing AE patients with matched controls. 
Wang et al., (2016) reported reduced thalamic volumes in a group of 20 drug naïve CAE 
(4 more than us). Although it is possible that the amount of patients made differences in 
the statistical power, we argue that the patients from Wang et al., (2016) had longer 
disease duration (1.86 years) than our sample (Table 3.1); therefore this difference in the 
syndrome specific group may have driven the differences. Contrary to AE, thalamus, 





matched controls. Also, shape analysis showed that thalamus, pallidum and 
hippocampus had significant regional deflation in the entire drug naïve group compared 
to healthy controls. When the patients were split into their specific syndromes (AE and 
JME), most of these effects were not large enough to be detected; the only area of 
difference was the right pallidum being smaller in the JME group compared to controls. 
Our results are concordant with previous literature reporting reduction the grey matter 
volume in subcortical areas like thalamus (Saini et al., 2013) and pallidum (Du et al., 
2011). In addition, we found differences in bilateral hippocampi confirming previous 
findings (Saini et al., 2013). Therefore, we have shown that thalamus, pallidum and 
hippocampus show volumetric differences in GGE patients before starting treatment, 
and that these are not related to AED. This was supported also from the lack of 
differences between volumes measured at drug naïve and post-treatment stages. On the 
contrary, cortical grey matter volumes calculated in prefrontal cortex, pre-central gyrus, 
cingulate and cuneus did not show statistical significant differences between drug naïve 
and healthy controls. Therefore, it is possible that the volumes of the cortical areas are 
influenced by AEDs. However, the prefrontal cortex did show a trend towards reduced 
volume in GGE compared to controls which may point to a difference that was not large 
enough to be detected with the statistical power in our study. Therefore, although this is 
the largest group available, given the complexities of the recruitment, this trend needs to 
be interpreted carefully and awaits replication.   
The longitudinal data allowed the examination of changes in relation to disease 
progression. We did not find any difference between the volumes of subcortical and 





over the time period we used to follow-up (6 months) either do not occur or are too 
small to be detectable in our data. However, this is in accord with the negative 
correlation found between volume and disease durations (Woermann et al., 1998; Kim et 
al., 2013). Also our results are in accordance with previous results that suggested that 
structural abnormalities are present even before the onset of first seizure and they are 
possibly developmental in origin (Pulsipher et al., 2011). As 93% of our patients were 
diagnosed within 1 week from the pre-treatment scan, this suggests that structural 
abnormalities are present at the point of receiving the diagnoses. However, the real point 
of disease onset may be substantially different to the average point of diagnosis which is 
very difficult to establish given how subtle some epileptic features such absence seizures 
can be, particularly early in life. This was reflected in some parental reporting that was 
vague regarding the first seizures and the actual start of the condition.  
For the first time, we also explored the relationship of volumetric abnormalities and 
treatment outcome. We observed differences in the shape of left pallidum between drug 
naïve patients who will respond to treatment and those who will not. In addition to this, 
a trend of decreased grey matter volumes in sub-cortical areas in patients not responding 
to treatment (including refractory post-treatment and refractory long-term) compared to 
patients responders to treatment was found. In particular, these reductions in subcortical 
grey matter volumes were found at the drug naïve stage. Overall, our results suggest that 
there may be an underlying difference in grey matter volume between patients 
responding and not responding to treatment. Further analysis with a bigger sample size 





longitudinal data that is possible to gain unbiased information. In practice this is difficult 
to achieve given that we recruited over 11 sites for 3 years.   
In addition, we reported no differences between NBV across groups supporting the idea 
that all differences in grey matter volumes found were not influenced by differences in 
the ratio between cortical/subcortical grey/white matter volumes. However, we found 
bigger NBV in DN compared to PT patients suggesting an influence of AED on NBV. 
This group did not show any differences in subcortical and cortical areas raising the 
question about the possible influence of the ratio between not only grey matter, but also 
white matter as an effect of AED. Further analyses are needed to explore this point in 
more detail.   
Considering the reduced grey matter volume found in DN not responders compared to 
DN responders, we can speculate that this may also be a marker of treatment outcome.    
4.4.1 Syndrome related differences 
In this study we chose to consider all the drug naïve patients in one group given that 
similar studies suggested that there may be common factors shared between syndromes 
(Kjeldsen et al., 2003). Further evidence in support of this possibility comes from 
genetic studies that have identified the same recurrent chromosomal microdeletions in 
all the common GGE syndromes, showing substantial genetic overlap between 
syndromes (Dibbens et al., 2009; de Kovel et al., 2010). In these studies, the most 
frequently identified microdeletions have been reported in three of the four common 
GGE syndromes included in our study (de Kovel et al., 2010): microdeletions 15q11.2 
were identified in patients with JME, JAE, CAE and GTCSO; microdeletions at 





JME, JAE, and CAE. In addition, previous studies looking at EEG (Chowdhury et al., 
2014a), neuropsychological (Chowdhury et al., 2014b) and transcranial magnetic 
stimulation (Chowdhury et al., 2015) in the same subject group found endophenotypes 
shared across GGE syndromes.  
We also decided to explore each syndrome separately given that there is also evidence 
suggesting that GGE syndromes are phenotypically similar but may be genetically and 
mechanistically more distinct (Berkovic et al., 1987; Andermann and Berkovic, 2001). 
Our results showed differences only in the JME group compared to healthy controls 
when we separated the GGE sub-syndromes. Indeed, we found that the difference in 
GM volume and shape survived statistical threshold only in the JME group compared to 
healthy controls but not in the AE group. These results might suggest that most of the 
differences were contributed by the JME group. This is in accordance with previous 
findings that showed that the majority of patients with volumetric alteration were JME 
(Woermann et al., 1998) suggesting different patterns of cortical abnormalities in GGE 
sub-syndromes (Betting et al., 2006). However, there is also greater variability due to 
age variance within the AE group which can only be partially accounted for in a linear 
model. Therefore an alternative possibility is that the CAE group would require 
therefore a larger group to find a significant effect.    
We did not look at white matter differences. It might be possible that further important 
information will be extracted by exploring the underlying white matter structures in both 





4.4.2 Thalamo-cortical network 
The involvement of subcortical structures in the pathogenesis of GSW, the hallmark of 
GGE has been well established. Thalamocortical circuits are thought to play an 
important role in the pathogenesis of GGE in experimental animal models (Blumenfeld, 
2005a). In humans, electrophysiological studies demonstrate that the thalamus is integral 
to seizure generation (Crunelli and Leresche, 2002); EEG-fMRI studies have shown 
synchronous thalamic activation and cortical deactivation during GSW (Gotman et al., 
2005; Hamandi et al., 2006); brain connectivity studies indicate thalami-cortical circuit 
abnormalities in patients with GGE (Richardson, 2012). Subcortical areas are well 
connected with the neocortex and depending on which connections are abnormal, 
different behavioural manifestations can occur (Haber and Calzavara, 2009). For 
example, some executive dysfunction observed in the patients with JME seems to be 
related with volume loss in the anterior thalamic nucleus projecting to the frontal lobe 
(Hughes et al., 2012).  
Our results reveal areas of abnormalities that are related with functions linked to GGE, 
such as deflation and volume loss in thalamus and pallidum. Although our approach did 
not allow us to parcellate the subcortical areas in nuclei, we note that the anterior, dorsal 
and posterior parts of the thalamus were different in shape in the drug naïve group. 
These areas connect to frontal, SMA, post-central cortex and occipital cortex 
(O'Muircheartaigh et al., 2011b), all cortical areas found associated with GGE and 
possibly involved in the manifestation of myoclonic jerks (Vollmar et al., 2011). The 
globus pallidus communicates to the thalamus directly and is involved in the regulation 





movement disorders. Atrophy of the hippocampi was reported in patients with JME (Lin 
et al., 2013) and its involvement in GGE might be related via connection to the thalamus 
(Irle and Markowitsch, 1982) and indirectly with frontal areas (Bird and Burgess, 2008). 
In addition, the hippocampi are often considered part of the DMN (Raichle et al., 2001) 
and this network has often been reported as being part of the GSW related BOLD 
response (Chapter 5). 
   
4.5 Conclusion 
For the first time we have demonstrated that subcortical abnormalities are present in 
very early onset GGE patients when drug naive. As 93% of our patients were diagnosed 
within 1 week from the drug naive scan, we also suggest that structural abnormalities 
are present since the beginning of the diagnosis given the limits of the definition of 
disease onset. Our data suggest that there is no rapid progression of volume loss with 
duration from disease diagnosis as the same pattern of differences was seen in pre-
treatment, post-treatment and refractory patients. We also identified that there is an 
interesting trend of volumetric measures differences between patients responding to 
treatment compared to those not responding to treatment. Having established these 
differences in structural measures, in the following chapter functional MRI and EEG 
will be used to acquire a more comprehensive picture of the diseases and look at the 






Chapter 5 : Core network in GGE part I: Spatio-temporal 
characterisation of the network associated with GSW in 
drug-naïve patients  
5.1 Background 
The network associated with GSW activity has been studied extensively using 
simultaneous EEG-fMRI (Gotman et al., 2005; Kay and Szaflarski, 2014; Pugnaghi et 
al., 2014). Overall agreement has been reached in the community that the fMRI response 
associated with GSW consists of a sub-cortical activation, particularly in the thalamus 
and deactivation of cortical areas including frontal and default mode brain regions 
(Gotman et al., 2005; Kay and Szaflarski, 2014). The suppression of the default mode 
network, found active during rest in healthy controls (Raichle et al., 2001), has been 
interpreted as central for seizure generation (Carney et al., 2010) setting against theories 
that the thalamic-cortical network is principally involved in the generation of GSW 
(Meeren et al., 2005). Since the last century, an open debate regarding the origin of 
GSW from the cortex (Luders et al., 1984; Holmes et al., 2004) or from the thalamus 
(Jasper HH, 1947) has been ongoing suggesting that generalised epilepsies may have a 
focal origin.   
Recent evidence points towards the thalamus as the originating point for GSW 
formation given a particular interaction with the cortex (McCormick, 2002). However, 
another hypothesis regarding the origin of GSW points towards the cortex; and cortex 
and thalamus form a unified oscillatory network in which both structures drive each 
other only after the oscillation has been set into motion form the cortex (Meeren et al., 




2002). Several studies have attempted to understand which mechanism was more likely 
in humans by exploring the temporal sequence of events. Therefore, using the temporal 
resolution of fMRI, previous studies have tried to determine which brain regions drive 
GSW onset by studying brain activity prior to GSW (here called “pre-GSW activity”). 
Up to date, contrasting results have been reported. For example, studies in GGE patients 
using EEG-fMRI have reported that cortical regions show an increase in BOLD activity 
several seconds before GSW onset. In fact, this activity was found in posterior cortical 
regions, especially precuneus (Bai et al., 2010; Benuzzi et al., 2012; Masterton et al., 
2013), as well as in frontal cortical regions such as orbital and medial frontal cortex (Bai 
et al., 2010; Benuzzi et al., 2012). Cortical regions then switch to a prolonged decrease 
in BOLD activity during GSW which lasts for several seconds after the discharge (Bai et 
al., 2010; Benuzzi et al., 2012). Thalamic activity has typically not been observed until 
GSW onset, although one study found thalamic activity several seconds before GSW 
onset (Moeller et al., 2008b). While another did not observe cortical changes prior to 
GSW (Moeller et al., 2008a); therefore, it remains unclear whether the cortex is driving 
the emergence of seizure activity or if the activity changes in cortex reflect a seizure-
permissive (but otherwise normal) brain state.  
Studies applying source imaging in MEG data have shown that the earliest activity 
related to GSW onset was in medial frontal and precuneus regions (Westmijse et al., 
2009; Sakurai et al., 2010; Gupta et al., 2011; Miao et al., 2014), with thalamus possibly 
involved in propagating activity between these cortical sites (Miao et al., 2014); 
although MEG data may not accurately capture the activity of deep grey matter sources. 
However, a study using distributed source imaging of EEG data suggested that the 




thalamus drives cortical regions at GSW onset (Moeller et al., 2013) and another study 
using MEG showed thalamic and frontal cortical sources simultaneously active at GSW 
onset (Tenney et al., 2013). Similarly, EEG distributed source analysis of GSW 
exclusively in JME showed that the precuneus was functionally most connected to other 
regions at GSW onset, suggesting that this region facilitates GSW onset (Lee et al., 
2014), a finding supported by causal modelling of fMRI data during GSW (Vaudano et 
al., 2009); conversely, other studies found that the onset of discharges was localised to 
orbitofrontal and medial frontal sources (Holmes et al., 2010; Braga et al., 2014). 
The variability of the results presented may be related to different factors. Indeed, the 
majority of the studies reported, have used mixed populations of patients who were 
under anti-epileptic medication (Gupta et al., 2011; Benuzzi et al., 2012) or who were 
previously on treatment (Carney et al., 2010; Masterton et al., 2013) . This will prevent 
unbiased comparisons between studies as treatment effects might interfere with the 
results. Up to date, we are aware of only two studies (Moeller et al., 2008a; Li et al., 
2009) which have used drug naïve patients to detect BOLD changes related to GSW 
using simultaneous EEG-fMRI and two studies which recorded MEG data (Tenney et 
al., 2013; Miao et al., 2014). Moeller et al. (2008a) and Li et al. (2009) had limited 
number of subjects (6 and 12, respectively), therefore group comparison needs to be 
interpreted carefully (Friston K.J., 1999). Tenney et al. (2013) and Miao et al. (2014) 
had intrinsic spatial configuration problems of the neuronal activity due to the inverse 
problem limiting the interpretation of MEG results (Hamalainen et al., 1993). Therefore, 
the current state of the field is such that all the studies have some limitations related to 




the potential influence of AED in the results, sample size and/or spatial resolution and 
no definitive conclusion can be reached. 
Here we tried to circumscribe these limitations by studying the largest group of drug 
naïve patients diagnosed with GGE using simultaneous EEG-fMRI to date. This sample 
will allow exploring spatial and temporal characteristics of brain activity associated with 
GSW events. In addition, given the use of fMRI, we gained a better spatial resolution 
and capability to measure changes in deep grey matter regions than MEG or EEG alone.  
We measured BOLD changes related to GSW onsets to identify if the pattern of 
activation/deactivation of thalamic-cortical network and default mode network is present 
in drug naïve patients as well as in treated patients (Kay and Szaflarski, 2014). In 
addition, we investigated BOLD changes occurring before GSW electrophysiological 
onset. Although most of the studies reported above focused on absence epilepsy 
patients, there is evidence that there is little difference between sub-syndromes of GGE 
in terms of the network generating the GSW (consistent with their electrophysiological 
similarity) (Pugnaghi et al., 2014). Therefore, the analysis presented here does not aim 
to distinguish between different syndromes but will concentrate on commonalities to 
answer the following questions: what are the BOLD changes related to GSW in a large 
group of drug naïve patients diagnosed with GGE? Are there region specific BOLD 
changes occurring before GSW electrophysiological onset? 




5.2 Methods  
5.2.1 Subjects 
Drug naïve patients who underwent simultaneous video-EEG-fMRI and presented GSW 
during the recording were selected for this study. The sample included 16 drug naïve 
patients with AE (mean age=9.7 years), and 15 drug naïve patients with JME (mean 
age=20.7 years). A full list of the demographic characteristics of the participants is 
available in Table 5.1. For specification of the sample refer to Chapter 3.  
Table 5.1: Sample selected for EEG-fMRI pre-GSW BOLD response analysis 






#1 M 6.03 / 
#2 M 14.00 Y 
#3 M 10.51 Y 
#4 M 6.37 Y 
#5 M 10.58 / 
#6 F 13.65 Y 
#7 M 8.03 Y 
#8 F 7.73 Y 
#9 M 10.28 Y 




#10 F 9.72 / 
#11 F 16.18 Y 
#12 M 7.15 Y 
#13 M 9.26 Y 
#14 M 5.92 Y 
#15 M 6.84 Y 
#16 F 13.50 / 
DRUG 
NAÏVE JME 
#47 M 21.71 Y 
#48 M 16.75 Y 
#49 F 16.58 Y 
#50 F 13.64 / 
#51 F 20.11 / 
#52 M 35.98 Y 
#53 F 15.38 Y 
#54 F 17.69 / 
#55 F 26.04 Y 
#56 M 14.44 Y 
#57 F 25.94 / 
#58 F 31.23 Y 
#59 F 16.46 / 
#60 M 20.86 / 
#61 F 19.18 Y 
 




5.2.2 Simultaneous video EEG-fMRI acquisition 
Details of simultaneous video EEG-fMRI acquisition are described in the common 
methods (Chapter 3). 
5.2.3 EEG-fMRI pre-processing 
MR gradient and pulse-related artefacts were removed off-line from the EEG recorded 
inside the MRI using template artefact subtraction method (Allen et al., 1998; Allen et 
al., 2000) implemented in a commercial EEG processing package (Brain Analyser, 
Brain Products). EEG was down sampled to 250 Hz. GSW were identified after visual 
inspection and manually marked on the EEG traces for each session. GSW were marked 
in runs with onset and duration (length of the run). 
All fMRI data were analysed using software package Statistical Parametric Mapping 
(SPM8) (http://www.fil.ion.ucl.ac.uk/spm) running under Matlab (Mathworks Inc., 
U.S.A.). After discarding the first four volumes to allow for T1-saturation effects, the 
EPI time series images were realigned to the first image, corrected with FIACH (Tierney 
et al., 2016), normalised to MNI space and spatially smoothed using an isotropic 
Gaussian kernel of 8mm FWHM (Friston et al., 1995). A more detailed specification of 
the pre-processing pipeline can be found in Chapter 3 Paragraph 3.8. 
5.2.4 EEG-fMRI analysis 
The fMRI data were analysed within the GLM framework to measure haemodynamic 
changes occurring before and during the electrophysiological onset of GWS. 




5.2.4.1 Single subject analysis 
For each subject, we created a nested model of GSW responses with two parts. In the 
first part we measured pre-GSW BOLD changes. We used a similar approach to 
Bagshaw et al. (2004). We defined a set of time points from 12s prior to the GSW, every 
3s until GSW onset (0s) (i.e. -12s, -9s, -6s, -3s, 0s from GSW onset). These were 
convolved with gamma functions with window length of 10 and order of 1 that result in 
a peak response ~3s after the effect of interests selected points (i.e. -9s, -6s, -3s, 0s, 3s 
from GSW onset). This was set to account for variability in the onset and shape of 
possible pre-GSW BOLD responses (Bai et al., 2010). The duration of pre-GSW onsets 
was set to be instantaneous (0s) as we assumed that any changes prior to the GSW onset 
would be independent from the subsequent electrophysiological duration of GSW. 
In the second part of the model we wanted a biophysically constrained but flexible 
model that could account for GSW duration. This is necessary because the duration of 
GSW events has a known influence on the BOLD response (Pugnaghi et al., 2014). We 
therefore convolved GSW with HRF, time and dispersion derivatives using GSW events 
defined by their EEG onset and duration.  
The full model was then able to fit effects of interest peaking at -9s, -6s, -3s, 0s and +3s 
with gamma functions; and from +6s with the canonical HRF, time and dispersion 
derivatives (Figure 5.1). Six inter-scan realignment parameters from image pre-
processing, 6 extra noise regressors from FIACH (Tierney et al., 2016) and the cartoon 
blocks were included in the GLMs as confounds. A high-pass filter of 128s was 
included to remove slow scanner drift unrelated to physiological BOLD changes.  




SPM[T+] contrasts were generated at the single subject level to create con images that 
were used at the second level analysis to measure commonalities across patients.  
 
Figure 5.1: Single subject level design matrix. In the zoomed section of the model, 
from left to right, there are: numbers from -12 to 0 representing effects of interest 
convolved with gamma functions (first 5 columns); HRF+Time+Dispersion 
derivatives represents effects of interests convolved with HRF, time and dispersion 
derivatives (columns 6, 7 and 8); columns numbers 8-20 include noise; last column 
includes the task regressor.  
 




5.2.4.2 Group level analysis 
We calculated common areas of BOLD changes across patients using a 3x2 full factorial 
design at the second level. The first factor, “Basis functions”, had 8 levels, one for each 
effect of interest explaining GSW BOLD responses: gamma functions with onsets at   -
12s, -9s, -6s, -3s, 0s, (instantaneous duration) and canonical HRF and its time and 
dispersion derivatives (onset 0s, duration based on GSW marking). The second factor 
was “Syndrome” having 2 levels, patient with AE and patients with JME (Figure 5.2). 
Con images derived from the single subject level contrasts were entered in this second 
level model. SPM[F] contrasts were calculated to identify pre-GSW and post-GSW 
related BOLD signal changes (Ashburner J, 2012b). A statistical threshold of p<0.05 
FWE cluster level correction (which corresponds to p<0.001 uncorrected with extent 
threshold k=102 at voxel level) was used to determine significant results.  
SPM[F] contrasts were built to explore the temporal evolution of BOLD changes related 
to GSW. We explored pre-GSW BOLD responses by constructing one SPM[F] contrast 
per effect of interest (onset times at -12s, -9s, -6s, -3s and 0s convolved with gamma 
functions). An SPM[F] representing all pre-GSW changes was calculated to test for 
regions with any pre-GSW changes. Correspondingly the spatial region of 
activation/deactivation related with electrographic GSW onset was calculated by 
performing an SPM[F] contrast across the post-GSW model (i.e. the GSW onsets 
convolved with HRF, time and dispersion derivatives).  
5.2.4.3 Group level regional response extraction 
As we were interested in the direction and dynamics of the BOLD response from 12s 
before GSW onsets up to their electrophysiological onsets, we wanted to visualise the 




average fitted temporal response to GSW in regions exhibiting a significant response in 
the SPM[F] contrasts calculated from gamma functions (Paragraph 5.2.4.2). Also, as we 
were interested in the spatial location of main networks related with GSW, we wanted to 
visualise the average fitted temporal response to GSW in regions exhibiting a significant 
response in the SPM[F] contrasts calculated from HRF, time and dispersions derivatives 
(Paragraph 5.2.4.2). The results of the group level model give the betas for every voxel 
in the brain. The fitted response is therefore the product of the basis set described in 
Paragraph 5.2.4.1 and the group level betas taken from the second level model 
estimation. To achieve this, we created a design matrix containing the basis set used in 
the model described in Paragraph 5.2.4.1 with higher temporal resolution (0.2s) than the 
repetition time used for fMRI acquisition (2.160s). The mean temporal responses of the 
voxels within the clusters of interest were plotted with +/- the standard deviation of the 
response across the cluster.   
 


























































































































































































(gray   not uniquely specified)
Design description...
Design : Full factorial
Global calculation : omit
Grand mean scaling : <no grand Mean scaling>
Global normalisation : <no global normalisation>
Parameters : 16 condition, +0 covariate, +0 block, +0 nuisance
16 total, having 16 degrees of freedom
leaving 152 degrees of freedom from 168 images





We recorded GSW during simultaneous video-EEG-fMRI in 21 patients. We excluded 
12 patients from our analysis; in one patient the MRI was corrupted by artefacts and in 
11 patients we did not record GSW events. We included 12 drug naïve patients 
diagnosed with AE and 8 patients diagnosed with JME. We recorded a total of 119 runs 
of GSW in the AE patients group (mean duration= 6.87s, SD=5.65) and 60 runs in the 
JME patients group (mean duration=1.41s, SD=1.15).   
5.3.1 GSW-related BOLD response at GSW-onset using canonical 
HRF, Time and Dispersion derivatives 
The GLM presented in Figure 5.2 allowed us to explore BOLD responses pre and post-
GSW onset. The post-GSW model was created via the convolution of the onsets with 
canonical HRF and its time and dispersion derivatives to allow for variability of 
response shape. The directionality of the BOLD response for the time and dispersions 
derivatives cannot be meaningfully assessed using t-tests (the derivative estimates 
depend on the size (and sign) of the HRF estimate (Ashburner J, 2012a)). Therefore the 
network associated with GSW events was assessed using an SPM[F] contrast across the 
combination of the HRF, time and dispersion derivatives and information about the 
directionality and shape was extrapolated from the fitted response.  
SPM[F] maps showed changes in mesial frontal cortex, bilateral parietal cortices, 
posterior cingulate and bilateral caudate. Other areas of activity were found in the 
bilateral dorso-lateral middle frontal cortices, occipital cortex, unilateral fusiform gyrus, 




unilateral insula, superior and middle temporal gyri and inferior frontal gyrus (Figure 
5.3, Table 5.2).   
 
Figure 5.3: SPM[F] maps of post GSW-related BOLD response (onsets and 
durations convolved with canonical HRF, Time and Dispersion derivatives). 
   
5.3.2  Fitted response of GSW “classical” core network 
 GSW SPM[F] maps of the HRF time and dispersion derivatives showed areas of 
activity which included the “classical” GSW-related networks: sub-cortical areas such as 
caudate; and cortical regions such as bilateral parietal cortex, PCC and mesial frontal 
cortex. We plotted the fitted response for these areas to explore the directionality of the 
BOLD response following canonical HRF and its time and dispersion derivatives 
(therefore peaking at about +6s from onset). Parietal cortex (most prominently left) and 
PCC showed a negative BOLD response whilst mesial frontal cortex and bilateral 
caudate showed a positive BOLD response (Figure 5.4).  





Figure 5.4: Group level BOLD fMRI response calculated with SPM[F] maps for 
selected cluster representing the “classical” network related to GSW convolved 
with HRF, time and dispersion derivatives. The mean cluster BOLD fitted response 
(blue) is plotted with +/- standard deviation (green). Red line marks the 




electrophysiological onset of GSW. R=right, L=left, FC=frontal cortex, 
PCC=posterior cingulate cortex.   
 
5.3.3 GWS-related BOLD response pre-GSW using gamma functions 
A basis set of gamma functions was used pre-GSW to look for early BOLD signal 
changes that cannot be captured by the canonical HRF and derivatives. SPM[F] maps 
showed no changes surviving the statistical threshold of p<0.05 FWE corrected, cluster 
level, at onsets of 12s and 9s before electrophysiological recording of GSW. A 
significant BOLD response was found in the mesial superior frontal cortex at 6s before 
GSW electrophysiological onset and caudate/thalamus at 3s before GSW onset. Bilateral 
caudate was found significant at the onset of GSW together with bilateral insula, right 
inferior frontal gyrus and right superior temporal and middle frontal gyri (Figure 5.5, 
Table 5.2).      





Figure 5.5: BOLD response changes 6s and 3s before and at onset of GSW using 











Table 5.2: GSW-related BOLD response for each effect of interest. 
SPM[F] contrast AE+JME x, y, z 
-12 /  
-9 /  
-6 S MESIAL FC -10 40 54 
-3 R THALAMUS/ 
L CAUDATE 
-10 2 10 
0 BILATERAL CAUDATE 
L INSULA 
R STG/R INSULA 
R IFG/MFG 
6 8 14 
-26 12 12 
50 14 6 
48 36 12 
-12+-9+-6+-3+0 BILATERAL CAUDATE 6 8 14 
HRF+Time+Dispersion R FUSIFORM GYRUS 
 L INFERIOR PARIETAL 
R INFERIOR PARIETAL 
MESIAL FC 
L DORSO-LATERAL MFG 









48 -52 -24 
-44 -58 52 
46 -54 48 
-6 42 28 
-2 26 26 
52 32 26 
-2 -96 14 
-52 -58 22 
12 6 4 
56 18 -2 
-12 6 12 
-8 -44 42 
36 20 6 
-58 -50 -4 
GSW-related BOLD changes (p<0.05 FWE corrected, cluster level). R=right, 
L=left, PCC=posterior cingulate cortex, FC=frontal cortex, ITG=inferior temporal 
gyrus, MFG=middle frontal gyrus, STG=superior temporal gyrus, IFG=inferior 
frontal gyrus.  
 
5.3.4 Early BOLD changes associated with GSW 
SPM[F] maps showed significant pre-GSW and GSW-onset related BOLD responses at 
statistical threshold of p<0.05 FWE corrected, cluster level as implemented in the 
random field theory framework in SPM (Figure 5.3, Figure 5.5). However, for all the 




areas, BOLD response at the second level is a static map related to the particular effect 
of interest with no time information (Ashburner J, 2012a). Therefore, fitted responses 
across time of the clusters resulted significant in the SPM[F] contrasts of each gamma 
functions and across all 5 gamma functions were plotted (Figure 5.6). We found that 
caudate, thalamus, right inferior frontal gyrus and right superior temporal gyrus showed 
a positive BOLD response from 12s to 3s before GSW onset; negative BOLD response 
was measured during GSW onset and a positive BOLD response was measure 2s after 
GSW onset. Different was the mean BOLD response found in the left insula cluster that 
showed a very low amplitude positive BOLD response prior to GSW onset, a settled 
negative BOLD response at GSW onset and a positive BOLD response changes after 
GSW onset. Mesial frontal cortex showed positive BOLD response 10s and 3s before 
GSW onset, negative BOLD response around 7s prior to GSW onset and at GSW onset 
following positive BOLD response after 3s since GSW onset (Figure 5.6).  




     
(Figure 5.6 continues in the following page)  




     
 
Figure 5.6: Group level BOLD fMRI response calculated with SPM[F] maps for 
each and all onsets time (-6s, -3s, 0s) convolved with gamma functions. The cluster 
mean BOLD fitted response (blue) is plotted with +/- standard deviation (green). 
Red line marks the electrophysiological onset of GSW. Selected visualisation of the 
cluster plotted is on the left. R=right, L=left, FC=frontal cortex, IFG=inferior 
frontal cortex, STG=superior temporal gyrus.  
  
5.4 Discussion 
In this study we measured GSW-associated BOLD responses in the biggest group of 
drug naïve patients diagnosed with GGE studied to date. We measured BOLD response 




changes at the onset of the GSW to identify if drug naïve patients showed the same 
pattern of activation and deactivation of the thalamic-cortical network and DMN found 
in treated patients. We also measured changes before GSW onset to understand early 
BOLD changes that might relate to seizure initiation.  
We found that DMN and the thalamic-cortical network were involved in GSW BOLD 
response changes in drug naïve patients, as in patients already treated with AEDs. 
Selecting the BOLD responses peaking 6 seconds after GSW onset following HRF and 
its time and dispersion derivatives shape, the DMN was found deactivated during GSW 
while caudate was found being activated. Therefore, we are confident to conclude that 
the same pattern of activation/deactivation of the thalamus/cortex is found in drug naïve 
patients as has been previously described in patients on AED treatment (Gotman et al., 
2005; Hamandi et al., 2006; Laufs et al., 2006) 
We also measured BOLD responses in brain areas prior to GSW onset. The earliest 
BOLD response changes we found were at about 6s before GSW onset in the frontal 
cortex. This suggests a role for this area in first generating GSW. BOLD changes in the 
thalamus were found later on, starting about 3s before GSW onset, suggesting a 
secondary role in the generation of GSW.  
5.4.1 Drug naïve GSW BOLD changes 
Significant BOLD responses in the thalamic-cortical network and in the default mode 
network were found at the electrophysiological onset of GSW in the largest group of 
drug naïve patients diagnosed with GGE available in literature. This suggests that the 
pattern of activity in the functional networks is independent of AED intake. Additional 




areas were seen at GSW onset: bilateral insula, occipital cortex, fusiform gyrus and 
temporal cortex. These areas were found inconsistently across studies. For example, 
insula was reported only in one study (Gotman et al., 2005) while occipital and temporal 
cortices were reported more frequently (Aghakhani et al., 2004; Gotman et al., 2005; 
Hamandi et al., 2006; Laufs et al., 2006). Considering that some studies have relied on 
previous findings and used regions of interest analysis (Moeller et al., 2008b; Moeller et 
al., 2008a), in which only specific brain regions related to the thalamic-cortical network 
and DMN were targeted, it is possible that additional areas were neglected from the 
results. For this reason, we decided not to use ROIs. In addition, exploring whole brain 
activity has given the opportunity to fully interrogate the unknown GSW BOLD 
response of drug naïve patients.   
The insula is a region of convergence of multisensory inputs that has recently been 
implicated in focal seizures (Isnard et al., 2004) but not in generalised discharges. 
However, the insula has widespread thalamic connections (Mufson and Mesulam, 1984; 
Cho et al., 2013), and connection with cortical areas involved with GSW such as frontal 
cortex and dorsal-posterior cingulate (Cauda et al., 2011), which may explain its 
activation during GSW found in our study. The activity of the visual cortex can be 
interpreted as a brain network that somehow interacts with the ictal onset mechanisms to 
allow GSW onset. Hints that pre-ictal cortical changes seen in fMRI studies might 
represent a seizure-permissive brain state have been found. For example, the rare 
syndrome of eyelid myoclonia with absences (EMA, Jeavons Syndrome) shows 
abnormally increased BOLD signal in visual brain regions during eye closure, 
suggesting that a hyperexcitable network has been activated by eye closure, from which 




seizures might emerge (Vaudano et al., 2014). Patients with photoparoxysmal response 
on EEG (an abnormal response to stroboscopic light, which can evolve into GSW) 
showed activity in a set of visual cortical regions during the photoparoxysmal response, 
which additionally engages thalamus if a GSW arises (Moeller et al., 2013). This is 
reflected in a study of white matter connectivity using DTI, which showed abnormalities 
in visual regions in subjects with photoparoxysmal response alone, but also in thalamic 
connections in subjects with photoparoxysmal response and GGE (Groppa et al., 2012; 
Bartolini et al., 2014). 
No functional or structural connection exists between the fusiform gyrus and areas of 
thalamic-cortical network of DMN. Therefore, we hypothesise that the activity found in 
the right fusiform gyrus relates to the cartoon task we are presenting during 
simultaneous EEG-fMRI recording. Although we account for the effect of the cartoon in 
our model, it is possible that a different state of the brain, not being at rest but watching 
a carton, will lead to additional BOLD responses. In fact, this area has been found 
related with face processing (Rossion et al., 2003) as well as active during our cartoon 
task (Shamshiri, 2016). In addition, given the strong connection between the fusiform 
gyrus with the occipital cortex (Catani et al., 2003), it is also possible that the activity of 
the occipital cortex found is related to the cartoon effect.  
Given the importance of understanding the effect that GSW have on cognitive functions 
(Berman et al., 2010), we explored the effect that cartoon has in relation with GSW. 
This analysis has been presented in Chapter 6.  




5.4.2 Directionality of pre-GSW BOLD signal changes 
As SPM[F] maps do not allow the identification of the directionality of the BOLD 
response, we plotted the mean fitted response of each cluster.   
We measured early changes in the mesial frontal cortex and then in thalamus and 
caudate. In particular, we found that the mesial frontal cortex BOLD response changed 
from positive to negative around 6s before GSW onset while thalamus and caudate did 
not change BOLD responses until about 3s before GSW onset. Particularly, thalamus 
and bilateral caudate were found switching BOLD response from positive to negative 2s 
before up to 2s after GSW onset.  
In addition, although BOLD responses were not found in any SPM[F] contrasts using 
gamma functions, results of the effects of interest convolved with HRF showed a 
potential pattern of positive and negative BOLD changes prior to the onset of GSW in 
the parietal cortices.  
Overall, these results suggest that there is an early activity in the cortex preceding GSW 
onset. These results replicate previous findings identifying the mesial frontal cortex as 
the area of first activation prior to GSW onset (Gupta et al., 2011; Miao et al., 2014). 
Given the later BOLD response changes of subcortical areas, we hypothesise that 
thalamus together with caudate appear to behave physiologically and reactively to the 
onset of epileptiform activity and play a critical role in facilitating and sustaining 
seizures as it has been previously reported (Meeren et al., 2002; Carney et al., 2010). 
These sub-cortical areas show a striking and very strong bi-phasic haemodynamic 
response around GSW onset on EEG. This suggests that they are essential to the 
generation of this activity and have a strong change in their activity from being 




inhibitory (negative BOLD) to excitatory (positive BOLD) that this is concomitant with 
GSW generation.  
5.4.3 Methodological considerations 
We decided to use the canonical HRF together with time and dispersion derivatives 
(Friston et al., 1998) to measure GSW-related BOLD responses at event onset time to 
capture the higher degree of variability of the BOLD response. There is a debate 
regarding the accuracy of the HRF in capturing the effective response to GSW in adult 
(Grouiller et al., 2010) and in a paediatric populations (Jacobs et al., 2008). Previous 
studies have demonstrated the usefulness of modelling the event-related response with a 
canonical HRF and its partial derivatives, and assessed the contribution of the different 
basis functions by a series of SPM[F]-contrasts. Significant variability was captured by 
both the temporal derivative and dispersion derivative, confirming that different regions 
exhibited different shaped responses and the canonical HRF and its two partial 
derivatives were sufficient to capture the majority of experimental variability at stimulus 
onset (Henson, 2001). Similarly, in patients with epilepsy comprehensive responses of 
epileptic-type activity were captured in patients with epilepsy using HRF and its 
derivatives (Chaudhary et al., 2012b; Pugnaghi et al., 2014).  
We captured differences in the BOLD response to prior and at the electrophysiological 
onset of GSW using gamma functions peaking at -9s, -6s, -3s, 0s and +3s. Considering 
the overall inconsistency regarding the activity prior GSW in the literature (Hawco et 
al., 2007; Moeller et al., 2008a; Amor et al., 2009), and the unknown shape of the HRF 
response in pathological situations (Bai et al., 2010) we decided to use an exploratory 




approach based on nested HRF models with different latencies that could locate areas of 
activation that were previously undetected and or clarify the BOLD response as was 
demonstrated in focal (Bagshaw et al., 2004) and generalised (Aghakhani et al., 2004) 
epilepsies. Importantly by including the regressors within the same model statistical 
inference can be made to determine responses relative to each other via the nature of an 
SPM[F]-test being analogous to a model comparison.    
5.5 Conclusion 
Drug naïve patients diagnosed with GGE showed a spatial-temporal pattern of activation 
and deactivation of subcortical areas and DMN, respectively; suggesting that these 
networks, reported by previous literature, are GSW-related networks associated to GGE 
independent of AED effects. Early changes in the cortex followed by changes in 
subcortical areas supported the theory that generalised epilepsy may have a focal onset. 
However, given that evidence of causality is still insufficient, we concluded that the 
cerebral cortex and thalamus, together, can form cyclical loops of activity that may 




Chapter 6 : Core network in GGE part II: Brain state 
dependence of GSW associated networks 
6.1 Background 
Previous EEG-fMRI studies have looked at GSW related BOLD changes where subjects 
were typically asked to lay in the scanner with eyes closed without performing any 
specific engaging task (Gotman et al., 2005; Hamandi et al., 2006; Moeller et al., 2008a; 
Kay and Szaflarski, 2014). In epilepsy studies this was chosen to increase the yield of 
epileptic discharges. However, the healthy brain has been shown to have measureable 
spontaneous fluctuations in large-scale brain networks in the so called ‘resting state’. 
One of the most observed networks is the default mode network in which, from both 
PET and fMRI studies, increased metabolic activity at rest or a relative decrease in 
comparison to any other cognitive task was measured (Raichle et al., 2001; Fox and 
Raichle, 2007).  
The deactivation of the DMN has been consistently found during GSW by group level 
studies in patients diagnosed with GGE (Kay and Szaflarski, 2014). This phenomenon 
has been interpreted as an interruption of the conscious state in this patient population 
(Gotman et al., 2005; Hamandi et al., 2006; Laufs et al., 2006), given the functional role 
of DMN in consciousness (Cavanna and Trimble, 2006). However, an alternative 
explanation is that the DMN deactivation is simply the perturbation of the ongoing brain 
activity by the GSW event; at rest this would be the DMN.  
Evidence suggesting the latter argument is related to the fact that not all the patients 
have shown this pattern of DMN deactivation at the single subject level (Gotman et al., 




2005) and additional cortical activity was found outside of the DMN brain areas 
(Aghakhani et al., 2004).  
A pattern of activation of the thalamic-cortical network was found more consistently 
across patients. This may suggest that the thalamo-cortical BOLD activation represents 
the key brain regions associated with GSW (Gotman et al., 2005) and the level of DMN 
deactivation is specific to the individual or their state during the GSW. 
Indeed, a possible explanation about the inconsistency of DMN during GSW may be 
due to differences in the inter-burst baseline that might modify the BOLD response 
during GSW. Given that different a state of drowsiness changes the activity of DMN 
(Maquet, 2000) and that the border between resting state and drowsiness is slight 
(Tagliazucchi and Laufs, 2014), there are open questions related to the role of DMN 
deactivation that might not be specific for or causally related to GSW.  
Taking into account the necessity to model the level of vigilance (Hamandi et al., 2006; 
Tagliazucchi and Laufs, 2014), some studies have investigated brain structures involved 
in the interaction between GSW and cognitive task using reaction time measures under 
continuous attention (Bai et al., 2010; Berman et al., 2010; Moeller et al., 2010a) and 
under a more cognitive demanding working memory task (Chaudhary et al., 2013). 
Although the first studies found that the pattern of activation and deactivation of the 
cortex and subcortical areas was replicated during resting state and tasks, Chaudhary et 
al. (2013) additionally found that during the task, active areas were deactivated in 
association with GSW. This supports the idea that GSW may perturb the networks 
which happen to be activated at the moment when GSW occur rather than the disruption 
of specific functional brain networks (Blumenfeld, 2005b).    




However, none of these studies compared the response of GSW in different brain states. 
In addition, the neuropsychological tests used may suppress interictal discharges and/or 
change GSW amount or length of the discharges (Binnie et al., 1987; Binnie, 2003), 
preventing the detection of GSW on the EEG and/or leading to fMRI reduced signal 
changes (Hamandi et al., 2006; Chaudhary et al., 2013). Therefore, there is the need to 
explore GSW BOLD responses between different brain states using a different task 
which would not strongly alter GSW occurrence rates.   
We hypothesised that GSW would deactivate whichever network was active in a 
particular brain state and that the DMN was therefore not an important part of the core 
network necessary to generate GSW. To test this, we used simultaneous recordings of 
EEG-fMRI in GGE patients during periods of rest and during a low level attention task 
involving watching a cartoon. The aim of this was to provide a different pattern of active 
brain areas in each period without dramatically affecting epileptic discharge rate 
(Centeno et al., 2016). We expected a greater deactivation associated with GSW in the 
key nodes of the DMN during rest than during the cartoon and correspondingly a greater 
deactivation associated with GSW in the key nodes of the task active network during the 
cartoon compared to rest.     
6.2   Methods 
6.2.1 Subjects 
We selected 16 patients (mean age (Y)=15.26, 6 F) who had GSW during at least one 
session of rest and at least one session of cartoon during simultaneous video-EEG-fMRI. 
We have previously demonstrated GSW-related networks are similar in drug naïve 
patients recently diagnosed with GGE to those found in patients already on treatment 




(Chapter 5). Therefore, in this analysis, we could reasonably include drug naïve, post-
treatment and refractory patients and compare their results and how they were affected 
by brain state.  
The list of patients selected for this analysis is in Table 6.1 further details of the patients 
are found in Chapter 3, Table 3.1. 
 
Table 6.1: Sample information 















#3 M 10.51 1 
(6.4960)+1 
(8.18) 
8 (5.2) 1 (8.1080) 
#4 M 6.37 2 (2.4367) 17 (3.02) 1 (4.2960) 
#6 F 13.65 1 (28.67) 1 (5.67) / 
#7 M 8.03 1 
(5.34)+10 
(1.56) 
2 (6.84) / 
#12 M 7.15 1 
(0.4560)+3 
(4.2464) 
14 (5.14) 2 
(5.308)+2 
(2.6312) 




#11b F 16.78 1 (0.4375) 1 (1.75) 1 (1.5331) 














#24 F 7.00 2 
(0.3707)+6 
(1.0549) 
4 (0.839) 4 
(0.8693)+1 
(1.128) 

































Age is in years; number of GSW per session for each patient is listed; in brackets 
there is the mean duration of GSW in seconds.  
 
6.2.2 Simultaneous video-EEG-fMRI acquisition  
Details of simultaneous video EEG-fMRI acquisition are described in the common 
methods (Chapter 3). 
6.2.3 EEG-fMRI pre-processing 
MR gradient and pulse-related artefacts were removed off-line from the EEG recorded 
inside the MRI using template artefact subtraction method (Allen et al., 1998; Allen et 
al., 2000) implemented in a commercial EEG processing package (Brain Analyser, 
Brain Products). EEG was down sampled to 250 Hz. GSW were identified after visual 




inspection and manually marked on the EEG traces for each session. GSW were marked 
in runs with onset and duration (length of the run). 
All fMRI data were analysed using software package Statistical Parametric Mapping 
(SPM8) (http://www.fil.ion.ucl.ac.uk/spm) running under Matlab (Mathworks Inc., 
USA). After discarding the first four volumes to avoid T1-saturation effect, the EPI time 
series images were realigned to the first image, corrected with FIACH (Tierney et al., 
2016), normalised to MNI space and spatially smoothed using an isotropic Gaussian 
kernel of 8mm FWHM (Friston et al., 1995).  
Specification of the pre-processing pipeline can be found in Chapter 3. 
6.2.4 EEG-fMRI analysis 
The fMRI data were analysed within a mass univariate GLM framework as implemented 
in SPM8 to measure haemodynamic changes related to GSW recorded during rest and 
during cartoon periods. 
6.2.4.1 Single subject analysis 
For each subject, a model was built that would enable us to test and compare the 
differences between GSW-associated responses during rest and during the cartoon brain 
states. To achieve this, GSW events were separated into those which occurred during 
rest and those occurring during cartoon watching using a full factorial design. It should 
be noted that cartoon had two short periods where the subject was asked to wait for the 
next cartoon segment (Figure 3.1). Therefore, the experimental design had 2 factors: 
GSW and task. GSW had 1 level: presence of GSW. Task had 3 levels: as first level we 
had “Cartoon”, the second level “Rest” and the third level is “Please Wait” calculating 




the  presence of GSW during break time in between episodes of the cartoon. Any GSW 
during this please wait period were treated as effects of no interest. This is because the 
‘please wait’ epochs were short and therefore insufficient GSW occurred to evaluate the 
GSW-associated network in this state (which is different from rest and from cartoon). 
Effects of interests were convolved with the canonical HRF and its time and dispersion 
derivatives, resulting in 3 regressors for each combination of levels. The block of the 
task (rest, cartoon, please wait), six inter-scan realignment parameters from image pre-
processing and 6 extra regressors from FIACH (Tierney et al., 2016) were included in 
the GLM as confounds. To enable a test for differences between GSW events in the 
cartoon and rest periods all the sessions were concatenated together; an extra regressor 
was introduced to account for any inter-session differences in the mean signal (Figure 
6.1). A high-pass filter of 500s was included to remove slow scanner drift related BOLD 
effects (Ashburner J, 2012a) taking into account the low frequency of the task. SPM[T+] 
contrasts were used to generate T-maps (con images) revealing patient-specific BOLD 
changes for each effect of interests convolved with HRF, time and dispersion derivatives 
that were transported at the group level analysis. This was performed to allow variable 
response shapes to GSW (as observed in Chapter 5) where significant explanatory 
power is found in the canonical response and its derivatives.     





Figure 6.1: Single subject level GLM  




6.2.4.2 Group level analysis 
We wanted to discover the common and different regional group level BOLD changes 
associated with GSW while allowing for flexibility in the haemodynamic response. To 
achieve this, we used a 3x2 full factorial design, random effect at the second level of 
analysis. The first factor “task” had 2 levels; cartoon and rest. The second factor “Basis 
functions” had 3 levels; canonical HRF, time derivative and dispersion derivative. 
Scanner type was included in the model as covariate to remove any influence of the two 
scanning centres from the analysis (Figure 6.2). For each level, we entered the relevant 
Con images generated by the SPM[T+] contrast for each individual at the single subject 
level. An inclusive mask of the areas of interests was applied. We set out to test for 
differences in the response within brain regions that showed GSW associated response. 
We therefore confined our analysis to bilateral thalami, hippocampi, caudate, pallidum, 
putamen, frontal cortex, precuneus, occipital cortex and fusiform gyri (Figure 6.3) taken 
from the results in Chapter 5 showing the GSW-associated network. Amongst these 
areas, areas belonging to the cartoon network as defined by Shamshiri et al., (2016) 
were included (Figure 6.4, Figure 6.5). SPM[F] contrasts across the HRF, time and 
dispersion derivatives (Ashburner J, 2012b) were calculated to identify BOLD changes 
(with flexible shape) related to GSW occurring firstly during rest, secondly GSW 
occurring during the cartoon and thirdly the brain regions exhibiting differences in the 
GSW-associated response during rest and cartoon. SPM[F] maps will have a threshold 
set at p<0.05, FWE corrected cluster level as implemented by the random field theory, 
corresponding to p<0.001 uncorrected, k=194. Conjunction analysis implemented in 




SPM8 (Friston et al., 2005) was performed to detect common areas between GSW 
during rest and GSW during cartoon.   
Given our a-priori hypothesis, coordinates of precuneus and fusiform gyrus were 
selected from Hamandi et al., (2006) and Shamshiri et al., (2016). BOLD fitted 
responses of these core areas of DMN, thalamic-cortical network and cartoon watching 
were plotted during rest and task periods to identify differences in BOLD responses 
during different brain states.  





Figure 6.2: Full factorial design group level analysis GLM 
 





Figure 6.3: Regions of Interests mask.  
 





Figure 6.4: Cartoon network from Shamshiri et al. (2016). We extracted the 
cartoon network from Shamshiri et al. (2016) who reported SPM maps activated in 
a group of 17 healthy controls children during cartoon watching. Activity was 
found in the bilateral fusiform gyrus, bilateral middle occipital cortex with 
extensions in middle temporal regions (Shamshiri, 2016). 
 
 





Figure 6.5: Overlay of cartoon network from Shamshiri et al. (2016) in red, ROI 
mask used in this analysis (Figure 6.3) in blue. This overlaid displays the inclusion 
in our mask of the main clusters of the cartoon network: right fusiform, left middle 
occipital cortex, right middle occipital cortex, left fusiform. R=right, L=left, 
Occi=occipital, MNI=Montreal National Institute coordinates. 
 
6.3 Results 
Fourteen patients were included in the analysis. Two patients were excluded as the GSW 
were only recording during the period of “Please Wait”. One session of one patient was 
discarded due to the presence of a-typical epileptiform events occurring only in the 
frontal EEG electrodes. Although this is a feature seen in GGE patients (Seneviratne et 
al., 2014), we decided to discard it from the analysis to allow more consistency in the 
type of GSW discharge for comparison between states. 




We included a total of 58 runs of GSW recorded during the cartoon period and a total of 
113 runs of GSW recorded during rest. 25 runs of GSW were included as effects of no 
interest as they were recorded during “Please Wait” periods. There was no significant 
statistical differences between the number of GSW recorded during cartoon and during 
rest U=57.5, p=0.062. No differences were found in duration between GSW runs during 
rest and GSW runs during cartoon U=81.0, p=0.454. This suggests that stereotypical 
electrophysiological events of 3 Hz GSW are characterised in both conditions although 
there is a trend in reduction in GSW during cartoon.  
6.3.1 GSW associated BOLD map during rest 
SPM[F] map of HRF, time and dispersion derivatives of GSW during rest showed that 
right inferior frontal cortex, left precuneus and left middle occipital cortex survived 
p<0.05, FWE corrected at cluster level (Figure 6.6, Table 6.2).    
 
Figure 6.6: SPM[F] map of GSW during rest. The map had a threshold set at 
p<0.05 FEW, cluster level. List of significant clusters is included in Table 6.2.  
 




6.3.2 GSW associated BOLD map during the cartoon 
SPM[F] map of HRF, time and dispersion derivatives of GSW during cartoon showed 
that right inferior frontal gyrus and right middle occipital cortex survived p<0.05, FWE 
at the cluster level (Figure 6.7, Table 6.2).  
 
Figure 6.7: SPM[F] map of GSW during cartoon. The map had a threshold set at 
p<0.05 FWE corrected, cluster level. List of significant clusters is included in Table 
6.2.  
 
6.3.3 Cartoon vs Rest in a priori coordinates 
Differences were not found between cartoon and rest surviving a statistical threshold of 
p<0.05 in precuneus and right fusiform, the key nodes of the DMN and cartoon network 
using the coordinates from Hamandi et al., (2006) and Shamshiri et al., (2016), 
following our spatial hypothesis.  
However, BOLD responses were plotted for precuneus and fusiform gyrus (Figure 6.8) 
for exploratory purposes. We found that the right fusiform gyrus showed a positive 




BOLD response and subsequent negative undershoot during rest whilst a negative 
BOLD response was seen during cartoon periods. The precuneus was found to have a 
negative BOLD response during cartoon and rest with a more negative change to GSW 
during rest (as expected), although this is not statistically significant.  
 
Figure 6.8: BOLD fitted responses during cartoon and rest using a priori ROI 
coordinates from previous studies: right fusiform (38, -60, -12) on the left; 
precuneus (6, -48, 17) on the right.  
 
6.3.4 BOLD maps comparison between rest and cartoon 
Conjunction analysis between GSW during rest and cartoon did not show any areas of 
overlapping that were statistically significant.  
Under the assumption that differences between cartoon and rest in the a priori 
coordinates were not statistically significant and that the SPM[F] maps during rest and 
cartoon appeared spatially diverse, we decided to explore the variation in the GSW 
BOLD response between rest and cartoon across a wider range of areas included in the 
brain mask (Figure 6.3).  




SPM[F] contrast of the difference in activity between GSW during rest and during 
cartoon has showed no results at a statistical threshold of p<0.05, FWE corrected at 
cluster level. Clusters of differences were found setting an exploratory statistical 
threshold at p<0.05, uncorrected. We found that bilateral occipital cortex, bilateral 
inferior frontal gyri, bilateral hippocampi, bilateral fusiform gyri, bilateral thalami, 
bilateral caudate, bilateral superior frontal gyri, mesial frontal cortex and left precuneus 
were the areas marking BOLD differences between GSW recorded during rest and 
cartoon sessions (Figure 6.9, Table 6.2).  
Amongst these areas, we found cortical areas from which a priori coordinates were 
selected such as right fusiform gyrus and precuneus. In addition, we found left and right 
middle occipital cortex and left fusiform gyrus which were considered main clusters of 






 clusters) by Shamshiri et al. (2016) (Figure 6.5). 
Therefore, we exploratory measured the nearest locations from the a priori coordinates 
showing a difference between rest and cartoon GSW responses. We found that different 
coordinates, very close to those reported by Shamshiri et al. (2016) and Hamandi et al. 
(2006), within the right fusiform gyrus (34, -34, -26) and precuneus (16, -54, 20) did 
show state related differences (Figure 6.10). Similarly, we found that close coordinates 
to those reported by Shamshiri et al. (2016) in right middle occipital cortex (38, -76, 10) 
and left middle occipital cortex (-18, -88, 22) did show differences between GSW 
during rest and cartoon. We found a closed cluster to the left fusiform gyrus from 
Shamshiri et al. (2016) which was on the border with left fusiform gyrus but falling on 
the inferior occipital cortex (-36, -76, -10). Therefore, the nearest coordinates we found 




in the left fusiform gyrus (-16, -38, -16) were not as closed as Shamshiri et al. (2016)’s 
(Figure 6.10). 
 
Figure 6.9: SPM[F] map of the difference between GSW during cartoon and GSW 
during rest (p<0.05 uncorrected). 
 
Table 6.2: List of significant cluster from SPM GLM  
CONTRAST STATISTICAL THRESHOLD Coordinates x, y, z 
p<0.05 FWE, 
cluster corrected 
p<0.05, uncorrected  
GSW during 
CARTOON 
R IFG / 56 16 6 
R MIDDLE 
OCCIPITAL 
/ 32 -74 42 
GSW during 
REST 
R IFG / 38 6 34 
L PRECUNEUS / 0 -64 44 
L MIDDLE 
OCCIPITAL 
/ -36 -70 40 









/ R OCCIPITAL 22 -74 22; 42 -68 
12; 48 -78 14;       
38 -88 8 
/ R IFG 48 16 20;              
36 20 -20  
/ L OCCIPITAL -28 -74 38; -36 -76 
-6; -36 -64 28; -16 
-86 22; -42 -84 10; 
-44 -82 8 
/ L FUSIFORM -16 -38 -16; -26 -6 
-36; -28 -20 -28 
/ R HIPPOCAMPUS 32 -32 -2; 38 -8 -20 
/ L CEREBELLUM -10 -32 -12 
/ L HIPPOCAMPUS -32 -22 -10;            
-14 -30 -8 
/ L IFG -22 10 -22;             
-42 28 -4; -40 20 8 
/ R PALLIDUM 24 -8 -6 
/ R FUSIFORM 34 -34 -26 
/ L SFG -36 50 20;               
-20 50 2; -22 34 26  
/ L THALAMUS -18 -16 8  
 / R MFG 34 38 46; 38 2 42; 
36 10 62; 30 56 28 
/ MESIAL FC 8 34 -10; -10 44 
52; 12 34 36; 2 40 
34; -2 34 -14;       
16 44 -4  
/ L PALLIDUM -16 0 -6  




/ R CAUDATE 22 4 20 
/ R THALAMUS 20 -22 8 
/ L CAUDATE -8 8 16  
/ R SFG 32 4 66; 32 10 64; 
16 62 22 
/ L PRECUNEUS -14 -64 42 
/ L MFG -50 26 36 
List of significant clusters for each SPM[F] contrasts. L=left, R=right, 
IFG=inferior frontal gyrus, MFG=middle frontal gyrus, SFG=superior frontal 
gyrus, FC=frontal cortex.  
 





Figure 6.10: MNI coordinates from Shamshiri et al. (2016) and Hamandi et al. 
(2006) (on the left) and MNI coordinates of the nearest subthreshold cluster within 
the same cortical area resulted from SPM[F]contrast of GSW during cartoon vs 




GSW during rest (on the right). R=right, L=left, Occi=occipital, MNI=Montreal 
National Institute coordinates. 
 
6.4 Discussion 
For the first time, we explored the relationship between GSW and functional brain 
networks in different brain states in a group of patients diagnosed with GGE. We tested 
differences and commonalities in the GSW-related BOLD response during rest and 
during a low demanding cognitive task.  
We found that the SPM[F] map during rest was different from the SPM[F] map during 
cartoon. Indeed, the first map showed the typical spatial pattern of the DMN, whilst the 
map of GSW during cartoon exhibited only right inferior frontal gyrus and right middle 
occipital cortex. The conjunction analysis between the two GSW-related maps did not 
show common brain areas. This suggested that the functional correlates of GSW may be 
brain state specific.   
All the BOLD responses to GSW found were related to the brain regions most active 
during the state in which the GSW occurred. In fact, the right inferior frontal gyrus, 
found during cartoon and during rest has been reported to be associated with attention 
processes (Collette and Van der Linden, 2002; Derrfuss et al., 2004; Hedden and 
Gabrieli, 2006; Hampshire et al., 2010) and during video watching (Anderson et al., 
2006). Middle occipital cortex was found in both conditions as well. This is in 
accordance with Berman et al. (2010) and Aghakhani et al. (2004) who found a similar 
pattern of activation during attentional tasks in 6 patients with AE and during rest in 2 




patients, respectively. In addition, the precuneus was found in our BOLD map, 
signalling a strong link with GSW during rest.  
We measured differences in the BOLD response in the core areas of the cartoon and rest 
networks. We plotted the fitted responses in the coordinates of the right fusiform gyrus 
from Shamshiri et al. (2016) and the precuneus from Hamandi et al. (2006).  Shamshiri 
et al. (2016) found that the fusiform gyrus was the global maximum in a group of 
healthy control children during cartoon watching.  Hamandi et al. (2006) tested GSW 
activation during rest and found the precuneus to be the fourth most significant cluster. 
Although we did not find significant BOLD changes at these coordinates, interestingly, 
we found an early opposite direction of the BOLD response between rest and cartoon in 
the right fusiform gyrus (Figure 6.8) pointing towards the hypothesis that activity in the 
network in use at the time of the occurrence of the GSW may be impaired. This would 
support also the results of Chaudhary et al. (2013) who found perturbation of the active 
network in a working memory task in one patient. In addition, the precuneus showed a 
negative BOLD response both during rest and cartoon with a greater negative BOLD 
response during rest than during cartoon.  
Given that we did not find BOLD changes at the a priori coordinates as we 
hypothesised, we performed an exploratory search for the nearest locations showing a 
difference between rest and cartoon GSW responses. We found that different 
coordinates, very close to those reported by Shamshiri et al. (2016), within the fusiform 
gyrus (34, -34, -26), middle occipital cortex (38, -76, 10; -18, -88, 22) and precuneus 
(16, -54, 20) did show state related differences. However because they were not 
preselected any activity surviving p<0.05 uncorrected for multiple comparisons may be 




due to insufficient control of false positives. Further, we also exploratory investigated 
SPM[F] maps of the difference in activity between GSW during rest and GSW during 
cartoon. Although the SPM[F] map did show changes in the fusiform gyrus, an area 
involved in watching video (Anderson et al., 2006; Shamshiri, 2016) as well as areas of 
the DMN such as precuneus (Raichle et al., 2001), in addition changes were noted in the 
thalamic-cortical network as thalamus. Thus, these differences were only seen at a 
threshold of p<0.05 uncorrected for multiple comparisons, and due to the chance of false 
positives at the low statistical threshold used to reveal these clusters, the relationship 
between differences in BOLD maps related to GSW during cartoon and rest need further 
exploration in order to draw any strong conclusions. 
Taken together, these results do not allow us to confirm that GSW deactivates the DMN 
more during rest than during cartoon or that GSW deactivated the areas of the cartoon 
network during task. However, considering the dissimilarities in the BOLD maps of 
GSW during rest and during cartoon, and the variations in the shape of fitted BOLD 
responses, results suggest that there could be an influence of different brain states on 
GSW networks derived from EEG-fMRI.  
6.4.1 Effects of cartoon on DMN and limitations 
In this study, a cartoon task was used for the first time in GGE patients by us. Also, this 
is the first investigation which explored the relationship between the baseline of brain 
states and their interaction with GSW BOLD response. Therefore, there are some 
considerations that require attention as they may have led us to reject our hypothesis.  




First of all, consideration about the sensitivity of our task is needed. In contrast to any 
other study (Bai et al., 2010; Chaudhary et al., 2013), was our use of a low demanding 
task. It is possible that during the cartoon, the DMN activity may be too close to rest and 
therefore, not able to provide a large enough baseline difference against which the GSW 
perturbations can be measured. However, Shamshiri et al. (2016) and Anderson et al. 
(2006) found a clear activity in fusiform gyrus and occipital cortex, areas involved 
during video watching. Similarly, we also found activity in the occipital cortex, 
suggesting the involvement of the same visual component associated with cartoon 
watching in our results. Therefore, we consider this alternative unlikely as GSW BOLD 
changes related with the cartoon were found.  
Another explanation may be related to GSW and functional connectivity. In fact, 
substantial differences were found in the functional connectivity of DMN and cartoon 
network in relation to IED (Shamshiri, 2016). Therefore, we can hypothesis that 
connectivity measures will reveal significant differences within rest and cartoon 
networks during GSW. Future analysis will address this question.    
6.4.2 Effects of cartoon on GSW 
We found that watching cartoon did not alter the average length of GSW, allowing 
BOLD related changes of stereotypical epileptic activity. However, we noticed that the 
number of GSW runs was larger during rest than during the cartoon. Although this did 
not reach statistical significance, it did approach significance (p<0.062). In addition, it is 
important to note that the selection criteria for this study required that the same patient 
showed GSW during rest and cartoon. This does not include all those patients who 
showed GSW during cartoon or rest only. Seven patients were excluded because GSW 




only occurred during the cartoon and 6 were excluded because GSW only occurred 
during rest. Therefore, although there is evidence that IED rate is unaffected by cartoon 
watching in focal epilepsy (Centeno et al., 2016), it is difficult to confirm the same in 
generalised epilepsy. Indeed, even though there is not a very strong effect in the 
influence of cartoon on GSW rates, this needs to be confirmed in more patients.   
6.4.3 Brain state baseline 
SPM[F] maps of the differences between GSW recorded during rest and during cartoon 
were found at the statistical threshold of p<0.05, uncorrected for multiple comparisons. 
Although we are aware of the limits of this threshold, we wanted to present these results 
given the interesting exploratory information we gained. This is the first study that has 
looked at the effect of differences in brain states on GSW with the largest group of 
subjects with GGE. With these results we wanted to demonstrate that there are 
differences in GSW related BOLD response dependent on the cognitive state of the 
patients. Although outcomes need to be replicated and further analysis is needed, our 
results do suggest that baseline brain state and level of consciousness may be important. 
6.5 Conclusion 
In this study we tested if GSW-related BOLD responses were dependant on brain state. 
We found that BOLD maps of GSW during rest was spatially similar to the DMN while 
the BOLD map of GSW during cartoon consisted of mainly visual cortex suggesting 
contradistinction in activation across brain states. However, the statistical differences 
between the brain states did not reveal clear results. Although our results may point 
towards variation in the GSW responses during rest and task, we did not have a 




statistically significant difference in the brain locations selected a priori and so cannot 
confirm our hypothesis. Therefore, we are unable to conclusively show that the DMN 
involvement in GSW is an epiphenomenon related to the baseline brain state used in 
previous studies. However, there was not a strong spatial correspondence between the 
GSW-related responses in the two states suggesting that the relationship between brain 




Chapter 7 : Arterial Spin Labelling – differences in blood 
perfusion due to drug intake.  
 
7.1 Background 
Arterial spin labelling is a quantitative MRI technique that is able to measure differences 
in regional and global cerebral blood flow (CBF) (Williams et al., 1992). It has been 
used extensively in many areas of clinical research (Petersen et al., 2006) including 
pharmacological imaging (Wang et al., 2011; Zelaya, 2016). Cerebral blood flow is 
measured by magnetically labelled arterial blood water and via the pair-wise subtraction 
between sequentially acquired tag and control images. ASL provides whole brain maps 
of CBF measured in units of ml of blood/100 g tissue/min and provides cerebral blood 
flow estimates comparable with those obtained by other methods (Buxton et al., 1998a; 
Hoge et al., 1999). ASL has been particularly useful in pharmacological-MRI (phMRI) 
(Tracey, 2001; Detre et al., 2009). In fact, it is possible to detect drug effects on CBF 
during rest and during the execution of a cognitive or sensory paradigm (Wang et al., 
2011).  
Unlike ASL, the amplitude of conventional BOLD fMRI reflects a complex interplay 
between cerebral blood flow, cerebral blood volume and the change in cerebral 
metabolic rate of oxygen consumption (Hoge et al., 1999). Hence, an observed drug 
effect on the BOLD fMRI signal may in fact be the result of changes in one of the above 
parameters at baseline. Indeed, there have been several studies demonstrating an 
interaction between basal physiological and metabolic states and task-induced BOLD 





found to affect the magnitude and the dynamics of the BOLD response induced by 
neural activity (Cohen et al., 2002) resulting in different BOLD activation. 
In addition, studies interested in antiepileptic medication effects identified that epilepsy 
treatment can lead to an alteration in cerebral blood flow after drug intake (Bartenstein 
et al., 1991; Gaillard et al., 1996; Spanaki et al., 1999; Joo et al., 2006) suggesting an 
alteration of neuronal functioning related to the drug that might alter BOLD maps.  
Therefore, if fMRI BOLD maps are to be compared between two conditions that consist 
of two different pharmacologic states, it is important to account for possible alterations 
in CBF, in order to distinguish between effects resulting from altered neuronal activity 
and those that may be caused by global haemodynamic influences (Tracey, 2001). Given 
that our simultaneous EEG-fMRI uses BOLD responses and these are potentially 
alterated by CBF changes induced by AED, we measured CBF longitudinally in patients 
diagnosed with GGE. CBF measures were taken using ASL before, and approximately 
six months after the first anti-epileptic drug treatment.       
7.2 Methods 
7.2.1 Subjects 
Although all the patients were encouraged to complete the full MRI protocol, ASL was 
acquired in those patients who were able to tolerate the additional scanning time. 
Amongst the entire group of patients (0, Paragraph 3.3), we acquired ASL in 22 drug 
naïve patients (mean age=17.05, SD=7.7) and in 11 post-treatment patients (mean 





Table 7.1: Patients’ demographics  
CODE AGE GENDER SCANNER 
TYPE 
SCANNING TIME 




#1 6.03  M 
1.5 T 
Y / 
#2 14.00  M Y / 
#6, #6b 13.65 14.21 F Y Y 
#7, #7b 8.03 8.54 M Y Y 
#9, #9b 10.28 10.77 M Y Y 
#10 9.72  F Y / 
#11, #11b 16.18 16.78 F Y Y 
#12 7.15  M Y / 
#13, #13b 9.26 9.78 M Y Y 
#47, #47b 21.71 22.95 M 
3.0 T 
Y Y 
#49 16.58  F Y / 
#50, #50b 13.64 14.14 F Y Y 
#51, #51b 20.11 20.78 F Y Y 
#52, #52b 35.98 36.44 M Y Y 
#53 15.38  F Y / 
#54, #54b 17.69 18.26 F Y Y 
#55 26.04  F Y / 
#57, #57b 25.94 26.48 F Y Y 





#59 16.46  F Y / 
#60 20.86  M Y / 
#61 19.18  F Y / 
Patients’ demographics. DN= drug naïve, PT= post-treatment.  
   
7.2.2 ASL acquisition 
Pulse sequence parameters for the ASL sequences can be found in Chapter 3, Table 3.4.  
7.2.3 ASL pre-processing 
For 1.5T data, post-processing of the ASL was performed using a custom built script 
running in Matlab R2013b. Signal intensity values from the multi-TI non-background 
suppressed ASL acquisition were used to fit a TI inversion recovery curve in each voxel, 
to obtain maps of T1 and the reference image (M0). CBF maps were calculated offline 
for each patient using custom-written Matlab code using recently published guidelines 
(Alsop et al., 2015).   
For 3T data, four control-label pairs were acquired plus a proton density (PD) image. 
The mean difference image was used to compute the CBF maps by dividing it by the PD 
image and scaling the ratio using recently published guidelines (Alsop et al., 2015). 
These maps were automatically computed by the scanner and written to the DICOM 
data-base. 
For 1.5T and 3T datasets, CBF maps were visually inspected and overlaid on the M0 
map to verify quality of the brain extraction. Manual segmentation was applied using 





7.2.4 ASL analysis 
Patients from different scanners were separated in two groups. For each scanner type, 
we calculated the mean global CBF values using FSL for each patient 
(http://fsl.fmrib.ox.ac.uk/fsl/). Mean values of CBF pre-treatment versus CBF post-
treatment scans were compared using a Mann-Whitney U test as implemented in SPSS 
23 (IBM Inc). Due to the small number of participants, we did not have sufficient 
statistical power to carry out a whole brain, voxel-wise statistical comparison. However, 
we did run an exploratory Wilcoxon Signed Ranks test for those patients who performed 
ASL pre and post-treatment.  
7.3 Results 
Nine patients pre-treatment and 5 patients post-treatment (diagnosed with AE) were 
scanned at the 1.5T scanner and included in the first group of patients. Thirteen patients 
pre-treatment and 6 patients post-treatment (diagnosed with JME) were scanned at 3T 
and included in the second group of patients. 
We found no statistically significant differences between global CBF pre-treatment 
compared to post-treatment in patients diagnosed with AE (U=19; p=0.69); and between 
CBF pre-treatment compared to CBF post-treatment in patients with JME (U=22; 
p=0.15) (Figure 7.1). Paired Wilcoxon Signed Ranks test was performed for those 
patients who had mean global CBF perfusion pre and post-treatment in the 1.5T and 3T 
groups. We found no differences between pre-treatment and post-treatment mean global 





significant differences between pre-treatment and post-treatment mean global CBF 
perfusion in patients diagnosed with JME (Z=-0.31; p=0.753).  
 
Figure 7.1: Boxplot of mean global CBF calculated mL blood per minute per 100g 
of tissue. Differences were calculated between i) AE drug naïve patients and AE 
post-treatment patients, ii) JME drug naïve patients and JME post-treatment 
patients. Upper limit of the box represents the upper quartile, lower limit 
represents the lower quartile, red line in the box is the median, error bars 
represent minimum and maximum values. No statistical significant differences 








Figure 7.2: Boxplot of mean global CBF calculated mL blood per minute per 100g 
of tissue. Differences were calculated between pairs of patients who have drug 
naïve and follow-up CBF measures. Comparisons were made between i) AE drug 
naïve patients and AE post-treatment patients, ii) JME drug naïve patients and 
JME post-treatment patients. Upper limit of the box represents the upper quartile, 
lower limit represents the lower quartile, red line in the box is the median, error 
bars represent minimum and maximum values. No statistical significant 
differences were found longitudinally within groups.   
 
7.4 Discussion 
We did not observe statistically significant differences between global CBF pre and post 
treatment in drug naïve patients diagnosed with GGE. The mean global CBF in patients 
diagnosed with AE who came back for pre and post-treatment showed a trend towards 
differences in lower CBF after treatment. Interestingly, although not surviving statistical 





is when comparing the whole group of AE and JME and those patients with 
longitudinally repeated measures.  
Although our results suggest that there is no significant difference in CBF pre and post-
treatment, previous studies have attempted to measure antiepileptic medication effects 
on CBF using SPECT, PET or/and SPET and they all showed significant changes due to 
medication (Bartenstein et al., 1991; Spanaki et al., 1999; Joo et al., 2006). Although the 
manner in which quantitative estimation of CBF is made in individual laboratories when 
using radio-tracer techniques may lead to potential differences in the results, it is 
important to note that they all showed decreased CBF as a consequence of medications. 
In addition, most studies have tested patients with focal epilepsy (Bartenstein et al., 
1991; Spanaki et al., 1999). Given evidence pointing towards differences in blood 
perfusion depending on seizure type (Theodore et al., 1996; Nersesyan et al., 2004), and 
considering that we only included GGE patients, our results are difficult to compare to 
previous studies. In addition to this, these studies looked at AED effect on CBF using 
chronic patients who were taking at least one AED prior to the measurements. This may 
create additional differences between the effects of AED on drug naïve brain compared 
to already-treated brains giving reasons for the clear differences they found between 
CBF measures that were missing in our results.  
Only one study showed differences in CBF maps as an effect of lamotrigine in drug 
naïve patients diagnosed with JME. Similar to our experimental paradigm, the post-
treatment scans were performed 4 to 5 months after the first AED intake (Joo et al., 
2006). They focused their analysis solely on lamotrigine, while we did not select based 





speculate that the different AEDs which our patients were on and different dosages 
might mask significant differences in CBF longitudinally (details of AEDs are listed in 
Table 3.1). However, given the limited number of patients available, we could not 
control for different AED type. Also, we had to limit our analysis to global CBF 
measures as we did not have sufficient statistical power to make a proper voxel-wise 
comparison. Therefore, regional differences as reported by Joo et al. (2006) would have 
been not identified.  
Moreover, considering the fact that we found a trend of reduced CBF in AE and the 
mean global CBF values were found to be lower in the post-treatment scan compared to 
pre-treatment in all patients, it is possible that our non-significant results are a reflection 
of a lack of statistical power. We do recognize this as a limitation to our study. 
Therefore, given the low sample size, the trend found in the AE group and the 
consistency of previous results, we are unable to conclude that there is no drug effect in 
the post-treatment global CBF. As this analysis was performed as a prelude to future 
work in which pre and post-treatment maps will be compared, these preliminary results 
will inform future analysis in which the impact of baseline perfusion changes need to be 
considered in any analysis of treatment effects using BOLD fMRI.  
 
7.5 Conclusion 
We found that global CBF was not significantly different before and after treatment 
suggesting no influence of the drugs used in this study on global cerebral blood flow. 
However, given the limited number of patients and a trend found in AE patients towards 





explore further potential AED effects on CBF. Therefore, any future BOLD based 
results we will perform, will consider the value of these preliminary results to prevent 
any biases by any global physiological effects related to drug intake. Differences in 
BOLD response pre and post-treatment will be treated as purely disease related under 
















SECTION 4: DISCUSSION AND CONCLUSION 
Chapter 8 : Discussion 
In Chapters 4 to 7, I described the application of multimodal neuroimaging in a group of 
drug naïve patients diagnosed with GGE and related age matched groups of healthy 
controls and refractory patients.  
The main findings of the studies in this thesis are: 
 Grey matter volume reductions and shape deflection in subcortical areas were 
found at the very beginning of the disease. 
 Simultaneous video EEG-fMRI showed that activation of the thalamic-cortical 
network and deactivation of the DMN are present at the drug naïve stage in 
presence of GSW during rest. 
 Simultaneous video EEG-fMRI showed that there are BOLD changes 6s before 
the onset of GSW, particularly in the frontal cortex, supporting a cortical onset. 
Thalamus and bilateral caudate were found switching BOLD response from 
positive to negative 2s before GSW onsets, in concomitant with GSW 
generation, suggesting a later reaction subcortically that plays a role in seizures 
initiation and sustain.  
 GSW BOLD maps during rest showed DMN areas; GSW BOLD maps during 
cartoon showed areas of the cartoon network. No clusters were overlapping 
between GSW during rest and GSW during cartoon and a trend of higher 





baseline may alter GSW related BOLD changes but further investigations are 
needed.  
 A trend for reduced CBF post-treatment was found compared to drug naïve pre-
treatment CBF in GGE.   
How do these findings provide further understanding of GGE? Here, I am presenting my 
perspective particularly focussing on treatment effect, longitudinal approach and brain 
state differences. I will also include what I plan to do in the near future as further 
analysis.  
8.1 Treatment Effect 
This study was conceived with the intention to fill the gap in the literature regarding the 
understanding of mechanisms behind GGE at the early stage of onset and when the 
effect of AED has not interfered with the diseases processes. The present collection of 
studies is the first one that presents such a big number of newly diagnosed and drug 
naïve patients (31 patients), possibly due to the difficulties of the recruitment of this 
patient population which makes this sample very rare. The possibility of excluding one 
confound such as AED has allowed us to disentangle its unknown effects from current 
knowledge of mechanisms of GGE. Below, I present the knowledge we were able to 
reach via the analysis of this drug naïve population.    
8.1.1 Drug naïve vs treated patients 
We found commonalities between changes in the volume and in the shape of subcortical 
areas, particularly thalamus, in drug naïve patients (Chapter 4) and those reported by 





2014). Similarly, SPM maps of GSW calculated via regressing out the effect of cartoon 
(classic model presented in previous studies) showed activation of thalamic-cortical 
network and deactivation of the DMN (Chapter 5) in accordance with previous studies 
(Aghakhani et al., 2004; Gotman et al., 2005; Hamandi et al., 2006; Moeller et al., 
2008a). Therefore, we concluded that features reported in GGE during treatment are 
present already at the very early stage of the disease also when there is no treatment 
effect to consider as confound.  
However, we cannot exclude that measures reported by previous studies in treated 
patients (usually refractory to treatment) are biased by treatment outcome. In fact, we 
can speculate that patients who will present good or bad outcome would present with 
differences in their brain measures. Indeed this was found as a trend of decreased grey 
matter volume and differences in shape in subcortical areas in patients who presented 
bad outcome compared to those who presented good outcome. With the current dataset, 
it is possible to disentangle this effect and future analysis will look into this (using a 
longitudinal prospective study design).  
8.1.2 Dynamic activity 
Exploring the time course of the BOLD response in drug naïve GGE revealed that the 
response to GSW is not static but it is dynamic. Following the debate of the cortical 
(Luders et al., 1984; Holmes et al., 2004) versus subcortical (Jasper HH, 1947) focus of 
onset for GGE, and the idea that dynamic changes in the brain lead to GSW (Bai et al., 
2010; Petkov et al., 2014) , we explored the BOLD activity occurring up to 12 seconds 





followed by thalamus and caudate (Chapter 5), suggesting a more cortical focus in GGE 
(Gupta et al., 2011; Miao et al., 2014) and a gateway role of the thalamus which would 
contribute to seizures initiation and sustain as proposed by previous studies (Meeren et 
al., 2005).  
Our results are consistent with early cortical activity found in treated patients (Benuzzi 
et al., 2012; Masterton et al., 2013) suggesting that treatment effect may have not played 
a role in altering BOLD dynamic prior to GSW. However, one study explored pre-GSW 
activity in 6 drug naïve patients and did not find any prior GSW BOLD changes 
(Moeller et al., 2008a). Reasons for this results may be related to, firstly, the limited 
number of patients they presented which may have led to statistical power problem; and 
secondly, the use of canonical HRF solely which our evidence suggests may limit the 
detection of changes in regions that show very different BOLD response shapes to a 
canonical response shape (Bagshaw et al., 2004; Bai et al., 2010).    
8.2 How does the brain state change GSW related activity? 
The experimental paradigm used for simultaneous EEG-fMRI was designed to improve 
tolerability of scanning for children during sedation free sessions (Centeno et al., 2016). 
However, it has also allowed us to understand if different brain state baselines (cartoon 
and rest) would have changed the BOLD responses related to GSW. Following the 
results presented in Chapter 6, we suggested the possibility of differences between GSW 
BOLD related activity during rest and cartoon. In fact, GSW map during rest showed the 





right inferior frontal gyrus and right middle occipital cortex, areas of the cartoon 
network (Shamshiri, 2016). 
However, we could not conclude strongly due to the lack of statistical significance of 
the results when we compared the differences between GSW during rest and GSW 
during cartoon.  
This was the first time that comparisons of brain states and related GSW activity was 
made given that other studies looked at GSW activity either during rest (Aghakhani et 
al., 2004; Gotman et al., 2005; Hamandi et al., 2006) or during cognitive tasks (Berman 
et al., 2010; Moeller et al., 2010a; Chaudhary et al., 2013) separately. Shamshiri et al. 
(2016) reported a well-defined cartoon network suggesting a clear change in alertness 
and attention by the cartoon. However, this was also the first time that “Tom & Jerry” 
video clip was used for this purpose, thus the amount of difference in the baseline state 
may be insufficient. Future studies are needed to further explore these results and 
clarifying the influence that baseline brain state has on GSW-related brain networks. We 
are planning to explore functional connectivity in the DMN and in the cartoon network 
to identify if connectivity perturbations in the different baseline states will reveal 
changes in relation to GSW more sensitively than the magnitude of GSW-related BOLD 
responses.  
8.3 Longitudinal prospective study design 
Our sample allows us to compare activity at drug naïve (pre-treatment) and post-
treatment stages and exploring early predictive markers of treatment outcome. The 





due to the limited time available to complete all post-treatment scans prior to the 
deadline for thesis submission. Up to now, we measured differences in grey matter 
volume and shape and cerebral blood flow.  
For the volume and the shape of grey matter, we measured not only the differences 
between pre and post-treatment but also differences at the drug naïve stage between 
patients who subsequently had good or bad treatment outcome at the post-treatment time 
point (Chapter 4). We did not see any changes between pre and post-treatment neither in 
the volume nor in the shape suggesting the possibility that abnormalities are present 
since the beginning of the disease and do not progress (at least within 6 months follow-
up). These results support the finding of Pulsipher et al. (2011) who also reported early 
changes in grey matter volume in GGE patients. However, considerations about the 6 
months follow-up we used to identify longitudinal changes are relevant given that 
changes in the grey matter volumes at 24 months follow-up have been reported 
(Pulsipher et al., 2011). Though, Pulsipher et al. (2011) recorded the first time point 
within 12 months from the diagnoses with mean epilepsy duration of 8.36 months; 
hence, our post-treatment scan corresponds to their first scan. Yet, we consider our 
results complementary and more detailed to theirs given that they do not report any 
treatment outcome but they limited the comparison to between their patient group and 
healthy controls. In addition, our interest was to identify the earliest point in time in 
which it is possible to detect a marker predicting later treatment outcome (from a drug 
naïve stage). We identified that patients who were refractory to treatment at 6 months 
presented abnormalities in the shape of the left pallidum and a trend of smaller 





subsequently had a good outcome. This suggests that grey matter structural features 
such as volume and shape may possibly be markers predicting treatment outcome, and 
we identified that within 6 months from diagnoses a clinical prediction is possible 
allowing us to distinguish drug naïve patients who will subsequently show different 
treatment outcomes.  
Global cerebral blood flow was measured to inform future studies in which longitudinal 
measures of BOLD changes will be implemented. Our results did not indicate a 
significant reduction in global CBF post-treatment. However, the plot of the data 
suggests a direction towards decreased CBF post-treatment. Evidence from previous 
studies supports reduction in CBF with AED intake in generalised (Joo et al., 2006) and 
partial epilepsies (Bartenstein et al., 1991; Spanaki et al., 1999). Given the limited 
number of patients in which we measured post-treatment CBF, we are aware of our 
limits in statistical power. Therefore, future studies will consider potential CBF 
reduction as confound.  
8.4 Future directions 
The richness of the dataset we acquired serves numerous future analyses. However, it is 
in our interests to prioritise specific questions which will impact our understanding of 
GGE: are there any differences between patients with good and bad treatment outcome? 
Are these differences detectable at the drug naïve stage?    
In order to answer these questions, future steps will include: 
 Analysis of white matter differences. It is possible that associated with the grey 





patients (Yang et al., 2012). Is has been demonstrated that there are white matter 
abnormalities in patients with GGE who are on treatment (Liu et al., 2011; 
Vollmar et al., 2011; O'Muircheartaigh et al., 2012). Therefore, we will explore 
which white matter abnormalities are present at the drug naïve stage and if 
marker of treatment outcome based on white matter features are identifiable at 
disease onset. This would be complementary to the trend we found in grey 
matter volumes in the group of drug naïve patients presented in Chapter 4 where 
patients who longitudinally did not respond to treatment presented smaller grey 
matter volumes in subcortical areas at the drug naïve stage.  
 Functional connectivity. We are aware of the power of functional connectivity 
and the insight it can give to underpinning mechanisms of epilepsy (Kim et al., 
2014; Wei et al., 2015). We will divide these analyses in two studies. Study I: we 
are planning to explore differences in functional connectivity across brain states 
to identify if DMN plays a mechanistic role in GSW or if DMN deactivation is 
merely due to the brain state from which GSW happened to emerge. Once this 
will be clarified, we will go into Study II. Here, we will explore if there may be 
functional connectivity differences in the core networks of GGE (as defined 
from Study I – GGE related only and not brain state dependent) in patients 
classified as refractory or responding at the post-treatment stage. We will 
measure if treatment response can be predicted by baseline measures of 
functional connectivity. 
 We are planning to use the EEG signal alone to explore dynamic functional 





onset of GSW; we want to explore if the status of EEG will change prior to the 
appearance of GWS. On this basis, we are planning to study the baseline of 
functional connectivity before electrographical GSW onset and its changes 
toward the manifestation of GSW. We will interrogate the data to identify 
differences in network dynamics that generated GSW between pre-treatment, 
responding and refractory patients.  
8.5 Limitations 
Two main limitations that require considerations for planning future studies emerged 
from the analysis presented in this thesis.  
First of all, any analysis using the longitudinal prospective needs to account for the 
limited numbers of patients measured at the follow-up scan. In fact, although this is still 
a precious dataset, it is essential to consider that 17 patients (54.8% of the drug naïve 
group) may limit the statistical power essential for detecting significant differences 
when comparing groups. This was the case we encountered in Chapter 4 when we 
measured differences between drug naïve and post-treatment and/or responders and not 
responders and we identified trends. Similarly, this was also demonstrated in Chapter 7 
where the CBF values were closed to significance due to the limited statistical power.   
Second of all, it is important to consider the influence of GSW, particularly when 
applying functional connectivity. It has been demonstrated the importance of 
considering IED effects in functional connectivity studies and how baseline IED-free 
data would provide knowledge of pathological underlying mechanisms (Coito et al., 





patients presented GSW in their EEG, as for example, we recorded GSW in only 5 
patients post-treatment. Therefore, to allow comparisons between patients presenting 
and not presenting GSW, it is important to account for all the variance they caused. 
However, as demonstrated in Chapter 5, the shape of the HRF response of GSW is not 
clear and mostly not canonical, therefore, to fully control for the effect of GSW, it 
would be important to extract the best model which represents GSW response better and 
use it to account for all the GSW variance first. Dr. Charmichael’s group is currently 













Chapter 9 : Conclusion 
In this thesis I presented results on the biggest sample of drug naïve patients diagnosed 
with GGE currently known to us. We applied multimodal imaging to study structural 
and functional aspects of GGE drug naïve to disentangle treatment effect and disease 
mechanisms. We demonstrated that grey matter abnormalities and BOLD pattern of 
GSW emerging from the resting state measured with fMRI are concordant with previous 
literature. This suggests that treatment effect was not biasing previous findings.  
In addition to a resting state session, we acquired some of the fMRI data during the 
projection of cartoon video clip to provide a more child friendly environment in the 
scanner. The mechanism underlying the deactivation of DMN during GSW at rest is not 
clear. Therefore, we explored differences in the BOLD response of GSW during rest and 
during cartoon to detect if differences in the baseline status would alter DMN activity 
during GSW. We demonstrated that there are differences due to brain states in the GSW 
BOLD maps, signalling the need for further analysis to draw clearer conclusions. 
We compared pre and post-treatment measures in grey matter and in CBF to identify not 
only changes due to treatment but also to explore markers of future treatment outcome. 
We found no differences in grey matter volume and shape pre and post-treatment but we 
found a trend in subcortical differences when comparing drug naïve patients who 
reported good outcome compared to those who reported bad outcome. CBF was found 
not statistically different pre and post-treatment, but due to the sample size limits we 
abstained to draw conclusion and, due to the distribution of the sample, we support the 
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